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Abbreviation key 
µm micrometer 
µg/ml microgram per milliliter 
ACTB actin beta 
AlpA/B adherence-associated lipoproteins A/B 
APC antigen presenting cell 
APC allophycocyanin 
ASCT2 alanine serine cysteine transporter 2 
ATPase adenosine triphosphatase 
BabA blood group antigen-binding adhesin 
BMDC bone marrow-derived dendritic cell  
bp basepair 
cagA cytotoxin-associated gene A 
CagA cytotoxin-associated protein A 
cagPaI cytotoxin-associated gene pathogenicity island 
CAMP cationic antimicrobial peptides  
CCR4 CC chemokine receptor 4 
CD cluster of differentiation 
cDNA copy DNA 
CpG unmethylated cytosine guanine dinucleotides  
CT cholera toxin 
Ct treshold cycle values 
CTLA-4 cytotoxic T-lymphocyte-associated protein 4 
CXCL chemokine (C-X-C motif) ligand  
CXCR CXC chemokine receptors 
DC dendritic cell 
dmLT double mutant form of heat-labile toxin from enterotoxigenic E. coli  
DNA deoxyribonucleic acid 
dupA duodenal ulcer promoting gene A 
E. coli Escherichia coli 
ELISA enzyme-linked immunosorbent assay 
EPIYA Glu-Pro-Ile-Tyr-Ala  
ERK extracellular signal-related kinase 
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FA complete Freund's adjuvant 
FCS fetal calf serum 
FISH fluorescent in situ hybridization 
FITC fluorescein isothiocyanate 
Fla flagellin 
FoxP3 transcription factor Forkhead-box P3 
g gravitational acceleration 
GADPH glyceraldehyde-3-phosphate dehydrogenase 
GGT gamma-glutamyl transpeptidase 
GITR glucocorticoid-induced TNFR-related protein 
GM-CSF granulocyte macrophage colony-stimulating factor 
Grb2 growth factor receptor-bound protein 2  
GSH reduced glutathione 
h hour 
H. Helicobacter 
HBSS Hank's balanced salt solution 
HCl hydrochloric acid  
HE haematoxylin-eosin 
Hop Helicobacter outer membrane porins  
Hor Hop-related subgroups 
HpaA H. pylori adhesin A 
HP-NAP H. pylori neutrophil-activating protein 
HPRT(1) hypoxanthine guanine phosphoribosyltransferase 1 
HRP horseradish peroxidase 
IFA incomplete Freund's adjuvant 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
KC keratinocyte chemoattractant 
kDa kilodalton 
kHz kilohertz 
Leb Lewis b blood group antigens 
LEL lympho-epithelial lesion 
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Lex sialyl-dimeric-Lewis x glycosphingolipid 
LFA-1 lymphocyte function-associated antigen 1 
LIX LPS-induced CXC chemokine 
LPS lipopolysaccharide 
mAb monoclonal antibody 
MACS magnetic-activated cell sorting  
MALT mucosa-associated lymphoid tissue 
MAPK mitogen-activated protein kinase 
MDC macrophage-derived chemokine 
MHC major histocompatibility complex 
MIC minimal inhibitory concentration 
MIP-2 macrophage inflammatory protein 2 
MLST multilocus sequence typing 
MoDC monocyte-derived dendritic cells 
MOI multiplicity of infection 
mRNA messenger RNA 
NFAT nuclear factor of activated T-cells 
NF-κB nuclear factor κB 
NHPH non-Helicobacter pylori helicobacters 
NOD nucleotide-binding oligomerization domain 
ODN oligodeoxynucleotides 
OipA outer inflammatory protein A 
OMP outer membrane protein 
PAMP pathogen-associated molecular pattern 
PAS periodic acid-Schiff 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PD1 programmed cell death protein 1 
PE phycoerythrin  
pH measure of acidity or basicity 
PI propidium iodide 
PPI proton pump inhibitor 
PRR pathogen recognition receptor 
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qPCR quantitative real-time polymerase chain reaction 
r recombinant 
RNA ribonucleic acid 
ROR RAR-related orphan receptor  
ROS reactive oxygen species  
rRNA ribosomal RNA 
RT room temperature 
s.l. sensu lato 
s.s. sensu stricto 
SabA sialic acid-binding adhesin A 
SD standard deviation 
SHP-2 SH2-containing tyrosine phosphatase 
siRNA small interfering RNA 
SPEM spasmolytic polypeptide-expressing metaplasia 
SPF specific pathogen free 
STAT signal transducer and activator of transcription 
T4SS type IV secretion system 
TARC thymus and activation-regulated chemokine 
TEM transmission electron microscopy 
TGF transforming growth factor 
Th T helper 
TLR toll-like receptor 
TNF tumor necrosis factor 
Treg regulatory T-cell 
U Unit 
UreA/B/E/F/G/H/I urease subunit A/B/E/F/G/H/I 
v/v volume per volume 
VacA vacuolating cytotoxin A 
WT wild type 
ZO-I zonula occludens-1  
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1 The genus Helicobacter 
For a long time, the gastric environment was believed to be sterile. In 1984, Barry Marshall 
and Robin Warren reported for the first time that a bacterium, residing in the stomach, 
plays a role in gastric ulcer disease in humans. This bacterium was later named 
Helicobacter (H.) pylori (Marshall and Warren, 1984; Goodwin et al., 1989). Since the 
description of H. pylori, a large number of non-Helicobacter pylori helicobacters (NHPH) 
have been described in a wide variety of animals and humans. To date, the genus 
Helicobacter contains 45 identified species with validly published names. The 
Helicobacter bacteria can be divided into two major groups, gastric and enterohepatic 
species. The enterohepatic species live on the mucosal surfaces of the intestinal tract and/or 
in the liver (Sterzenbach et al., 2007). Gastric helicobacters are able to survive in the acidic 
environment of the stomach, mainly by expressing urease (Labigne et al., 1991). Most of 
the gastric NHPH are animal-associated bacteria, but some of them have zoonotic potential, 
as shown in Table I.  
 
Table I: Gastric Helicobacter spp. and their hosts (adapted from Flahou et al., 2016) 
Taxon Hosts Zoonotic potential 
‘Candidatus H. bovis’ cattle Yes 
‘Candidatus H. homininae’ chimpanzee, gorilla Unknown 
H. acinonychis cheetah, tiger, lion Unknown 
H. ailurogastricus cat Unknown 
H. baculiformis cat Unknown 
H. bizzozeronii cat, dog Yes 
H. cetorum whale, dolphin Unknown 
H. cynogastricus dog Unknown 
H. felis  dog, cat, cheetah Yes 
 
new Guinea wild dog 
 
 
rabbit 
 H. heilmannii dog, cat, cheetah Yes 
 
bobcat, tiger, lynx 
 
 
leopard, puma 
 H. mustelae ferret Unknown 
H. pylori human / 
H. salomonis cat, dog, rabbit Yes 
H. suis pig, mandrill monkey Yes 
 
rhesus macaque 
   crabeating macaque   
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2 Gastric non-Helicobacter pylori helicobacters in pigs and humans 
2.1 Nomenclature of gastric non-Helicobacter pylori helicobacters 
In the early years of H. pylori research, spiral-shaped bacteria, different in morphology from 
H. pylori were reported colonizing the human stomach (McNulty et al., 1989). They were 
originally referred to as ‘Gastrospirillum hominis’, but later renamed H. heilmanii, after the 
German pathologist Konrad Heilmann, who first studied the pathologies associated with these 
bacteria (Heilmann and Borchard, 1991). Analysis of the 16S ribosomal RNA (rRNA) gene of 
these uncultivated organisms resulted in their classification in the genus Helicobacter. 
Sequence analysis of the 16S and 23S rRNA gene enabled further subdivision in ‘H. 
heilmannii’ type 1 and ‘H. heilmannii’ type 2 bacteria (Haesebrouck et al., 2009). At that 
time, ‘H. heilmannii’ was not formally recognized as a valid species name. 
‘H. heilmannii’ type 1 is both morphologically and genetically identical to a bacterium 
colonizing the stomachs of pigs (De Groote et al., 1999; O’Rourke et al., 2004a) that was first 
designated ‘Gastrospirillum suis’ (Mendes et al., 1990). Almost 10 years later, sequencing of 
the 16S rRNA gene, fluorescent in situ hybridization (FISH) and electron microscopy showed 
that these organisms belong to the genus Helicobacter and are sufficiently different from all 
existing species to constitute a new taxon. Because at that time this species could not be fully 
characterized due to the lack of pure in vitro isolates, the organism was described as 
‘Candidatus Helicobacter suis’ (De Groote et al., 1999). In 2008, pure in vitro cultures were 
obtained using a new biphasic culture method, resulting in the official description of H. 
suis as a species (Baele et al., 2008). Besides pigs, this species also colonizes the stomach of 
humans and non-human primates, such as mandrills, macaques and baboons (O’Rourke et al., 
2004b). 
‘H. heilmannii’ type 2 does not represent a single species, but a group of different 
Helicobacter species. These species, including H. felis, H. bizzozeronii, H. salomonis, H. 
baculiformis and H. cynogastricus, mainly colonize the stomach of dogs and cats 
(Haesebrouck et al., 2009). This group also comprises H. heilmannii (also referred to as H. 
heilmannii sensu stricto or s.s.), which was isolated from the stomach of cats and 
characterized in 2013 (Smet et al., 2013). In an attempt to avoid further confusion in 
nomenclature, the term Helicobacter heilmannii sensu lato (H. heilmannii s.l.) was introduced 
to refer to the group of non-H. pylori Helicobacter species detected in the stomachs of 
humans or animals if only histopathological, electron microscopy, or crude taxonomic data 
are available. Helicobacter heilmannii sensu stricto (H. heilmannii s.s.) or the other species 
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names should be used if definite identification at the species level is achieved (Haesebrouck et 
al., 2009).  
During the last couple of years, several new Helicobacter species have been described 
including a feline gastric species, H. ailurogastricus, which is closely related to H. heilmannii 
(Joosten et al., 2015), and a putative Helicobacter species in wild gorillas and chimpanzees, 
for which the name ‘Candidatus H. homininae’ has been proposed (Flahou et al., 2014).  
In table II the most important characteristics of the main gastric helicobacters associated with 
human gastric disease are presented. Although differences in morphology have been 
described, microscopic investigation of biopsy samples is not an accurate method for species 
identification. 
 
Table II: The most important characteristics of the main gastric helicobacters associated 
with human gastric disease (adapted from Haesebrouck et al., 2009) 
Characteristics H. pylori H. suis H. heilmannii H. felis H. bizzozeronnii H. salomonis 
Length (µm) 2.5-5 2.3-6.7 5-10 5-7.5 5-10 5-7 
Cell width (µm) 0.5-1 0.9-1.2 0.5-0.6 0.4 0.3 0.8-1.2 
Urease + + + (+) (+) + 
GGT + + + + + + 
Nitrate reduction - - ND + + + 
Periplasmatic fibril - - - + - - 
# Flagella 4-8 4-10 10-20 10-20 10-20 10-23 
Distribution of 
flagella MP BP BP BP BP BP 
 
All taxa produce catalase and possess sheathed flagella. +, 100% of strains positive; −, 0% of strains 
positive; (+), 80 to 94% of strains positive; ND, not determined; BP, bipolar; MP, monopolar; GGT, 
gamma-glutamyl transpeptidase. 
 
 
2.2 Helicobacter suis infections in pigs  
 Morphology, isolation and cultivation of Helicobacter suis 
H. suis is a spiral-shaped, Gram-negative bacterium (Figure 1). This bacterium is on average 
2.3-6.7 µm in length and 0.9-1.2 µm in width. H. suis is highly motile because of flagella 
which can be found in groups of 4 to 10 on each side of the cell (Baele et al., 2008). 
Differentiation of H. suis from the other gastric NHPH species mentioned above can be done 
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by molecular methods, for instance by sequencing of the 16S and 23S rRNA encoding genes 
(Baele et al., 2008).  
 
Figure 1. TEM image of a cell of H. suis strain HS1 showing bipolar flagellae (Baele et al., 2008). 
 
H. suis is very fastidious. This bacterium has been cultivated for the first time in 2008 (Baele 
et al., 2008). Primary isolation and cultivation require specific growth conditions. Briefly, for 
primary isolation the pig stomach is rinsed and subjected to acid treatment to prevent bacterial 
overgrowth (submersion in a 1% HCl bath for 1 hour). After this, the mucus is scraped off 
using a glass slide and collected in a sterile tube. The mucus is slightly liquefied 
with Brucella broth supplemented with fetal calf serum and inoculated on Brucella agar 
containing fetal calf serum, amphotericin B, Campylobacter-selective supplement, Vitox 
supplement, activated charcoal and HCl (min. 37 %) to obtain a pH of 5. Plates are incubated 
at 37 °C under humidified microaerobic conditions (85% N2, 10% CO2, 5% O2) (Baele et al., 
2008). Light microscopic examination of the broth reveals the presence of spiral-shaped 
motile cells. For cultivation, H. suis is grown on the same Brucella agar plates used for 
primary isolation but without the supplementation of activated charcoal. In addition, Brucella 
broth with a pH of 5 is added on top of the agar to obtain biphasic culture conditions. 
Recently, a method has been developed to acquire pure cultures by growing the bacteria as 
individual colonies on 1% Brucella agar plates, after which they are purified and enriched by 
conventional biphasic subculture as described above (Liang et al., 2015). 
 Prevalence and transmission of Helicobacter suis in pigs 
The prevalence of H. suis infection in pigs is low before weaning. Hereafter, when the 
maternal immunity disappears, the prevalence gradually increases to 60% or even more, 
depending on the study, in European, Asian and American pigs at slaughter age (Barbosa et 
al., 1995; Grasso et al., 1996; Cantet et al., 1999; Park et al., 2004; Hellemans et al., 2007b). 
The regrouping of animals at the time of weaning most probably favors the spread of the 
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micro-organisms from the few piglets infected before weaning to non-infected animals. 
Transmission most likely occurs via the oral-oral route through saliva or via the gastric-oral 
route through vomiting or regurgitation.  
 Role of Helicobacter suis in the development of porcine gastric pathologies 
The involvement of H. suis in different gastric pathologies in pigs will be discussed below. A 
schematic overview of the different regions of the porcine stomach is depicted in Figure 2. 
 
 
Figure 2. Schematic overview of the different regions of the porcine stomach. The porcine stomach 
has four distinct areas which include the oesophageal, cardiac, fundic and pyloric (also referred to as 
the antral region) regions. The oesophageal region is located at the entrance of the stomach and does 
not secrete digestive enzymes. In the cardiac region of the stomach, mucus is secreted and mixed with 
the digested food. In the fundic region gastric glands secrete hydrochloric acid, resulting in a low pH. 
Other secretions in this region are present in the form of digestive enzymes, specifically pepsinogen. 
Pepsinogen is broken down by the hydrochloric acid to form pepsin, which is involved in the 
breakdown of proteins. Finally, the digesta moves to the pyloric region. This region is responsible for 
secreting mucus to line the digestive membranes to prevent damage from the low pH digesta as it 
passes through the small intestine (Karali et al., 1995).  
 
H. suis has been shown to cause gastritis in pigs, both after experimental (Hellemans et al., 
2007a; De Bruyne et al., 2012) and after natural (Grasso et al., 1996; Hellemans et al., 2007b) 
infection. This gastritis is characterized by a diffuse lymphocytic/plasmacytic infiltration as 
well as lymphocytic aggregates and lymphoid follicles, occasionally accompanied with 
neutrophilic infiltrates (Hellemans et al., 2007a; De Bruyne et al., 2012). In young pigs and 
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pigs at slaughter age, the highest H. suis colonization densities can often be found in the 
antrum. In adult boars and sows, higher colonization rates have been described in the fundic 
region (Hellemans et al., 2007b). 
Several studies also attribute a role to this pathogen in the development of hyperkeratosis and 
ulceration of the non-glandular stratified squamous epithelium of the pars oesophagea of the 
porcine stomach, although H. suis does not colonize this region (Queiroz et al., 1996; 
Roosendaal et al., 2000; De Bruyne at al., 2012). Others did not find this association (Grasso 
et al., 1996; Melnichouk et al., 1999; Park et al., 2004). Hence, the exact role of H. suis in the 
development of these lesions remains to be elucidated. Recently, it was found that a novel 
Fusobacterium sp., named F. gastrosuis, was abundantly present in the gastric microbiota of 
pigs and higher numbers were present in H. suis-infected animals. F. gastrosuis might also 
play a role in the development of gastric pathologies, since most Fusobacterium spp. are 
opportunistic pathogens that can aggravate necrosis when tissue damage is initiated by other 
micro-organisms or environmental factors (De Witte et al., 2017). In any case, the 
development of gastric ulcer disease is most likely multifactorial and in general, all conditions 
increasing the fluidity of the stomach content may cause a breakdown of the pH gradient 
between the proximal and distal parts of the stomach. This breakdown causes increased 
contact of gastric acid with the pars oesophagea, ultimately leading to ulcer formation. 
Several factors such as fine particle size of the feed, pelleting of the feed, presence of highly 
fermentable carbohydrates and short chain fatty acids in the diet, interruption in feed intake, 
overcrowding, stress and respiratory disease could also play a role in the development of 
gastric ulcers (De Bruyne et al., 2012). It has been demonstrated that H. suis infection in pigs 
results in an increased number of gastrin-producing cells and a decreased number of 
somatostatin-producing cells in the antrum (Sapierzynski et al., 2007). Since gastrin 
stimulates and somatostatin inhibits acid secretion by parietal cells, this may influence gastric 
acid production. Acid secretion may also be altered due to the tropism of this bacterium for 
parietal cells (Hellemans et al., 2007a; Flahou et al., 2010). This altered acid secretion could 
in turn be involved in the development of ulceration of the pars oesophagea. Ulceration may 
result in decreased feed intake, decreased daily weight gain and even sudden death due to 
fatal hemorrhage. Besides the substantial economic losses caused by H. suis infections, there 
is no doubt that this disease causes pain and discomfort for the animal.  
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2.3 Gastric non-H. pylori Helicobacter infections in humans with particular 
emphasis on Helicobacter suis 
NHPH have been demonstrated in 0.2–6 % of human patients with gastric complaints 
undergoing a gastric biopsy, which is probably an underestimation of their true prevalence 
(Haesebrouck et al., 2009). The pig-associated bacterium H. suis comprises 13.9% to 78.5% 
of human NHPH infections, which makes this species the most prevalent gastric NHPH in 
humans (Trebesius et al., 2001; Van den Bulck et al., 2005; Haesebrouck et al., 2009). 
Interestingly, a study by Blaecher et al. (2013) demonstrated a high prevalence (27%) of H. 
suis DNA in gastric biopsies from human patients with idiopathic parkinsonism. The putative 
significance of this bacterium in Parkinson’s disease requires further investigation. 
Clinical symptoms associated with NHPH in humans can be characterized by atypical 
complaints such as acute or chronic epigastric pain and nausea. Other aspecific symptoms 
include hematemesis, recurrent dyspepsia, irregular defecation frequency and variable stool 
consistency, vomiting, heartburn, and dysphagia, often accompanied by a decreased appetite. 
Some people infected with non-H. pylori helicobacters remain asymptomatic (Haesebrouck et 
al., 2009).  
It is not exactly known how NHPH are transmitted to humans, but most likely it occurs 
through contact with animals. Living in close proximity to animals such as dogs, cats, and 
especially swine (pig farmers, the staff of slaughterhouses and veterinarians) has indeed been 
identified as a significant risk factor for these infections (Holck et al., 1997; Svec et al., 2000). 
Joosten et al. (2013) described a H. suis infection in a human patient having regular contact 
with pigs and provided clear evidence for an association between H. suis and dyspepsia. It is 
remarkable that H. suis is the most prevalent gastric NHPH species in humans. This might 
indicate that the infectivity for humans of cat- or dog-related NHPH is less than that of H. suis 
(Haesebrouck et al., 2009). Despite numerous attempts, H. suis could not be detected in feces 
of infected pigs, which may indicate that fecal-oral spread between pigs and from pigs to 
humans is limited.  
Apart from the stomach of pigs and humans, H. suis has also been found in the stomach of 
mandrill monkeys (Papio sphinx), cynomolgus monkeys (Macaca fasicularis) and rhesus 
macaques (Macaca mulatta). Although it is clear that non-human primates may be infected 
with different types of gastric helicobacters, little information on these bacteria and their 
interaction with these hosts is available (Haesebrouck et al., 2009; Flahou et al., 2014). It is 
unknown whether these non-human primates constitute a source of infection for humans. 
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Additional possible transmission routes that require further investigation include consumption 
of water (Azevedo et al., 2008) and consumption of raw or undercooked contaminated pork 
(De Cooman et al., 2013). Since rodent models are easily colonized with most NHPH, the role 
of wild mice as vector might also be considered (Haesebrouck et al., 2009).  
Due to the fastidious nature of gastric NHPH, isolation is not an option for routine diagnoses. 
The urea breath test, which is frequently used to diagnose infection with H. pylori, is often 
negative in patients infected with NHPH (Matsumotu et al., 2014). This can be explained by 
the fact that infections with these bacteria are more often focal and predominantly found in 
the antrum of the stomach (Stolte et al., 1997). Therefore, analysis of gastric biopsies by 
molecular microbiological methods and histology is so far the only way to determine 
infections with these bacteria.  
In patients undergoing an endoscopy, a variety of lesions can be observed, ranging from a 
normal to slightly hyperemic mucosa to mucosal edema and to multiple erosions and 
ulcerations in the antrum or in the duodenum (Sykora et al., 2003; Haesebrouck et al., 2009). 
Histologically, the inflammation induced by NHPH in the gastric tissue is generally 
characterized by lymphocytic exudation into gastric foveolae, sometimes mixed with plasma 
cells. In some cases, lymphocytes are organized into lymphoid aggregates. The epithelial 
mucus layer is occasionally depleted (Haesebrouck et al., 2009). NHPH-associated gastritis is 
often less severe compared to H. pylori-associated gastritis (Stolte et al., 1997).  
Recently, a multilocus sequence typing (MLST) technique was developed to demonstrate 
genetic variation between different H. suis strains. This technique uses the following 
genes/gene clusters to distinguish different H. suis strains: atpA, efp, mutY, ppa, trpC, yphC 
and ureAB. The use of this technique should allow to investigate whether H. suis infection in 
human patients is a consequence of direct or indirect contact with pigs (Liang et al., 2013). 
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3 The inflammatory and immune response to gastric Helicobacter infection 
3.1 Virulence mechanisms of Helicobacter pylori and other gastric helicobacters 
Gastric helicobacters have developed a unique set of virulence factors, actively supporting 
their successful survival and persistence in their natural hostile ecological niche, the stomach. 
Abundant information is available on virulence factors of H. pylori, whereas little is known 
about the virulence factors of other gastric helicobacters. Therefore, this paragraph focusses 
on the major H. pylori virulence factors and their effects, which are presented in figure 3. The 
potential impact of these virulence factors on the host immune response will be addressed 
where appropriate.  
 
 
Figure 3. The major H. pylori virulence factors and their effects. The cagPaI (red) encodes a type 
IV secretion system (T4SS) which is the main stimulus to epithelial cell pro-inflammatory cytokine 
production and subsequent inflammation. CagA (green), which is translocated through the T4SS has 
other effects, but also contributes to inflammation. BabA (purple) encodes an adhesin which allows 
close contact and enhances virulence factor delivery and hence inflammation. The functions of the 
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products of oipA (orange) and dupA (yellow) are not known, but they have been shown to upregulate 
cytokine expression and inflammation. VacA (blue) has many effects on cells and increases disease 
risk, but has not been shown to increase inflammation. The ggt gene (black) encodes gamma-glutamyl 
transpeptidase which probably plays a role in damaging gastric epithelial cells (Adapted from 
Robinson et al., 2007). 
 Virulence mechanisms involved in colonization and adherence 
Urease 
Gastric helicobacters must survive the extremely acidic environment of the stomach lumen 
and penetrate the outer mucous gel layer of the stomach to reach their ideal niche, which has 
an external pH of approximately 5-6. All gastric Helicobacter sp. are able to increase the pH 
of their immediate surroundings as well as their cytosol and periplasm by producing urease. 
This enzyme consists of two subunits, UreA and UreB (Labigne et al., 1991), which are 
assembled into catalytically active, nickel-containing dodecamer via the actions of the 
accessory proteins UreE, UreF, UreG and UreH (Mobley et al., 1995). Urease activity is 
upregulated under acidic conditions by a proton-gated urea channel formed by the inner 
membrane protein UreI, allowing rapid entry of urea into the bacteria (Skouloubris et al., 
1998; Weeks et al., 2000). Urea is hydrolyzed into ammonia, which neutralizes the 
hydrochloric acid creating a neutral microenvironment around the bacterium, and carbon 
dioxide. Urease localizes mainly in the cytoplasm, but also associates with the surface of the 
viable bacteria after autolysis of surrounding bacteria (Haesebrouck et al. 2009). H. pylori 
mutants lacking either urease activity (through disruption of ureB) or a functional UreI were 
shown to be defective for colonization in animal models of infection (Eaton et al., 1994; 
Skouloubris et al., 1998; Eaton et al., 2002), thus demonstrating the essential role of urease in 
H. pylori pathogenesis. 
 
Motility 
Motility is essential for stomach colonization by all gastric helicobacters, allowing them to 
move towards the gastric mucosal surface. Next, the bacteria have to overcome the viscous 
mucous gel covering the gastric epithelium. The spiral shape of H. pylori is believed to 
enhance its ability to penetrate the mucus. Mutants lacking a helical twist show diminished 
colonization (Sycuro et al., 2012). H. pylori possesses 2-5 unipolar flagella, whereas H. suis 
possesses 4-10 flagella per cell, which are distributed bipolar (Haesebrouck et al., 2009). The 
flagella consist of a body, hook and flagellar filament. The filament is composed of two 
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flagellin subunits, the predominant FlaA and the minor FlaB (Suerbaum et al., 1993). It works 
as a propeller and is covered by a sheath which is suspected to play a role in acid protection, 
masking of antigens and probably adhesion. The basal body of the flagellum is embedded in 
the bacterial cell wall and contains proteins required for rotation and chemotaxis. The hook 
links the body and the filament (Haesebrouck et al., 2009). Mutants lacking flagella are 
unable to colonize in a gnotobiotic piglet model of infection (Eaton et al., 1996).  
 
Chemotaxis 
Several studies have shown that not only motility but also chemotaxis is an important factor 
for successful colonization of the stomach (Eaton et al., 1996; Foynes et al., 2000; Otteman 
and Lowenthal et al., 2002; Terry et al., 2005; Howitt et al., 2011; Rolig et al., 2012). H. 
pylori uses four methyl-accepting chemoreceptor proteins (TlpA, TlpB, TLpC and TlpD) to 
sense external stimuli and repellent ligands. Chemotaxis is used to colonize injured 
epithelium, which may possess high amounts of favorable nutrients (Aihara et al., 2014), and 
to respond to auto-inducer 2, a small signaling molecule involved in quorum sensing by which 
bacteria monitor the amount of bacteria in close proximity (Bassler et al., 1999; Surette et al., 
1999). Living in close proximity could lead to limiting resources and therefore spreading out 
might be more favorable than staying together. 
 
Outer membrane proteins 
In addition to motility and chemotaxis, adherence to the gastric epithelium is important 
because this facilitates colonization and persistence, by preventing the bacteria from being 
washed out from the stomach by mucus turnover and gastric peristalsis, by evasion from the 
immune system and by efficient injection of bacterial effector proteins into the gastric cell 
(Oleastro and Ménard, 2013). The outer membrane protein (OMP) profile of H. pylori strains 
differs significantly from that of other Gram-negative species as no major OMPs predominate, 
but rather multiple lower-abundance OMPs are observed (Alm et al., 2000). Approximately 
4% of the H. pylori genome encodes an extraordinary large set of OMPs (~64 OMPs) divided 
into five paralogous gene families. This unusual set of OMPs may reflect the adaptation of H. 
pylori to its unique environmental niche. The known H. pylori adhesins all belong to the 
major OMP Family 1, comprised of the Hop (for H. pylori OMP, 21 members) and Hor (for 
Hop related, 12 members) proteins (Oleastro and Ménard, 2013). The best characterized 
adhesins are the blood group antigen-binding (BabA) and sialic acid-binding (SabA) proteins, 
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the outer inflammatory protein A (OipA) and the adherence-associated lipoproteins AlpA and 
AlpB. BabA mediates the binding of H. pylori to fucosylated Lewis b blood group antigens 
(Leb) on blood group O (H antigens), A and B antigens, that are expressed on mucins and 
gastric epithelial cells (Aspholm-Hurtig et al., 2004). SabA mediates the binding to sialyl-
dimeric-Lewis x glycosphingolipid (Lex), which is upregulated on the inflamed gastric tissue 
after H. pylori infection (Mahdavi et al., 2002). Both lipoproteins AlpA and AlpB have been 
shown to contribute to host laminin binding and to influence gastric inflammation (Senkovich 
et al., 2011). OipA is involved in the adherence of H. pylori to gastric cell lines 
(Dossumbekova et al. 2006), but its host receptor remains to be identified. Families 2 and 3 
comprise the Hof (for Helicobacter OMP, 8 members) and Hom (for Helicobacter outer 
membrane, 4 members) proteins, respectively. Families 4 and 5 are composed of iron-
regulated OMPs (6 members) and efflux pump OMPs (3 members), respectively (Oleastro 
and Ménard, 2013). 
Before the start of this research, information about the OMPs from gastric NHPH species was 
limited. In addition, it was also unknown which OMPs are involved in adhesion to and 
colonization of the gastric mucosa. The genomes of H. bizzozeronii (Schott et al., 2011), H. 
felis (Arnold et al., 2011), H. heilmannii (Smet et al., 2013), H. suis (Vermoote et al., 2011a), 
H. acinonychis (Eppinger et al., 2006), H. cetorum (Kersulyte et al., 2013) and H. mustelae 
(O’Toole et al., 2010) have recently been published. Similar to H. pylori, they also harbor a 
large repertoire of OMP-encoding genes. Remarkably, all canine, feline and porcine 
helicobacters seem to lack the well-characterized and important H. pylori Hop and Hom 
adhesins, suggesting that other OMPs may be used by these species for adhesion to the gastric 
mucosa. H. suis also contains some similar members of the major OMP families described 
for H. pylori. These include the gastric epithelial cell adhesin HorB and the surface 
lipoprotein, H. pylori adhesin A (HpaA). HpaA, also annotated as neuraminyllactose-binding 
hemagglutinin, is found exclusively in Helicobacter species and binds to sialic acid-rich 
macromolecules present on the gastric epithelium.  
 
 Major virulence factors involved in lesion development 
Cytotoxin-associated gene (cag) pathogenicity island (PaI) 
Probably the most important and definitely the best-characterized H. pylori virulence factor 
is the cytotoxin-associated gene (cag) pathogenicity island (PaI), whose presence in a 
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functional form is associated with increased risk of developing peptic ulcer disease and 
gastric adenocarcinoma (Blaser et al., 1995; Nomura et al., 2002). It has, however, not been 
reported to be present in any other Helicobacter species. The cagPaI contains about 31 genes 
and encodes a bacterial type IV secretion system (T4SS) and its only known effector protein, 
CagA, which is injected into the gastric epithelial cells of the host. This T4SS represents a 
pilus-like structure (T4SS pilus), induced upon host cell contact and protruding from the 
bacterial membrane (Odenbreit et al., 2000). The presence of the T4SS itself is the major 
stimulus of epithelial cell pro-inflammatory cytokine/chemokine expression, including 
interleukin-8 (IL-8) (Peek et al., 1995). Translocation of CagA into the host epithelial cytosol 
results in profound cellular changes, benefiting the bacterium. The ‘injected’ CagA is 
recognized by epithelial cells as a signaling molecule and activated by phosphorylation on 
tyrosine residues by host src kinases (Selbach et al., 2002; Stein et al., 2002). It interacts with 
SHP-2 and induces MAP kinase signaling, resulting in abnormal proliferation and 
cytoskeletal changes (Higashi et al., 2002; Rieder et al., 2005). Phosphorylated CagA can 
also bind to Crk proteins, leading to the disruption of epithelial cell tight junctions and tissue 
damage (Suzuki et al., 2005). Non-phosphorylated CagA can interact with other cellular 
receptors such as Grb2 and ZO-I to induce other morphological cellular changes and 
proliferation (Mimuro et al., 2002; Amieva et al., 2003). CagA represents a prime example of 
tyrosine phosphorylatable effector proteins of bacteria. Site-directed mutagenesis and mass 
spectrometry has revealed numerous phosphorylation sites in CagA known as the Glu-Pro-
Ile-Tyr-Ala (EPIYA) motifs A, B, C and/or D (Hatakeyama, 2003; Yamaoka et al., 2010). 
The motif present in East Asian strains of H. pylori (D type) is a more potent activator of 
SHP-2 than the corresponding (C type) motif found in Western strains (Hatakeyama, 2004). 
Several studies have shown that strains possessing CagA with more phosphorylation motifs 
are more closely associated with the development of atrophy and gastric carcinoma than 
strains possessing CagA with fewer motifs (Argent et al., 2004). The actions by which CagA 
increases cancer risk remain unclear. It could be due to increased IL-8 secretion, however 
contradicting results exist (Ando et al., 2002; Backert et al., 2004).  
 
Vacuolating cytotoxin A (VacA) 
Vacuolating cytotoxin A (VacA) is the second most extensively studied H. pylori virulence 
factor. The VacA toxin binds to host cells after secretion through a type V autotransporter 
secretion system. In addition to vacuolation, VacA can induce multiple activities in the host 
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cell, including membrane-channel formation, cytochrome c release from mitochrondria 
leading to apoptosis, and binding to cell membrane receptors followed by initiation of a pro-
inflammatory response (Kusters et al., 2006). VacA can also specifically inhibit T-cell 
activation and proliferation (Boncristiano et al., 2003). The coding gene vacA is present in 
nearly all H. pylori strains, although not all strains induce vacuolation of epithelial cells in 
vitro. The vacA gene possesses several polymorphic sites, namely the signal (s) region, the 
midregion (m) and the intermediate (i) region. Type s1/m1 strains have been shown to 
produce higher levels of cytotoxins in vitro compared to s1/m2 strains, whereas s2 genotypes 
are inactive in vacuolating cytotoxicity assays (Atherton et al., 1995). Strains carrying s1/m1 
vacA alleles are associated with increased bacterial load and neutrophil infiltration (Atherton 
et al., 1997). However, the i-region has been reported to be a more reliable predictor of severe 
gastric disease than the s- or m-regions of vacA (Rhead et al., 2007). Vermoote et al. (2011a) 
demonstrated that a vacA homolog was absent in H. suis strain 5, whereas a vacA paralog was 
present in H. suis strain 1. Sequence analysis, however, suggested that no functional toxin is 
produced (Vermoote et al., 2011a). 
 
Gamma-glutamyl transpeptidase (GGT) 
The enzyme gamma-glutamyl transpeptidase (GGT) is well conserved in the genus 
Helicobacter and has been shown to play an important role during the metabolism of 
extracellular L-glutamine (L-Gln) and reduced glutathione (GSH) (Flahou et al., 2011). The 
Helicobacter GGT is very efficient in using both glutamine and gluthatione from epithelial 
cells as a source of glutamate (Shibayama et al., 2003; Flahou et al., 2011). It is probably 
involved in gastric epithelial cell damage as glutamine is an important nutrient for host cells 
and gluthatione a crucial antioxidant. They thus both play a role in maintaining healthy 
gastric tissue. In addition, degradation of reduced glutatione by H. suis GGT results in more 
extracellular oxygen radicals, further increasing oxidative damage of epithelial cells (Flahou 
et al., 2011). GGT also inhibits T-cell proliferation, indicating its role in immune evasion 
(Zhang et al., 2013).   
 
 
  
General Introduction 
 
25 
 
3.2 Immune response to Helicobacter pylori 
Despite induction of innate and adaptive immune responses in the H. pylori infected 
individual, the host is unable to clear the bacteria, leading to chronic inflammation. One 
widely accepted hallmark of H. pylori is that it successfully evades host defense mechanisms. 
In the next paragraphs, the innate and adaptive immune responses to H. pylori and the 
different mechanisms by which H. pylori evades immune-mediated clearance will be 
discussed. A simplified presentation of the host immune response following H. pylori 
infection is depicted in figure 4.  
 
 
 
Figure 4. Simplified presentation of the host immune response following Helicobacter pylori 
infection. H. pylori T4SS is induced by contact with the host cell and forms a pilus-like structure that 
protrudes from the bacterial surface. T4SS delivers the effector protein of the cagPAI, CagA, and H. 
pylori cell wall peptidoglycan into the host cell. The latter is recognized by the cytoplasmic pathogen 
recognition molecule NOD1. This triggers a pro-inflammatory signaling cascade in epithelial cells, 
characterized by the translocation of NF-κB to the nucleus and activation of mitogen-activated protein 
kinases (MAPKs), p38 and extracellular signal regulated kinase (ERK), leading to the production of 
pro-inflammatory cytokines/chemokines including IL-8, by which innate immune cells (including 
neutrophils, macrophages and dendritic cells) are attracted. The subsequent expression of cytokines by 
these cells leads to skewing of naive CD4+ cells into T helper (Th) 1, 2, 17 or regulatory T-cells. 
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 The innate immune response to Helicobacter pylori infection 
Innate immune recognition of H. pylori 
H. pylori is mainly considered as an extracellular pathogen (Amieva et al., 2003). Before 
attaching to the gastric epithelium, H. pylori has to cross the thick mucus layer covering the 
mucosal surface. As described above, the unipolar sheathed flagella allow H. pylori to quickly 
move from the inhospitable low pH of the gastric lumen to the epithelial surface where the pH 
is higher and favorable for successful colonization (Khatoon et al., 2016). Colonization of the 
gastric mucosa triggers innate host defense mechanisms, thus stimulating the expression of 
pro-inflammatory and anti-bacterial factors by gastric epithelial cells (Jung et al., 1997; 
George et al., 2003). Toll-like receptors (TLR’s) are important pathogen recognition receptors 
(PRR) expressed by epithelial cells and cells of the innate immune system, including dendritic 
cells and macrophages (Kaparakis et al., 2010). They are involved in pathogen-associated 
molecular pattern (PAMP) recognition. TLR1, TLR2, TLR4, TLR5 and TLR6 bind to their 
ligands on the cell surface and recognize microbial membrane components. TLR3, TLR7, 
TLR8, TLR9 are found in intracellular vesicles and are mainly involved in the recognition of 
microbial nucleic acids (Smith et al., 2014). Various in vitro experiments have shown that H. 
pylori can stimulate pro-inflammatory gene expression via TLR2, TLR4, TLR5 and TLR9. 
However, some of these results are conflicting and the role of TLR4 in particular remains 
controversial (Robinson et al., 2007). It has been shown that H. pylori lipopolysaccharide 
(LPS) initiates inflammatory signaling in human epithelial cells via TLR2, rather than the 
more classical sensor of Gram-negative LPS, TLR4 (Yokota et al., 2007; Smith et al., 2011).  
NOD1 is a member of the nucleotide-binding oligomerization domain (NOD)-like receptor 
(NLR) family and an intracellular PRR. It is responsible for the recognition of H. pylori 
peptidoglycan, delivered by the CagA type IV secretion system (Viala et al., 2004). This 
results in the induction of NF-κB activation and subsequent production of pro-inflammatory 
cytokines/chemokines, including IL-8 (Viala et al., 2004). H. pylori is known to elude 
recognition by PRRs by multiple methods, including avoidance of recognition by TLR’s and 
inhibition of C-type lectin receptor (DC-SIGN)-mediated signaling. To avoid recognition by 
TLR’s the bacterium modulates its surface molecules (including LPS and flagellin) (Lina et 
al., 2014). LPS is a glycolipid found on the outer membrane of Gram-negative bacteria 
(Cullen et al., 2011) and consists of lipid A, a core polysaccharide of five sugars and the O-
antigen (Appelmelk and Vandenbroucke-Grauls, 2001). As determined by serological 
techniques, the O-antigen of LPS of more than 80% of H. pylori strains tested worldwide 
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express Lewis blood group antigens (Appelmelk and Vandenbroucke-Grauls, 2001). Lewis 
antigens, which are composed of carbohydrates, resemble human blood group antigens (Wang 
et al., 2000). By exploiting this form of molecular mimicry, the bacterium is able to evade 
TLR’s because the normally detectable O-antigens are recognized as a “self” molecule by this 
type of PRR. The bacterium also modifies the lipid A portion of the LPS molecule. 
Modification of this unit is achieved through several pathways, resulting in an alteration of the 
net charge of the microbial surface, which leads to an inability of cationic antimicrobial 
peptides (CAMP’s) to bind to typically negatively charged structures like lipid A. This 
reduced binding of LPS to TLR4 results in a decreased activation of monocytes and 
macrophages (Lina et al., 2014). In addition, several studies showed that the major H. pylori 
flagellin, FlaA, was not recognized by TLR5 and thus failed to induce NF-κB activation 
(Andersen-Nissen et al., 2005). 
 
The role of infiltrating leukocytes 
Cytokines and chemokines secreted by gastric epithelial cells stimulate the migration of 
granulocytes, monocytes and lymphocytes into the inflamed mucosa. High densities of 
infiltrating cells are associated with more severe inflammatory pathologies (Ernst et al., 
2000). A major H. pylori pro-inflammatory factor involved in the enhancement of early 
immune responses is the H. pylori neutrophil activating protein (HP-NAP). A homologue of 
the coding gene is found in the H. suis genome (Vermoote et al., 2011a). HP-NAP promotes 
the adherence of neutrophils to the endothelium, their transendothelial migration, chemotaxis 
of leukocytes and the release of reactive oxygen species (ROS) by neutrophils and monocytes 
(Polenghi et al., 2007). H. pylori produces catalase and superoxide dismutase to detoxify 
ROS. H. pylori can also downregulate CXCR1 and CXCR2 expression in human neutrophils, 
which act as receptors for the neutrophil recruiting chemokine, IL-8, thus resulting in an 
inhibitory effect on neutrophil migration and reduced bacterial killing (Lina et al., 2014). 
Professional antigen-presenting cells (APC), represented by macrophages, dendritic cells 
(DCs) and B cells, internalize antigen by phagocytosis or endocytosis, process the antigens 
and present them to CD4+ T-cells via MHC class II molecules. This leads to the initiation of 
antigen specific T-cell responses. Phagocytosis is an important anti-bacterial innate immune 
mechanism, but H. pylori seems to partially evade phagocyte-mediated killing. A large 
proportion of engulfed bacteria appear to survive inside phagosomes which fuse to become 
‘megasomes’ and may provide a protected intracellular niche contributing to the persistence 
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of infection. Urease and possibly the cagPaI are involved in megasome formation and H. 
pylori survival (Allen et al., 2000).  
The role of DCs in H. pylori pathogenesis is complex. There is a growing consensus that DCs 
may play an important role in promoting tolerance (Shiu and Blanchard, 2013). H. pylori uses 
several mechanisms to interrupt antigen presentation by DCs, in which the virulence factors 
VacA and CagA possibly play a role (Lina et al., 2014). Kaebisch and colleagues (2014) 
infected DCs with H. pylori strains deficient for one of the following virulence factors: CagA, 
BabA, UreA/B, GGT or VacA. The expression of CD86/CD83 double positive cells was 
significantly higher when DCs were infected with CagA deficient bacteria, whereas deletion 
of the other factors did not influence the phenotypical maturation of DCs. In addition, 
comparable results were observed when DCs were infected with the SS1 strain, which has a 
non-functional CagY and does not translocate CagA into the host cells, indicating that CagA 
translocation is mainly responsible for the H. pylori-induced incomplete DC maturation. In 
the same study, it was shown that CagA impairs DC maturation and function through IL-10-
mediated activation of STAT3, favoring a Treg response (Kaebisch et al., 2014). Similar 
studies have been carried out in mouse models, confirming that CagA suppresses DC 
maturation and function (Tanaka et al., 2010), however conflicting results exist. In a study by 
Oertli et al. (2013), VacA and GGT were pointed out as the main virulence factors involved in 
murine DC tolerization. Kim et al. (2011) demonstrated that VacA inhibits DC maturation via 
restoration of E2F1, an important regulator of DC maturation, since transfection of murine 
DCs with E2F1 siRNA showed recovery of maturation inhibition caused by VacA. In 
addition, H. pylori is also known to cause an impaired antigen presentation by murine DCs by 
inhibiting export of MHCII molecules to the cell surface (Wang et al., 2010). Several studies 
demonstrated that depletion of DCs improved clearance of H. pylori and induced protective 
immunity upon infection (Hitzler et al., 2011; Oertli et al., 2012). These results suggest that 
DCs are most likely dispensable for immunity to H. pylori and instead are an essential 
element of immuno-regulation, preventing control of the infection. 
In addition, mast cells have been reported to be present at higher frequencies in the infected 
human gastric mucosa, declining after H. pylori eradication therapy (Bamba et al., 2002). The 
role of these cells during infection has not been widely studied. They may be involved in 
tissue repair and/or increased inflammatory responses (Yakabi et al., 2002).  
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 The adaptive immune response to H. pylori infection 
Effector T-cell responses 
Naive CD4+ T helper cells can be induced to differentiate towards effector T helper 1, Th2, 
Th17 and regulatory T-cell (Treg) cells depending on the cytokine milieu (Larussa at al., 
2015). The Th1 phenotype is defined by differentiation in the presence of IL-12 and IFN-γ 
and secretion of IL-2 and IFN-γ. The number of IFN-γ secreting cells in the human gastric 
mucosa correlates with severity of the gastritis (Larussa et al., 2015). Th2 cells secrete IL-4, 
IL-5, IL-6 and are responsible for B-cell activation and differentiation. In general, most 
intracellular bacteria induce Th1 responses, whereas extracellular pathogens stimulate Th2 
responses (Larussa at al., 2015). Th17 cells produce IL-17A, IL-17F, IL-21 and IL-22. They 
are involved in host defense mechanisms to extracellular bacteria and fungi, but also in the 
pathogenesis of auto-immune diseases (Larussa at al., 2015). IL-17 has been shown to be 
involved in neutrophil infiltration during H. pylori infection (Shiomi et al., 2008). Mice 
infected with H. pylori have been shown to develop a mixed Th17/Th1 response, with the 
Th17/IL-17 pathway preceding and modulating the Th1 response (Shi et al., 2010).  
Given the critical role of effector T-cells (Th1 and Th17 subsets) in controlling H. pylori, it is 
no surprise that these bacteria have developed elaborate mechanisms to suppress human T-
cell activity, proliferation and clonal expansion. Several virulence factors play a role in 
interfering with T-cell responses including VacA, GGT and arginase (Lina et al., 2014). All 
H. pylori strains express the secreted virulence factors VacA and GGT. Hexameric VacA 
binds to the β2 integrin subunit of the heterodimeric transmembrane receptor LFA-1. The 
receptor complex is internalized upon protein kinase C-mediated serine/threonine 
phosphorylation of the β2 integrin cytoplasmic tail. Cytoplasmic VacA prevents nuclear 
translocation of NFAT by inhibiting its dephosphorylation by the Ca2+/calmodulin-dependent 
phosphatase calcineurin and thereby blocks IL-2 production and subsequent T-cell activation 
and proliferation. Interestingly, murine T-cells are resistant to VacA, because they do not 
express this receptor (Algood et al., 2007; Sewald et al., 2008); rather, it appears that VacA 
promotes persistence in mice through a mechanism involving its interaction with DCs (Oertli 
et al., 2013). The inhibitory effect of GGT on T-cell proliferation could be linked to a cell 
cycle arrest in the G1 phase and to its enzymatic activity (Schmees et al., 2007). Another 
virulence factor that impairs T-cell function is arginase, which hydrolyzes L-arginine, an 
amino-acid required for T-cell activation and function, into urea and ornithine (Zabaleta et al., 
2004). 
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Regulatory T-cell responses 
There is increasing evidence that H. pylori may elicit Treg responses to suppress immune and 
inflammatory responses and thus maintain chronic colonization in order to limit tissue injury. 
Tregs can be divided into several subsets according to how they are derived and the markers 
they express. ‘Inducible’ Tregs develop in the periphery upon stimulation of T-cells in the 
presence of IL-2 and TGF-β, whereas ‘natural’ Tregs are thymus derived. They express 
FoxP3, which is a member of the forkhead/winged-helix family of transcriptional regulators. 
They also express high levels of the surface marker CD25 and an array of secreted and 
surface exposed regulatory molecules including IL-10, TGF-β, CTLA-4, PD1 and GITR 
(Bollrath and Powrie, 2013). FoxP3-expressing CD4+CD25high regulatory T-cells have 
previously been demonstrated in the gastric mucosa of H. pylori infected humans (Lundgren 
et al., 2005). Multiple in vivo and in vitro studies have shown that H. pylori specifically 
targets DCs to promote their tolerogenic properties, as described above. H. pylori stimulated 
DCs fail to mature, as shown by the impaired expression of MHCII and co-stimulatory 
markers including CD80, CD86 and CD40 (Oertli et al., 2012; Kaebisch et al., 2014). 
However, these semi-mature DC are excellent inducers of Treg differentiation in vitro and in 
vivo (Kao et al., 2010; Oertli et al., 2012). Induction of Treg cells appears to depend on the 
age at which the host acquired the infection, since H. pylori infected children have increased 
levels of FoxP3-expressing cells and reduced gastric pathology compared to adults (Harris et 
al., 2008). H. pylori may utilize several yet unknown mechanisms to induce Treg responses, 
while maintaining a suboptimal level of Th17 cells in the host, which helps to establish a 
chronic infection (Lina et al., 2014).  
 
Humoral immunity 
The majority of people infected with H. pylori develop a specific antibody response, which is 
not sufficient to clear an existing infection. In a study of mice lacking B-cells, the animals 
were protected against H. pylori challenge suggesting that the humoral response might be 
dispensable. To further support this, another B-cell knockout study showed that with an H. 
pylori urease vaccine, mice deficient in B-cells had equal protection as wild type mice and 
stomach CD4+ T-cells were equal in both mouse strains (Ermak et al., 1998). It was also 
demonstrated that differences in this specific antibody response occur. Infected individuals 
who develop gastritis or duodenal ulcers were shown to have a greater IgG response than 
those who develop gastric cancer. In contrast, patients with gastric cancer mount a more 
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distinct IgA response compared to those with gastritis and duodenal ulcers (Manojlovic et al., 
2004). Interestingly, a study showed that H. pylori evades antibody-mediated recognition 
through lack of surface binding of host elicited antibodies (Darwin et al., 1996). 
In conclusion, the immune response to H. pylori includes both innate effectors and a complex 
mix of Th1, Th17, and Treg adaptive immune responses. The clinical outcome of infection 
may well depend to a large extent on the relative balance of these responses.  
 
 
  
General Introduction 
 
32 
 
3.3 Animal models used for the study of the inflammatory and immune 
response following gastric Helicobacter infections  
In order to study the pathogenic outcome and immune responses evoked by gastric 
Helicobacter infections, animal experiments remain fundamental. Current studies most 
commonly use mice, Mongolian gerbils or non-human primates. Because of cost, ease of 
manipulation, availability of reagents and genetic tools, the laboratory mouse is often the 
model of choice. However, the function of the H. pylori type IV secretion system is 
commonly lost during colonization of mice. This occurs less frequently in Mongolian gerbils. 
However, for the latter less genetic tools and reagents are available.  
After the discovery of H. pylori, attempts were made to infect mice and rats, but remained 
unsuccessful. For 10 years, animal experiments were predominantly performed using H. felis 
in mice and H. mustelae in ferrets. H. felis causes lesions that are similar to those caused by 
H. pylori, but the lesions are more severe and rapidly progressive (Court et al., 2002). The 
mouse model was not frequently used until 1997 when strain SS1 was introduced (Lee et al., 
1997). SS1 is an H. pylori isolate from a human patient that was adapted to mouse 
colonization by several in vivo passages. SS1 colonizes mice well, persists indefinitely in 
most mouse strains, causes histological gastritis and is genetically tractable. This strain 
became the international standard for animal experimentation with H. pylori (Lee et al., 
1997).  
Progression and severity of gastric lesions in gastric Helicobacter-infected mice are enhanced 
by adoptive transfer of CD4+ T-cells or by absence or suppression of T-cell regulatory 
cytokines such as IL-10 (Eaton et al., 2001) or Treg subsets (Gray et al., 2013), as described 
above. Gastritis and secondary epithelial lesions are enhanced by Th1 and Th17 cytokines, 
IFN-γ in particular, which appears to be the principal inducer of gastritis and metaplasia in 
murine models (Sayi et al., 2009). This could explain the less severe lesions in H. suis 
infected BALB/c mice, in which a Th1 response is mostly absent. However, conflicting 
reports have been published regarding the immune response underlying H. suis-induced 
gastritis. Several authors have described the inflammation to be driven mainly by a Th1 
response (Cinque et al., 2006; Mimura et al., 2011). Others have described a mixed Th1/Th2 
response (Park et al., 2008). However, these studies used gastric mucosal homogenate or 
gastric mucus from H. suis infected mice to inoculate the animals. Studies using pure in vitro 
isolated H. suis strains revealed that experimental H. suis infection in mice causes an 
upregulation of IL-17, IL-10, and IL-4 expression, in the absence of IFN-γ upregulation 
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(Flahou et al., 2012), which also clearly contrasts to the immune response elicited by H. pylori 
in this same animal model. Other pro-inflammatory cytokines, such as TNF-α (Thalmaier et 
al., 2002) and IL-1β (Huang et al., 2013) have also been associated with gastric disease in 
mouse models. 
The inflammatory infiltrate in both H. pylori infected mice and humans, consists of a mixture 
of neutrophils and mononuclear inflammatory cells that are rarely specifically identified, but 
probably are a mixture of lymphocytes, plasma cells, macrophages and dendritic cells. In 
humans, chronic infection is sometimes associated with loss of gastric glands and fibrosis 
(atrophic gastritis) and replacement of gastric-type glandular epithelium with intestinal type 
epithelium, complete with absorptive and goblet cells (intestinal metaplasia). Gastric cancer is 
thought to develop as a result of intestinal metaplasia progressing to dysplasia and neoplasia. 
In contrast, mice do not develop atrophy or intestinal metaplasia, but chronic colonization 
rather leads to epithelial hyperplasia and a type of metaplasia known as spasmolytic 
polypeptide-expressing metaplasia (SPEM) (Weis and Goldenring, 2009). Experimental H. 
suis infection in mice evokes inflammation in the glandular part of the stomach, epithelial cell 
hyperproliferation and necrosis of parietal cells. The loss of parietal cells might be involved in 
the development of several gastric pathologies, such as gastric erosion and ulcer formation 
(Flahou et al., 2010). Lesion severity associated with H. suis is often less than described for 
H. pylori (Stolte et al., 1997). In the case of H. suis more MALT lymphoma-like lesions are 
observed (Nakamura et al., 2007; Yang et al., 2014). 
Interestingly, a Th2 response, rather than a Th1-predominant response, has been shown to 
play a role in the development of low-grade B-cell MALT lymphoma (Flahou et al., 2012). In 
BALB/c mice experimentally infected with different H. heilmannii sensu lato bacteria, 
‘isolated’ in vivo in mice and originating both from humans and animals, gastric MALT 
lymphoma has been shown to start developing from 6 months post infection (O’Rourke et al., 
2004b). In this study, the most severe pathological changes were seen in mice infected with in 
vivo ‘isolates’ from a human patient, a bobcat, a crab-eating macaque, and mandrill monkeys. 
Except for the strain from the bobcat, these strains were in fact shown to be H. suis. Similar 
lesions were observed in C57BL/6 mice infected for at least 6 months with an in vivo ‘isolate’ 
of ‘Candidatus H. heilmannii’, which later was also shown to be H. suis (Nakamura et al., 
2007; Haesebrouck et al., 2009), as well as in Mongolian gerbils infected with an in vitro 
isolated strain of H. suis (Figure 5) (Flahou et al., 2010). These histopathological changes 
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resemble inflammation-related changes in the stomach of humans infected with NHPH, 
including H. suis.  
 
Figure 5. H&E staining of the fundus of a H. suis-infected BALB/c mouse. In this animal, infected for 
8 months, two large lymphoid aggregates can be seen in the lamina propria mucosae, accompanied by 
loss of normal mucosal architecture. Original magnification: 200× (Flahou et al., 2010). 
 
The first published description of the gerbil model appeared in 1991 (Yokota et al., 1991). In 
1998, it was demonstrated that long term infection of Mongolian gerbils with H. pylori led to 
gastric adenocarcinoma in approximately one-third of infected animals, without the co-
administration of carcinogens, which was subsequently confirmed by others (Watanabe et al., 
1998; Ogura et al., 2000). This closely resembled the development of gastric 
adenocarcinomas in H. pylori-infected humans. H. pylori colonizes deep within the gastric 
mucus gel layer near the epithelia, similar in topography to where the bacteria are found in 
human gastric specimens (Schreiber et al., 2004). Similar observations were made in 
Mongolian gerbils infected with H. suis, where inflammation is limited to the antrum and a 
narrow zone at the forestomach-stomach transition, which also resembles more closely the 
human situation (Figure 6). Therefore, the Mongolian gerbil might be a more suitable model 
for human gastric disease compared to mice. Several authors describe the increased 
expression of IL-17 and IFN-γ mRNA in H. suis-infected gerbils, which indicates a 
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predominant Th17/Th1 response in this animal model (Liang et al., 2015, Zhang et al., 2015). 
IL-1β, a cytokine that inhibits acid secretion, is also increased within the gastric mucosa of 
both H. pylori and H. suis infected gerbils. In addition, in this animal model also increased 
serum levels of gastrin are observed, which can promote cell growth and is directly related to 
gastric epithelial cell proliferation (Peek et al., 2000; Joosten et al., 2013). In Mongolian 
gerbils infected with H. suis, generally more severe inflammation is observed, evolving to a 
pathology that resembles gastric MALT lymphoma.  
 
Figure 6. Immunohistochemical Helicobacter staining of a gerbil stomach, showing H. 
suis colonization. H. suis bacteria (brown) are seen (A) in the glands of the antrum and (B) at the 
forestomach/stomach transition zone, accompanied by a focal infiltrate of mononuclear cells. Original 
magnification: 200× (Flahou et al., 2010). 
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4 Control of gastric Helicobacter infections 
4.1 Antimicrobial therapy  
Eradication of H. pylori infection provides symptomatic benefits for many dyspepsia patients, 
heals and prevents recurrence of peptic ulcer disease, reduces the risk of development of 
gastric cancer and can be a curative therapy for gastric MALT lymphoma (Molina-Infante and 
Graham, 2016). Over the last 20 years, the most recommended first-line treatment for 
eradication of H. pylori by all international guidelines has been the standard triple therapy, 
consisting of a proton pump inhibitor (PPI) and the combination of two antibiotics 
(clarithromycin and amoxicillin or metronidazole) (Chey and Wong, 2007; Fock et al., 2009; 
Malfertheiner et al., 2012). However, the effectiveness of triple therapy has dramatically 
declined due to the increased resistance to clarithromycin (Graham and Fischbach et al., 
2010), which reaches up to 40% in adults in southern and central European countries 
(Megraud et al., 2013). Global guidelines recommend that first-line therapies for H. 
pylori infection should have a minimum of 90% eradication success rate. This eradication rate 
is frequently not achieved with the standard PPI-based triple therapies. Novel empiric 
therapeutic schemes have been explored to overcome acquired antibiotic resistance. The 
choice of therapy may depend on the patient’s previous antibiotic treatment, local patterns of 
antimicrobial resistance and drug availability. Optimization of all eradication regimes 
(including duration, PPI/ antibiotic doses and dosing intervals) is key to maximize efficiency. 
Currently, the most effective first-line eradication regimens are 14-day bismuth and non-
bismuth concomitant quadruple therapies. These regimens consist of bismuth salicylate, 
metronidazole, tetracycline, and PPI. No trial has compared the efficacy of both regimens yet 
(Graham et al., 2014; Molina-Infante and Gisbert et al., 2014).  
In human patients presenting severe pathology and clinical symptoms associated with the 
presence of NHPH, treatment is warranted, although the efficacy of such treatment is not 
always easy to determine due to the lack of randomized trials. In general, treatment regimens 
identical to those used for H. pylori have been prescribed and may be effective (Haesebrouck 
et al., 2009). Because of the low number of in vitro isolates available, very little data exist on 
the antimicrobial susceptibility and acquired resistance of gastric NHPH species. 
Determination of minimal inhibitory concentrations (MICs) of various antimicrobials against 
in vitro isolates indicates that acquired resistance to metronidazole may occur in H. 
bizzozeronii and H. felis strains of animal origin (Van den Bulck et al., 2005). 
Experimental H. felis infections in mice showed that several therapies using only one 
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antimicrobial were effective in only 25 to 70% of the animals tested, while triple therapy 
using metronidazole, tetracycline, and bismuth subcitrate eradicated H. felis from all the 
animals (Dick-Hegedus et al., 1991). In a BALB/c mouse model it was shown that treatment 
with ampicillin/omeprazole resulted in the suppression of H. suis. Differences in sensitivity 
were seen between different H. suis isolates, which might indicate acquired antimicrobial 
resistance (Hellemans et al., 2005). Vermoote et al. (2011b) developed a combined agar and 
broth dilution method to analyze the activity of antimicrobial agents against H. suis isolates. 
MICs were determined by software-assisted calculation of bacterial growth. Results of this 
study showed that acquired resistance to fluoroquinolones may occur in H. suis field isolates. 
As the results of this study are based on a small number of strains, additional tests are needed 
to determine if these results reflect the susceptibility of the H. suis population. 
 
4.2 Vaccination against gastric Helicobacter infections 
 Current status in Helicobacter pylori vaccination 
Although antibiotic treatment combined with proton pomp inhibitors may lead to eradication 
of infection, several difficulties including side-effects and the development of antibiotic 
resistance may occur. Epidemiological studies have reported a reinfection rate of 20-30%/year 
after antibiotic treatment in low- and middle-income countries, which is accompanied by the 
return of peptic ulcer disease and the risk of gastric cancer (Parsonnet et al., 2003). Therefore, 
large scale control of H. pylori infections is probably best achieved through vaccination 
strategies (Robinson et al., 2007). However, due to the complex pathogenicity and large 
variability, vaccine development remains a major challenge. Efforts to develop a Helicobacter 
pylori-specific vaccine began in the early 1990s with the recognition that infection with this 
bacterium is the main cause of peptic ulcer disease and is a strong risk factor for gastric 
cancer in humans. Vaccination protocols with a wide range of different antigens, adjuvants 
and delivery routes can significantly reduce H. pylori colonization in rodent models and 
humans, however, sterilizing immunity is rarely achieved (Müller and Solnick, 2011). 
 
Protective immune mechanisms for eradication of Helicobacter pylori  
For the development of an effective vaccine, the protective immune mechanisms that will lead 
to bacterial eradication need to be identified. As this is an extracellular bacterium, it was 
originally presumed that a secretory IgA response would be sufficient to prevent infection. 
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However, early studies in mice clearly showed that CD4+ T helper cells, but not CD8+ T-cells 
or antibodies were crucial for vaccine-induced protection (Ermak et al., 1998; Blanchard et 
al., 1999; Pappo et al., 1999). Several studies attributed a major role for Th17 responses in 
vaccine-induced protection against H. pylori in mice, possibly through IL-17-mediated 
induction of neutrophil chemo-attractants (DeLyria et al., 2009; Velin et al., 2009). The 
importance of a Th1 response for protection was shown by several research groups (Akhiani 
et al., 2002; Sayi et al., 2009), but contradicted by others (Sawai et al., 1999; Garhart et al., 
2002; Flach et al., 2011). In any case, CD4+ T helper cells with the ability to migrate to 
gastric mucosal effector sites and secrete either Th1 or Th17 cytokines, or both, are crucial for 
vaccine-induced protection. Garhart et al. (2003) demonstrated, by using gene knockout 
studies, that IL-4 is dispensable for the induction of protective immunity.  
 
Choice of antigens 
A number of vaccine antigens have been tested over the years including whole-cell lysates 
(Sutton et al., 2000; Kotloff et al., 2001) and single or combined purified or recombinant 
proteins (subunit vaccines).  
Whole-cell lysate vaccines consist of bacteria that have been inactivated by physical or 
chemical processes. The advantage of such preparations is that they contain all the known 
immunodominant and protective antigens (Raghavan, unpublished results). The lysate also 
contains a high concentration of pathogen-associated molecular patterns such as LPS, 
flagellin and unmethylated cytosine, guanine oligonucleotides (CpG DNA), that potentially 
trigger an inflammatory reaction when given together with a strong mucosal adjuvant. 
Drawbacks are batch-to-batch variation and lack of thorough characterization of the 
preparation. However, in several studies both after prophylactic (Garhart et al., 2002; 
Raghavan et al., 2010) and therapeutic immunization (Raghavan et al., 2002, Nÿstrom et al., 
2006), a strong reduction in H. pylori colonization was observed when using whole-cell 
lysates.  
Subunit vaccines may have the disadvantage of sometimes being less immunogenic, but have 
an excellent safety profile. This is due to their high purity which limits the risk of adverse 
reactions (Gerdts, 2015). The important H. pylori virulence factors CagA (Rossi et al., 2004) 
and VacA (Marchetti et al., 1998) have been used as antigens for immunization. However, 
VacA has been shown to inhibit T-cell activation and proliferation and CagA is not secreted 
by all H. pylori strains and not by NHPH species, which could make these antigens less 
General Introduction 
 
39 
 
suitable for vaccination (Blanchard and Nedrud, 2010). Several other antigens have also been 
used including, urease (Kleanthous et al., 1998; Weltzin et al., 2000), HP-NAP (Satin et al., 
2000), catalase (Radcliff et al., 1997), heat shock proteins (Kamiya et al., 2002) and 
lipopolysaccharide (Taylor et al., 2008). The use of bacterial vectors for the delivery of 
antigens has also been investigated. Attenuated Salmonella Typhi, Lactobacillus ssp. and 
polio virus all have been used as vectors for urease (Corthesy et al., 2005; Smythies et al., 
2005; Aebischer et al., 2008). The advantage of this approach is that there is less need for an 
adjuvant.  
Another alternative is DNA vaccination by which DNA encoding an antigen is inserted into a 
bacterial plasmid. Since this type of vaccines induces host cells to newly synthezise foreign 
antigens, they are effective in inducing both cellular and humoral responses. Mucosal 
administration of an ureB DNA vaccine was shown to induce both innate and cellular 
adaptive immunity in the gastric mucosa of mice and to significantly reduce H. pylori 
colonization densities after challenge infection (Hatzifoti et al., 2006). 
 
Choice of adjuvants  
The mucosal route of immunization requires the use of a strong adjuvant because proteins are 
poor mucosal immunogens. Most adjuvants are used with inactivated whole-cell or subunit 
vaccines. Live-attenuated vaccines rarely require adjuvants due to a different mode of action, 
resulting in a higher immunogenicity (Gerdts, 2015). Adjuvants are required to assist vaccines 
to induce potent and persistent immune responses, with the additional benefits that the dose 
and dosing schedule of the antigen(s) can be decreased and modulated, which reduces the cost 
and logistical complexity of administering vaccines (Davies et al., 2009). Mineral salts, such 
as alum-based vaccines and oil-water emulsions (either water-in-oil or oil-in-water) have been 
successfully used since the early 1940s in both humans and animals, and are still being used 
today.  
The strongest and most frequently used mucosal adjuvants in prophylactic H. pylori 
vaccination studies are cholera toxin (CT) and the heat-labile toxin from Escherichia (E.) coli 
(LT). CT is the virulence factor of Vibrio cholerae and consists of an A and B subunit 
(Giuliani et al., 1998). The pentameric B subunit binds to receptors on the plasma membrane 
and delivers the A subunit into the cytoplasma to exert its enzymatic activities and hence 
toxicity. CT is known to elicit strong T-cell as well as B-cell responses to vaccine 
components. However, both CT and LT cause severe diarrhea, limiting their use in humans. 
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In addition, in 2000, an intranasal vaccine (NasalFlu) was introduced in Switzerland that 
contained LT as an adjuvant. The vaccine was withdrawn after being associated with an 
increased risk of a form of transient facial paralysis called Bell´s palsy (Mutsch et al., 2004). 
The LT adjuvant shares 80% homology with CT, which is also a potent adjuvant, but can be 
toxic when used intranasally (Pizza et al., 2001). Although the adverse reactions induced by 
CT and LT prevent their use as a vaccine component, it remain excellent research tools. Their 
strong immune enhancing properties warrant their use as a reference in experimental studies 
dealing with the efficacy of other adjuvants.  
For half a century, incomplete (IFA) and complete Freund’s adjuvant (FA) have also been 
commonly used for experimental work (Billiau and Matthys, 2001). Freund’s adjuvant is a 
solution of antigen emulsified in mineral oil. The complete form is composed of inactivated 
mycobacteria (usually M. tuberculosis) whereas the incomplete form (IFA) lacks the 
mycobacterial components. FA is designed to provide continuous release of antigens, 
necessary for stimulating a strong, persistent immune response. The main disadvantage is that 
it can cause granulomas and inflammation at the inoculation site, therefore it should be 
injected subcutaneously or intraperitoneally. Intravenous injections can cause lungembolism. 
The mycobacteria in Freund’s complete attract macrophages and other cells to the injection 
site which enhances the immune response. Mostly, FA is used for the initial injections and 
IFA is used for the boosts, to minimize the side-effects. Due to its toxicity, the use in human 
patients is forbidden. Research on transgenic mice that were injected intraperitoneally with H. 
pylori lysate and FA showed a clear decrease in the number of colonizing bacteria by Th1-
mediated immune response. The combined use of FA and IFA induced a mix of Th1 and Th2 
responses (Eisenberg et al., 2003).  
Other, less frequently used adjuvants are CpG-DNA and Curdlan. Synthetic 
oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells that express 
TLR9 (including human plasmacytoid dendritic cells and B-cells) to mount an innate immune 
response characterized by the production of Th1 and proinflammatory cytokines. When used 
as vaccine adjuvants, CpG ODNs improve the function of professional antigen-presenting 
cells and boost the generation of humoral and cellular vaccine-specific immune responses. 
The adjuvant properties of CpG ODNs are observed when administered either systemically or 
mucosally, and persist in immunocompromised hosts. Preclinical studies indicate that CpG 
ODNs improve the activity of vaccines targeting infectious diseases and cancer. Clinical trials 
demonstrate that CpG ODNs have a good safety profile and increase the immunogenicity of 
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co-administered vaccines (Bode, 2011). Cox et al. (2006) also describe CpG-ODN motifs 
with immunostimulatory properties for several domestic animals, including pigs, making 
them a potentially interesting adjuvant. 
Curdlan is a β-(1,3)-glucan, produced by the bacterium Alcaligenes faecalis. It is a PAMP 
recognized by several receptors including dectin-1, which is predominantly expressed on the 
surface of cells of the monocyte/macrophage and neutrophil lineages (Taylor et al., 2002). 
Activation of dectin-1 promotes signaling, ultimately resulting in the production of pro-
inflammatory cytokines, thus inducing inflammation. Curdlan, when used as an adjuvant, is 
known to elicit a predominant Th17 response and can be administered intranasally as well as 
subcutaneously. 
 
Vaccination routes 
In addition to different antigens and adjuvants, the choice of the administration route also 
plays an important role in the development of a vaccine. In general, Helicobacter vaccination 
strategies have been designed to generate an optimal immune response at the mucosal surface, 
in line with strategies designed for other mucosal bacterial infections (Blanchard and Nedrud, 
2010). Alternatives to the intragastric route have been investigated, due to additional 
challenges on the stability of the antigen and adjuvants used. The intranasal and sublingual 
route of immunization have consistently proved to induce a stronger protection against H. 
pylori infection compared to the intragastric route. However, intranasal immunization is 
associated with a risk of translocation of GM1-binding adjuvants like CT to the olfactory bulb 
of the brain, restricting its applicability in humans (Van Ginkel et al., 2000). The sublingual 
route has been reported to be safe in mice and particularly suitable when using antigens or 
adjuvants that might be sensitive to the harsh environment of the stomach (Czerkinsky et al., 
2011). However, mucosal immunization alone often requires two or three boosters for an 
effective immune response leading to reduction in the bacterial load in the stomach of mice 
(Sutton et al., 2000). 
Since H. pylori also recruits inflammatory cells from the circulation (Blanchard and Nedrud, 
2010), protective immunity may also be achieved through parenteral vaccination. A certain 
degree of protection has been described using prophylactic and therapeutic vaccination via 
several parenteral administration routes, mostly accompanied by adjuvants, such as Freund’s 
complete and incomplete adjuvant (Eisenberg et al., 2003; Morihara et al., 2007) and 
aluminum hydroxide (Ermak et al., 1998; Gottwein et al., 2001; Nyström et al., 2006). 
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Complete protection was however rarely observed and culture techniques were used to assess 
protection, which might not be the most sensitive evaluation method. 
 
Obstacles for successful vaccination 
The role of Tregs in H. pylori vaccination was first described in the mouse model where it 
was shown to dampen the H. pylori induced-immunopathology by reducing the activation of 
CD4+ IFN-γ producing cells (Raghavan et al., 2003; Kaparakis et al., 2006; Rad et al., 2006; 
Sayi et al., 2009). Vaccination combined with Treg depletion has been suggested as strategy 
to enhance the protective effect of the vaccine. However, further investigation is required 
since blocking Treg activity might evoke auto-immune manifestations (Bayry et al., 2014). 
Several studies have characterized the immune cell infiltration in the stomach of immunized 
mice compared to immunized infected mice, reporting enhanced infiltration of CD4+ T-cells, 
B-cells, neutrophils, M1 macrophages, DCs, mast cells, eosinophils and chemokine and 
cytokine response post challenge (Ermak et al., 1998; Quiding-Jabrink et al., 2010; Flach et 
al., 2011; Hitzler et al., 2011; Flach et al., 2012). This is referred to as post-immunization 
gastritis. It is often associated with the degree of protection against colonization as shown by 
a clear correlation between the severity of post-immunization gastritis and reduction of the 
bacterial load (Goto et al., 1999; Garhart et al., 2002; Morihara et al., 2007). Post-
immunization gastritis may be transient, challenge strain dependent, and may or may not 
occur in different animal models (Robinson et al., 2007). For example, protection in the 
Mongolian gerbil model is not accompanied by post-immunization gastritis (Jeremy et al., 
2006). Further studies are warranted for the future development of vaccines based on the 
induction of appropriate immune responses with minimal post-immunization gastritis. 
In conclusion, combating H. pylori infections remains a major challenge for developing 
countries, where relatively high prevalence rates exist. As mentioned above, antibiotic therapy 
is a non-sustainable and sometimes inadequate strategy in the battle against H. pylori due to 
increased antimicrobial resistance. Therefore, the development of new vaccination strategies 
should be one of the main foci of future research. Certain progress has been made in the 
development of vaccines against H. pylori infection. However, unresolved issues for vaccine 
production include the complicated host immune response evoked by this pathogen, and the 
high genetic diversity in H. pylori. In addition, given the importance of adjuvants to, not only 
gastric Helicobacter vaccines, but vaccines in general, we can conclude that further research 
is required to better understand adjuvant action and how this might relate to adjuvant toxicity. 
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New adjuvants are needed that are potent enhancers of a specific type of immune response, as 
required for induction of protective immunity without compromising safety for humans and 
animals.  
 Vaccination against gastric non-Helicobacter pylori helicobacters  
Apart from H. felis, only a limited number of studies investigated immunization strategies 
against other gastric NHPH (Table III). Dieterich et al. (1999) performed immunization with 
‘Helicobacter heilmannii’ urease B administered intranasally together with CT as adjuvant in 
a BALB/c mouse model. Protection was achieved however, these results should be interpreted 
with caution since gastric tissue of ‘H. heilmannii’-infected mice was used for the challenge 
and the exact species of this strain was unknown. Urease, which is a highly conserved protein 
among Helicobacter species had already been used in different vaccination studies against H. 
pylori (Kleanthous et al., 1998; Marchetti et al., 1998) or H. felis infections (Michetti et al., 
1994). Given the high degree of amino-acid conservation between H. pylori and H. felis 
urease enzyme, this protein most probably plays a role in the induction of cross-protection 
(Ferrero et al., 1994). In an immunization experiment by Hellemans et al. (2006) it was shown 
that both mucosal (with CT) and systemic immunization (with a saponin-based adjuvant) with 
heterologous whole bacterial cell lysate of H. pylori or H. felis and challenge with 
‘Candidatus H. suis’, which was at that time unculturable, caused a decrease in faecal 
excretion of ’Candidatus H. suis’ DNA in mice. However, as shown by conventional PCR on 
the stomach samples, complete clearance was not achieved.  
As previously mentioned, H. suis was successfully cultivated in vitro in 2008, which paved 
the way for new immunization studies with this bacterium (Baele et al., 2008). Prophylactic 
subcutaneous immunization of mice with whole bacterial cell lysates of H. suis, H. 
cynogastricus and H. bizzozeronnii was not protective against H. suis challenge (Flahou et al., 
2009). Prophylactic intranasal immunization using a homologous (H. suis) or heterologous 
(H. cynogastricus and H. bizozeronnii) whole-cell lysate induced a protective response against 
H. suis, resulting in a minority of animals being H. suis negative, as shown by conventional 
PCR and urease activity test. However, increased mortality rates were observed in these 
vaccinated and challenged animals (Flahou et al., 2009).  
An effective subunit vaccine might be a useful alternative for whole-cell lysates to control 
gastric NHPH infections. Vermoote and colleagues evaluated the protective efficacy of 
several subunit vaccine candidates, which was compared with that of whole-cell lysate in a 
General Introduction 
 
44 
 
mouse model. A subunit vaccine based on H. suis UreB, which was recombinantly expressed 
in E. coli (rUreB) was developed. Intranasal immunization with rUreB and cholera toxin (CT) 
resulted in a significant decrease of the bacterial load in the gastric mucosa, but could not 
prevent Helicobacter colonization. Immunization with whole-cell lysate, however, induced 
higher levels of protection compared to immunization with rUreB (Vermoote et al., 2012). 
Therefore, the efficacy of rUreB in combination with another H. suis protein was investigated 
(Vermoote et al., 2013). Simultaneous and consecutive immunization with the recombinant H. 
suis GGT (rGGT) and rUreB induced better protection against a subsequent H. suis challenge 
compared to immunization with single proteins. A complete clearance was observed in 
approximately 50% of the mice which is similar to the protection induced by a whole-cell 
lysate. This suggests that multiple antigens may be necessary for the development of a truly 
protective vaccine against H. suis. However, again, increased mortality rates were observed 
which might be due to the intranasal use of CT as adjuvant, which might have caused swelling 
of the nasal cavity mucosae, resulting in oxygen deficiency. 
Although these studies show promising results, it is still unclear how to promote the 
development of immunity with the final goal of a successful vaccine. Further research should 
focus on a better understanding of the innate and adaptive immune responses towards a H. 
suis infection in animal models and pigs, with emphasis on the role of dendritic cells and the 
development of safe and efficient vaccine adjuvants. 
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Table III. Prophylactic vaccination studies against H. suis in mice 
 
Antigen Adjuvant Route Conclusions Reference 
H. heilmanni s.s. UreB CT IN BALB/c mice protected against H. heilmannii infection (prophylactic)  Dieterich et al. (1999) 
H. pylori urease 
  
Significantly reduces a pre-existing infection (therapeutic) 
       Immunization aggravates gastric corpus atrophy   
H. pylori whole-cell lysate 
CT/saponin-based 
adjuvant 
IN/SC Decrease in faecal excretion of “Candidatus H. suis” DNA 
Hellemans et al. 
(2006) 
H. felis whole-cell lysate     Complete clearance of challenge bacteria was not achieved   
H. suis whole-cell lysate 
CT/saponin-based 
adjuvant 
IN/SC H. suis colonization suppressed  Flahou et al. (2009) 
H. bizzozeroni whole-cell lysate 
  
Complete protection only in a minority of animals following  
 H. cynogastricus whole-cell lysate     intranasal immunization   
H. suis whole-cell lysate CT IN UreB and lysate induced a significant decrease in H. suis colonization Vermoote et al. (2012) 
H. suis UreB 
  
NapA induced no significant decrease in H. suis colonization  
 H. suis NapA         
H. suis whole-cell lysate CT IN All immunization protocols induced a significant reduction of H. suis  Vermoote et al. (2013) 
H. suis UreB 
  
colonization which was least pronounced in groep with rUreB and 
 H. suis GGT 
  
rGGT alone 
 H. suis UreB+GGT     Less gastric lesions in groups with combination of rUreB and rGGT  
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Helicobacter (H.) suis is a bacterium that predominantly colonizes the stomach of pigs and 
several non-human primates worldwide. In addition, this bacterium is the most prevalent non-
Helicobacter pylori Helicobacter species present in humans suffering from gastric disease. In 
pigs, infection with H. suis causes chronic gastritis and a decrease in daily weight gain. 
Several studies attribute a role to this pathogen in the development of gastric ulcers. For a 
long time, the research on H. suis was hampered by the lack of pure in vitro cultures. The 
development of an isolation and cultivation protocol in 2008, paved the way for further 
research on pathogenesis, host immune response and possible strategies to control H. suis 
infections.  
The overall aim of this doctoral research was to develop new control strategies against H. 
suis infection, based on a better understanding of the mechanisms of a protective immune 
response. 
Unlike H. pylori, limited information is available about the immune response evoked by H. 
suis infections in its different hosts. A good knowledge about innate and adaptive immune 
responses is necessary for the future improvement of vaccination strategies against gastric 
Helicobacter infections. The first specific aim was to investigate immunity to H. suis, both 
after experimental infection of BALB/c mice, and in naturally infected pigs at slaughter age. 
H. suis isolates obtained from primates seem to be more virulent compared to porcine strains, 
since experimental H. suis infection of mice has previously been shown to lead to the 
development of gastric lymphoid follicles, which is not observed when using porcine strains. 
However, direct comparison between these H. suis strains was not straightforward in the past, 
since no pure in vitro isolated H. suis cultures from primates were available. Recently, we 
succeeded in cultivating H. suis strains in vitro from the stomach of cynomolgus monkeys, as 
well as rhesus monkeys. Differences in virulence might influence the host response against 
infection. Therefore, the second specific aim was to obtain insights into potential differences 
between pig- and primate-associated H. suis strains in terms of virulence and pathogenesis in 
a BALB/c mouse and Mongolian gerbil model.  
Antibiotic-based treatment to control gastric Helicobacter infections is not recommended due 
to the rise of antimicrobial resistance and as such, vaccination is considered to be a valuable 
approach to combat infections with this highly prevalent pathogen. Previously, only cholera 
toxin and a saponin-based adjuvant were used in H. suis vaccination studies. Therefore, the 
third specific aim was to investigate the efficacy and safety of several established and new 
vaccine adjuvants, along with H. suis whole-cell lysate, to protect against subsequent H. suis 
challenge in a BALB/c infection model. 
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ABSTRACT 
Background: Helicobacter (H.) suis is mainly associated with pigs, but is also the most 
prevalent gastric non-H. pylori Helicobacter species found in humans. In the absence of 
proper treatment, both H. pylori and H. suis may cause persistent infection of the stomach. 
Several immune evasion mechanisms have been proposed for H. pylori, which focus to a 
great extent on the major H. pylori virulence factors, which are absent in H. suis.  
Materials and methods: To gain more knowledge on immune evasion by H. suis, cytokine 
expression kinetics were monitored in the stomach of BALB/c mice after experimental H. suis 
infection. The cytokine expression profile in the stomach of naturally H. suis infected pigs 
was determined. Subsequently, the effect of H. suis on murine and porcine dendritic cell (DC) 
maturation and their ability to elicit T-cell effector responses was analyzed.  
Results: Despite an Th17/Th2 response in the murine stomach, the inflammatory cell influx 
was unable to clear H. suis infection. H. suis-stimulated murine bone marrow-derived 
dendritic cells induced IL-17 secretion by CD4+ cells in vitro. Natural H. suis infection in pigs 
evoked increased expression levels of IL-17 mRNA in the antrum and IL-10 mRNA in the 
fundus. In contrast with mice, H. suis-stimulated porcine monocyte-derived dendritic cells 
were unable to express MHCII molecules on their cell surface. These semi-mature DCs 
induced proliferation of T-cells, which showed an increased expression of TGF-β and FoxP3 
mRNA levels.  
Conclusions: H. suis might evade host immune responses by skewing towards a Treg-biased 
response. 
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Introduction 
Helicobacter suis (H. suis) is a pathogen of pigs worldwide. It mainly colonizes the porcine 
stomach (Haesebrouck et al., 2009). Infections with this bacterium have been associated with 
ulceration of the gastric non-glandular mucosa, gastritis and a decreased daily weight gain in 
pigs (Haesebrouck et al., 2009; De Bruyne et al., 2012). A good knowledge about the immune 
responses that can protect against gastric Helicobacter infections or that can clear an existing 
infection is necessary for the potential development of vaccines. However, available literature 
focusses mainly on the immune response evoked by H. pylori infections. Limited information 
is available about the immune response evoked by H. suis infections. In addition, to our 
knowledge the immune response following H. suis infection in its natural host, the pig, has 
not been investigated.  
In BALB/c and C57BL/6 mice, experimental H. suis infection generally causes a predominant 
Th17 response in their stomach, accompanied by a mild Th2 response, mainly in BALB/c 
mice (Flahou et al., 2012; Zhang et al., 2015). The immune response induced by H. pylori 
infection on the other hand, is characterized by a Th17/Th1 response and the absence of a Th2 
response in C57BL/6 and BALB/c mice (Shi et al., 2010). This different immune response 
could play a role in the development of different pathologies by Helicobacter species. Lesion 
severity associated with H. suis infection in humans is often less than with H. pylori infection 
(Stolte et al., 1997). Chronic H. suis infection in humans mainly causes the development of 
mucosa-associated lymphoid tissue (MALT) lymphoma-like lesions, whereas H. pylori causes 
predominantly metaplastic/dysplastic changes (Morgner et al., 2001; Nakamura et al., 2007; 
Yang et al., 2015). In addition, in humans H. pylori mainly colonizes the surface of the gastric 
epithelium, whereas H. suis is often found in the vicinity or in the canaliculi of parietal cells, 
which might also explain the differences in pathogenesis (Joo et al., 2007). Both H. pylori and 
H. suis may persist for life in the host in the absence of proper treatment. However, it remains 
largely unclear how they evade clearance in the presence of Helicobacter-specific immunity. 
Several immune evasion mechanisms have been proposed for H. pylori, which focus to a 
great extent on the CagA protein, encoded in the cag (cytotoxin-associated gene) 
pathogenicity island (cagPAI), and vacuolating toxin A (VacA) (Lina et al., 2014). VacA 
inhibits dendritic cell (DC) maturation and is known to impair antigen presentation by DCs 
(Wang et al., 2010; Kim et al., 2011). In addition, VacA may inhibit T-cell proliferation and 
signaling (Lina et al., 2014). CagA inhibits CD4+ T-cell differentiation towards Th1 effector 
cells (Tanaka et al., 2010). However, both CagA and VacA are absent in H. suis (Vermoote et 
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al., 2011). Gamma-glutamyl transpeptidase (GGT), a well conserved virulence factor in the 
genus Helicobacter, is also involved in inhibition of T-cell proliferation. The inhibitory effect 
of GGT can be linked to cell cycle arrest in the G1 phase and to its enzymatic activity 
(Gerhard et al., 2005; Schmees et al., 2007; Zhang et al., 2015). In addition, high levels of 
CD4+CD25high regulatory T-cells, that efficiently block effector T-cell responses, have been 
detected in the gastric mucosa of H. pylori infected patients, which probably also contribute to 
bacterial persistence (Lundgren et al., 2005).  
The aim of the present study was to investigate the immunity to H. suis infection. Therefore, 
the dynamics of cytokine expression in the stomach of BALB/c mice after experimental H. 
suis infection were monitored as well as the gastric cytokine expression profile of naturally H. 
suis infected pigs. Subsequently, the effect of H. suis on murine and porcine DC maturation 
and their ability to stimulate T-cell proliferation in vitro was investigated. To assess the T 
helper response to which H. suis-stimulated DCs skew naive T-cells, the mRNA expression 
profile of key transcription factors and cytokines involved in T-cell polarization was 
determined.  
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Materials and methods 
Experimental infection study in BALB/c mice 
Female SPF BALB/c mice of 4 weeks old were purchased from Harlan (Harlan NL, Horst, 
The Netherlands). The animals were housed on autoclaved wood shavings in filter top cages 
and were fed an autoclaved commercial diet (TEKLAD 2018 S, HARLAN). All animal 
procedures were approved by the Ethics committee of the Faculty of Veterinary Medicine, 
Ghent University (EC2009/87). Mice were inoculated once with 1.8 x 107 viable bacteria per 
inoculum (300 µl). The control mice received an equal volume of sterile bacterial growth 
medium. On days 1, 2, 3, 5, 7, 15, 28, 50, 70, 74 and 87 after inoculation, five mice from the 
infected group and five mice from the control group were euthanized and the stomachs were 
removed for further processing.  
 
Sample collection from pigs 
Stomachs (n=107) from approximately six-month-old slaughter pigs from ten different herds 
were collected in a Belgian abattoir. Samples from the different regions of the stomach (pars 
oesophagea, cardia, antrum and fundus) were taken for DNA and RNA extraction and 
histopathological examination. Whole blood samples (n=12) were collected from pigs in 
EDTA-coated recipients in a Belgian abattoir. 
 
H. suis strains 
H. suis strain HS5bLP, isolated from the stomach of a sow (Baele et al., 2008), was used for 
the inoculation of the mice, preparation of whole-cell lysate and heat-inactivation. Bacteria 
were cultured under microaerobic conditions (85% N2, 10% CO2, 5% O2; 37°C) on biphasic 
Brucella (Oxoid, Basingstoke, UK) culture plates supplemented with 20% fetal calf serum 
(HyClone, Logan, UT, USA), 5 mg/l amphotericin B (Bristol-Myers Squibb, Epernon, 
France), Campylobacter selective supplement (Skirrow, Oxoid; containing 10 mg/l 
vancomycin, 5 mg/l trimethoprim lactate and 2500 U/l polymyxin B) and Vitox supplement 
(Oxoid). In addition, the pH of the agar was adjusted to 5 by adding HCl to a final 
concentration of approximately 0.05%. Brucella broth (Oxoid) with a pH of 5 was added on 
top of the agar to obtain biphasic culture conditions. After 3 days of incubation, the Brucella 
broth, containing the bacteria, was harvested (Baele et al., 2008). For the preparation of the H. 
suis lysate, bacteria were washed, concentrated by centrifugation (5000g, 10 min, 4°C) and 
suspended in phosphate buffered saline (PBS). The bacterial suspension was sonicated 8 
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times for 30 seconds, with a frequency of 20 kHz (Sonicator ultrasonic processor XL 2015; 
MISONIX, Farmingdale, USA), resulting in lysis of the bacteria. After centrifugation 
(13000g, 10 min, 4°C), the supernatant fluid was collected and stored at -70°C until further 
use. The protein concentration of the sonicate was determined using the Lowry assay (Flahou 
et al., 2009). 
For preparation of heat-inactivated H. suis, bacteria were washed, centrifuged and placed in a 
hot water bath at 95°C for 10 minutes. 
 
Quantitative Real-Time PCR for the quantification of bacteria 
DNA was extracted from the murine and porcine stomach tissue using the DNeasy blood and 
tissue extraction kit (Qiagen, Venlo, The Netherlands). Quantitative Real-Time PCR (qPCR) 
was performed using the C1000TM Thermal cycler (CFX96TM Real-Time System, Bio-Rad, 
Hercules, CA, USA) for enumeration of colonizing bacteria. Each sample contained 5 µl of 
iQTM SYBR® Green Supermix (Bio-Rad), 0.25 µl of each primer, 3.5 µl of distilled water and 
1 µl of template DNA. A fragment of the ureA gene of H. suis was amplified using the 
following primers: sense primer BF_HsuisF1: 5′-AAA ACA MAG GCG ATC GCC CTG 
TA-3′ and anti-sense primer BF_HsuisR1: 5′-TTT CTT CGC CAG GTT CAA AGC G-3′. For 
generating the standard, part of the ureAB gene cluster (1236 bp) from H. suis strain HS5 was 
amplified using primers U430F and U1735R as described previously (O’Rourke et al., 2004). 
The copy number concentration was calculated based on the length of the amplicon and the 
mass concentration. The standard consisted of 10-fold dilutions starting at 107 PCR amplicons 
for each 10 µl of reaction mixture. Data analysis was done using the Bio-Rad CFX Manager 
Version 3.0 software (Bio-Rad). 
 
Quantitative Real-Time PCR for the analysis of cytokine/chemokine expression  
For RNA isolation, the murine and porcine stomach tissue and cell cultures were 
homogenized in Tri-reagent (MRC, Brunschwig Chemie, Amsterdam, The Netherlands) using 
a MagnaLyser (Roche Applied Science, Mannheim, Germany). Total RNA was extracted 
from the upper aqueous phase using the RNeasy mini kit (Qiagen). The mRNA (1 µg) was 
reverse transcribed into cDNA using the iScriptTM cDNA Synthesis Kit (Bio-Rad). For the 
qPCR reaction, a C1000TM Thermal cycler was used. All reactions were performed in a final 
volume of 12 µl containing 5 pM of the sense and 5 pM of the antisense primers, 5 µl iQ 
SYBR mix and 2 µl cDNA. The reaction protocol consisted of an initial activation phase at 
95°C for 15 minutes followed by 40 cycles of 95°C for 20 seconds, 60°C for 30 seconds and 
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73°C for 30 seconds. A melting curve was included by increasing the temperature with 0.5°C 
every 5 seconds starting from 65°C until 95°C. In the mouse model, H2afz, PPIA and HPRT 
were chosen for normalization, since they were the most stable reference genes as determined 
using GeNorm version 3.4 (Vandesompele et al., 2002). For the porcine samples, the 
reference genes Cyc-5, ACTB and HPRT were shown to have a stable expression and were 
included as references. The sequences of all used primers are summarized in Additional files 
1 and 2. The threshold cycle values (Ct) were first normalized to the geometric means of the 
reference genes and the normalized mRNA levels were calculated according to 2(-∆∆Ct) method 
for each individual animal (Livak and Schmittgen, 2001).  
 
Histopathological evaluation of the gastric wall 
Samples of murine and porcine stomachs were formalin-fixed, paraffin wax embedded, cut at 
5 µm and stained with hematoxylin and eosin according to standardized protocols. The 
presence of gastric follicles, lymphocyte and neutrophil infiltration in the mucosa and 
submucosa of the different parts of the stomach was scored using a scoring system adapted 
from the human updated Sydney System, but with some modifications: 0 = normal, 1 = mild, 
2 = moderate, 3 = severe (Stolte et al., 2001).  
 
Generation of murine bone marrow-derived dendritic cells  
Murine bone marrow-derived dendritic cells (BMDCs) were obtained from the femurs of 7-10 
week old uninfected BALB/c mice. Bone marrow was passed through a 40 µm cell strainer 
(Becton Dickinson, Erembodegem, Belgium). Cells were cultured in complete RPMI medium 
containing 1 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 10% FCS, 50 
µM β-mercaptoethanol and 20 ng/ml recombinant mouse (rm) granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (Gibco, Merelbeke, Belgium). On day 3, the medium 
was replaced and on day 6, non-adherent differentiated BMDCs were harvested and cultured 
with medium supplemented with 10 ng/ml rm GM-CSF and 1 µg/ml lipopolysaccharide 
(LPS) from Escherichia coli (0111:B4; Sigma Aldrich, Bornem, Belgium) or 5 µg/ml H. suis 
lysate. Hank’s balanced salt solution (HBSS; Invitrogen, Paisley, United Kingdom) served as 
negative control. On day 7, BMDCs were harvested for flow cytometric analysis and 
supernatant was collected for enzyme-linked immunosorbent assay (ELISA). 
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Generation of porcine monocyte-derived dendritic cells  
SIRPα+ cells, isolated from the peripheral blood mononuclear cell (PBMC) fraction from 
porcine whole blood samples were used to generate immature monocyte-derived dendritic 
cells (MoDCs). Peripheral blood mononuclear cells (PBMCs) were isolated from porcine 
whole blood samples by Ficoll Paque PLUS (GE Healthcare, Diegem, Belgium) density 
gradient centrifugation. Monocytes were enriched by immunomagnetic bead selection 
(MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) to a purity of >95%, using an 
antibody against the pan-myeloid marker SIRPα and goat anti-mouse IgG Microbeads 
(Miltenyi biotec). The cell suspension was loaded onto an LS Column (Miltenyi Biotec) 
which was placed in the magnetic field of a MACS separator. Monocytes were cultured in 24-
well plates (Cellstar, Greiner Bio one, Vilvoorde, Belgium) at a density of 5 x 105 cells/ml in 
Dulbecco’s modified Eagle’s Medium (Gibco) supplemented with 10% (v/v) FCS (Hyclone, 
GE Healthcare), 100U/ml penicillin (Sigma Aldrich), 100 µg/ml streptomycin (Sigma 
Aldrich), recombinant porcine (rp) granulocyte-macrophage colony stimulating factor (GM-
CSF, R&D systems, Abingdon, United Kingdom) and rp IL-4 (R&D systems) and incubated 
at 37°C in a humified atmosphere at 5% CO2 to generate immature monocyte-derived 
dendritic cells (MoDCs). On day 3 of the culture period, fresh medium was added. On day 4 
or 5 of the culture period, cells with long protrusions were present (Devriendt et al., 2013). 
MoDCs were stimulated with H. suis lysate (10 µg/ml) or heat-inactivated H. suis (MOI = 50) 
for 24 h at 37°C, 5% CO2 in a humified atmosphere. MoDCs stimulated with LPS (10 µg/ml) 
were used as positive control. MoDCs stimulated with HBSS served as negative control. After 
24 h, the cells were harvested for flow cytometric analysis and qPCR. 
 
Cell surface expression of DC markers 
To study the presence of cell surface markers on murine BMDC stimulated with H. suis, LPS 
or HBSS, cells were stained with CD11c-allophycocyanin (clone HL3; BD biosciences, 
Erembodegem, Belgium), MHCII-FITC (clone 14-4-4S; eBioscience, San Diego, United 
States), CD40-FITC (clone HM40-3; eBioscience), CD86 (B7-2)-FITC (clone GL1; 
eBioscience), CD80 (B7-1)-FITC (clone 16-10A1; eBioscience) or the isotype-matched 
controls for 1 hour at 4°C in the dark and subsequently washed with buffer. Propidium iodide 
(5 µg/ml) was added, the live CD11c+cells were gated, analyzed on a FACSCalibur (BD 
Pharmingen) and data were processed using CellQuest software. 
Likewise, to assess the cell surface expression of activation markers upon stimulation of 
porcine MoDCs by flow cytometry, the cells were stained for 20’ at 4°C with mAbs against 
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MHCII (MSA3, Divbio science, Ulvenhout, The Netherlands), CD40 (clone G28.5; Imtec 
diagnostics, Antwerp, Belgium), CD25 (clone K231.3B2; AbD Serotec, Kidlington, UK) and 
a human CTLA-mulgG2a fusion protein (Enzo lifesciences, Antwerp, Belgium), which is able 
to bind to porcine CD80 and CD86 (Vaughan et al., 2000), followed by FITC conjugated 
isotype-specific anti-mouse secondary antibodies (Life technologies) for 20’ at 4°C. Cells 
stained with the isotype-matched controls were used to assess aspecific binding. Next, the 
cells were washed, propidium iodide (5 µg/ml) was added and data were acquired on a 
FACSCanto or Cytoflex. Data were processed using FacsDiva 6.1.3 software (BD 
biosciences) or CytExpert software (Analis, Sint-Denijs Westrem, Belgium). 
 
Co-culture of murine BMDCs and CD4+ T cells  
CD4+ cells from murine lymph nodes were co-cultured with H. suis lysate-stimulated 
BMDCs. Negative controls consisted of CD4+ T helper cells co-cultured with untreated 
BMDCs. CD4+ T helper cells were isolated from gastric lymph nodes of infected mice by 
negative selection through magnetic bead depletion of unwanted cells (Stemcell 
Technologies, Grenoble, France) as described by the manufacturer. BMDCs pulsed with H. 
suis were co-cultured with CD4+ T helper cells (1:5) for 48 hours and the supernatant was 
stored at -70°C for ELISA.  
 
Co-culture of porcine MoDCs and CD6+ T-cells 
The T-cell stimulatory capacity of porcine MoDCs was analyzed in an allogenic T-cell 
proliferation assay. T-cells were isolated from the PBMC fraction by enriching CD6+ cells to 
a purity of >95% by positive immunomagnetic selection with the α-CD6 mAb (IgG2a, clone 
MIL8, AbD Serotec) and goat anti-mouse IgG microbeads (Miltenyi Biotec). Stimulated 
MoDCs were co-cultured in duplicate at titrated numbers with 2.0 x 105 allogenic CD6+ T- 
cells in round-bottomed 96-well microtiter plates (Greiner Bio one, Vilvoorde, Belgium) for 5 
days. Cell cultures were maintained in DMEM, 10% FCS, penicillin/streptomycin and 2-
mercapto-ethanol (50 µM) at 37°C in a humified atmosphere at 5% CO2. After 5 days, the 
cells were pulsed labelled with 1 µCi/well (3H methyl-thymidine, Amersham ICN, Bucks, 
UK) for 18 h. Cells were harvested onto glass fiber filters (Perkin-Elmer, Life science, 
Brussels, Belgium) and the (3H) methyl-thymidine incorporation was measured using a β-
scintillation counter (Perkin-Elmer). Cytokine expression was determined in the cell cultures 
after 5 days of co-incubation using qPCR. 
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Staining of cytokine secreting murine cells 
The mouse IL-17 secretion assay is designed for the isolation, detection and analysis of viable 
IL-17A-secreting mouse leukocytes (Mouse IL-17 Secretion Assay - Cell Enrichment and 
Detection Kit (PE), Miltenyi Biotec). Gastric lymph node cells were co-cultured with H. suis 
pulsed BMDCs or unstimulated BMDCs for 48 hours. Subsequently, an IL-17-specific catch 
reagent was attached to the surface of all leukocytes. The cells were then incubated for 45 
minutes at 37 °C to allow cytokine secretion. The secreted IL-17 binds to the IL-17 catch 
reagent on the positive secreting cells. Next, these cells were labelled with a second IL-17 
specific antibody, the mouse IL-17 detection antibody conjugated to Biotin and Anti-Biotin-
PE on ice. The IL-17-secreting cells were magnetically labeled with anti-PE Microbeads 
UltraPure and enriched over a MACS Column which was placed in the magnetic field of a 
MACS separator. Staining of the IL-17 secreting cells was performed using CD4-APC (clone 
GK1.5, Miltenyi Biotec). For optimal sensitivity, undesired non-T-cells such as B 
lymphocytes were stained with CD45R (B220)-VioBlue (clone RA3-6B2, Miltenyi Biotec). 
Dead cells were stained with propidium iodide (5 µg/ml). Data was analyzed using flow 
cytometry (FACSCalibur) and processed using CellQuest software. 
 
Neutrophil chemotaxis assay  
The murine gastric epithelial cell line GSM06 was cultured in DMEM/F12 medium 
supplemented with 10% FCS, 1 ml ITS (Gibco), 100 U/ml penicillin, 100 µg/ml streptomycin 
and 2 ng/ml murine epidermal growth factor (mEGF; Sigma Aldrich). Cells were grown at the 
permissive temperature of 33°C and experiments were conducted at 37°C. For the neutrophil 
chemotaxis assay, 5 x 105 GSM06 cells were seeded in 24-well plates. After 24 hours, cells 
were incubated in cell medium supplemented with 100 ng/ml recombinant mouse IL-17 
(recIL-17, eBioscience), live H. suis (MOI=100) or both for 24 h. HBSS-treated cells served 
as negative controls, while positive controls consisted of medium supplemented with 40 
ng/ml recombinant mouse MIP-2 (recMIP-2, eBioscience). Optimal concentrations of IL-17 
and MIP-2 were determined previously. Conditioned medium was centrifuged for 5 min at 
14000xg and 500 µl was added to the basolateral chamber of transwell polyester membrane 
filters (6.5 mm diameter inserts, 3.0 µm pore size; Corning, New York, United States). 
Neutrophils were isolated out of bone marrow from femurs of 7-10 week old BALB/c mice 
on a Percoll gradient as described by Boxio and colleagues (2004). The purity was assessed 
by flow cytometry after staining with FITC conjugated rat anti-GR-1 antibody (eBioscience) 
and was > 94%. 6 x 105 neutrophils/ml were put in the apical chamber. After 45 minutes, 
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transmigrated cells in the basolateral chamber were counted and normalized to the initial 
amount of cells in the apical chamber. 
 
ELISA 
Murine cell culture supernatant was analyzed for the presence of IL-6, IL-23 and IL-17 using 
commercially available ELISA kits (eBioscience) according to the manufacturer’s 
instructions. Briefly, microtiter plates were coated overnight at room temperature with capture 
antibody (Ab), washed, blocked and samples and standards were added in duplicate and 
detected with the detection Ab and the avidin-HRP system. Optical densities were measured 
in an ELISA plate reader at 450nm. Standard curves were included on each plate to determine 
concentrations expressed as pg/ml ± standard error. 
 
Statistical analysis. 
For statistical analysis, SPSS23 software was used. Statistical significance of DC marker 
expression, T-cell proliferation and cytokine secretion/expression was analyzed by non-
parametric Mann-Whitney U test corrected with Bonferroni. P-values <0.05 were considered 
statistically significant. 
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Results 
H. suis persistently colonizes BALB/c mice 
All mice were consistently colonized within one day after inoculation with H. suis strain 
HS5bLP. H. suis numbers increased progressively to reach a maximum on day 7 (1.6 x 106 ± 
0.3 x 106 bacteria/mg), after which numbers of colonizing H. suis bacteria remained relatively 
stable (Figure 1). H. suis was never detected in the control mice. 
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Figure 1. Kinetics of H. suis colonization after experimental infection of BALB/c mice. 
Colonization numbers of H. suis were assessed on day 1, 2, 3, 5, 7, 15, 28 and 50 after inoculation. 
The bacterial load is presented as log(10) of H. suis copies/mg stomach tissue at different time points 
(n=5 mice for each time point). The results are expressed as means ± standard error. 
 
 
Th17 is the dominant adaptive immune response in H. suis infected BALB/c mice 
The transcript levels of several chemo- and cytokines were evaluated to assess the kinetics of 
the local pro-inflammatory gene expression profile associated with H. suis colonization in the 
stomach. Keratinocyte chemoattractant (KC or CXCL1), LPS-induced CXC chemokine (LIX) 
and macrophage inflammatory protein-2 (MIP-2 or CXCL2) were all detected during H. suis 
infection (Figure 2). Increased mRNA expression levels of KC and LIX were detected starting 
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from day 5 post infection, while the MIP-2 mRNA expression level fluctuated more and 
increased expression was only significant on day 7 and day 50 post infection. The IL-17A 
mRNA expression level was upregulated in all infected mice 28 days post infection and 
continued to increase over time, while the mRNA expression level of the Th2 cytokine IL-4 
was significantly increased at day 50 post infection (Figure 2). No significant increased 
mRNA expression levels of the Th1 marker INF-γ were observed. These results demonstrate 
that BALB/c mice elicit a Th17/Th2 response, which is not preceded by a dominant Th1 
response in the initial phases after infection. 
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Figure 2. Relative gene expression of cytokines and chemokines in the stomach of BALB/c mice. 
The relative gene expression of KC, IL-17A, LIX, IL-4, MIP-2 and IFN-γ on day 1, 2, 3, 5, 7, 15, 28 
and 50 after infection is shown. Data are presented as the mean fold change ± standard error. An * 
indicates a value of P< 0.05 compared to the control group at the same time point. Squares represent 
the infected animals (n=5), while triangles represent the control animals (n=5). 
 
Infection of BALB/c mice with H. suis results in a mixed neutrophil/mononuclear cell 
influx 
As H. suis colonization triggered increased expression of several CXC chemokines involved 
in attracting neutrophils and mononuclear cells, the inflammatory cell influx in the gastric 
mucosa and submucosa due to H. suis infection was assessed. Samples of the stomach were 
taken from long term infected mice for histopathological evaluation (70, 74 and 87 days post 
infection). Both neutrophils and mononuclear cells were present in the mucosa and 
submucosa at all time points (Figure 3). The neutrophil influx fluctuated more than that of the 
mononuclear cells, which remained stable over the entire sampling period. Histopathological 
evaluation of gastric samples of uninfected mice was consistent with normal gastric mucosa, 
except for 1 mouse for which neutrophil and mononuclear cell infiltration scores in the 
mucosa was 1 and in the submucosa 2 (data not shown). 
 
 
Figure 3. Infiltration of neutrophils and mononuclear cells in the gastric mucosa and submucosa 
after H. suis infection. Mice were infected with H. suis or sham-inoculated and euthanized 70, 74 and 
87 days post infection (n=5). The influx of neutrophils (white bars) and mononuclear cells (filled bars) 
was scored for the mucosa and submucosa. Scores are presented as means + standard error. All 
uninfected mice had a score of 0, except for 1 mouse 74 days after infection, which had a score of 1 
for neutrophil and mononuclear cell influx of the mucosa and 2 for the submucosa (data not shown). 
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H. suis is unable to activate gastric epithelial cells to attract neutrophils in vitro 
We have established that H. suis infection leads to increased expression levels of IL-17A, KC, 
LIX and to a lesser degree, IL-4 and MIP-2 mRNA in gastric tissue and that their expression 
increased over time. To investigate if gastric epithelial cells exposed to H. suis could attract 
neutrophils, GSM06 cells were incubated with IL-17, H. suis or both for 24 hours. Using 
transwells, it was demonstrated that supernatant from H. suis-stimulated GSM06 cells did not 
significantly increase (P=0.145) the amount of attracted neutrophils as compared to 
supernatant from IL-17-stimulated cells (Figure 4). Moreover, H. suis did not amplify the IL-
17-mediated ability of gastric epithelial cells to attract neutrophils. 
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Figure 4. H. suis and IL-17 activate murine gastric epithelial cells to attract neutrophils. The 
transwell chemotaxis assay was used to evaluate the migration of neutrophils towards supernatant of 
H. suis-stimulated (HS) murine gastric epithelial cells (GSM06), IL-17-stimulated cells or both. MIP-2 
was used as a positive control. Data are presented as the mean + standard deviation (n = 4). * P< 0.01. 
 
H. suis matured murine BMDCs stimulate IL-17 production by CD4+ T lymphocytes 
Since DCs are important in the polarization of naive T-cells to a desired effector phenotype, 
the effect of H. suis on DC maturation and their ability to trigger Th17 effector cells was 
evaluated. As shown in figure 5, stimulation of murine BMDCs with H. suis significantly 
upregulated the cell surface expression of all investigated activation markers (MHCII, CD40, 
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CD80 and CD86) as compared to the unstimulated BMDCs, indicating a phenotypical 
maturation.  
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Figure 5. H. suis lysate induces murine DC maturation. The expression of activation markers 
(CD40, CD80, CD86 and MHCII) on CD11c+ BMDCs stimulated with H. suis lysate was assessed by 
flow cytometry. BMDCs were exposed to H. suis lysate for 24 hours. Data are presented as mean 
percentage relative increase + standard deviation (n=4) compared to immature MoDCs. *: P <0.05 or 
***: P<0.001. 
 
Moreover, both LPS and H. suis-stimulated BMDCs secreted more IL-6 and IL-23 as 
compared to untreated BMDCs (Figure 6A and 6B). As these cytokines are key to the 
differentiation of Th17 effector cells, we next investigated if H. suis could trigger DCs to 
induce Th17 cells. To this end, BMDCs stimulated with H. suis were co-cultured with CD4+ 
lymphocytes isolated from gastric lymph nodes of H. suis infected mice. Interestingly, 
colonization caused a marked increase in the size of these lymph nodes located at the 
gastroduodenal junction, while it was nearly impossible to locate these in uninfected animals 
(data not shown). BMDCs, which had been exposed to H. suis, successfully stimulated CD4+ 
cells to produce elevated levels of IL-17 (Fig. 6C). Moreover, flow cytometric analysis 
showed an increased fraction of IL-17 secreting CD4+ lymph node cells after co-culture of 
whole lymphocyte preparations and H. suis treated BMDCs (Figure 6D and 6E). 
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Figure 6. H suis-activated murine BMDCs elicit IL-17 secreting CD4+ T cells. (A, B) Supernatant 
of BMDCs after 24 hours stimulation with H. suis lysate or LPS was analyzed for IL-6 and IL-23 
using ELISA. Results are expressed as means ± standard error (n = 4). (C) Gastric CD4+ lymphocytes 
were isolated from H. suis infected mice and co-incubated with stimulated BMDCs. Supernatant was 
collected after 48 hours and IL-17 production was measured using ELISA. Results are expressed as 
means ± standard error (n = 4). (D, E) BMDCs pulsed with H. suis induced CD4+ gastric lymphocytes 
from H. suis infected mice to produce IL-17. Lymphocytes were isolated from the gastric lymph nodes 
of H. suis infected mice and cultured with H. suis pulsed BMDCs. After 48 hours, cells were stained 
for APC conjugated CD4+ and PE conjugated IL-17 as described in the materials and methods section. 
Results represent 4 independent experiments. * denotes P< 0.05, ** denotes P< 0.01 compared to 
unstimulated control cells. 
 
H. suis infection is highly prevalent in Belgian slaughter pigs  
In this study, 76% (n = 82) out of 107 porcine stomach samples, collected from 10 different 
herds in a Belgian slaughterhouse, were H. suis positive as determined by qPCR. Higher 
colonization rates were found in the antrum compared to the fundus in infected animals, but 
this difference was not significant (data not shown). All H. suis infected animals showed 
distinct histopathological lesions which consisted of diffuse lymphocytic infiltration with 
multiple lymphocytic aggregates or lymphoid follicles, mainly in the antrum, compared to the 
H. suis negative animals. 
 
CXC chemokine ligand 13 is highly expressed in the stomach mucosa of H. suis infected 
pigs 
Compared to H. suis negative pigs, IL-17 (p=0.032) and CXC chemokine ligand 13 (CXCL-
13) (p<0.01) expression was increased in the antrum of H. suis infected pigs (Figure 7). In the 
fundus of H. suis infected animals, CXCL-13 (p<0.001) and IL-10 (p=0.016) mRNA 
expression levels were significantly higher compared to the non-infected animals. IFN-γ, IL-4 
and IL-8 mRNA expression levels were never significantly upregulated in both antrum and 
fundus.  
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Figure 7. H. suis induces CXCL-13 mRNA expression in porcine gastric tissues. The mRNA 
expression levels of IL-4, IL-8, IL-10, IL-17A, IFN-γ and CXCL-13 in A) antrum and B) fundus of 
the stomach of H. suis infected pigs are shown. H. suis positive (n=20) and H. suis negative stomachs 
(n=20) were compared for differences in cytokine mRNA expression in the gastric mucosa by qPCR. 
Data represent the mean fold change + standard deviation. *: P <0.05, **: P<0.01 or ***: P<0.001.  
 
H. suis stimulation enhanced porcine dendritic cell activation marker expression 
To elucidate the effect of H. suis lysate and heat-inactivated H. suis bacteria on the 
phenotypical maturation of porcine MoDCs, the expression of co-stimulatory molecules 
(CD80/86, CD25, CD40) was determined 24h post stimulation of immature MoDCs using 
flow cytometry. Flow cytometry analysis revealed that both H. suis lysate and heat-
inactivated H. suis bacteria were able to induce the expression of the DC activation markers 
CD25, CD80/86 and CD40, although this increase was not statistically significant compared 
to the HBSS treated (immature) MoDCs (Figure 8). Interestingly, a non-significant 
downregulation of MHCII expression was observed when compared to HBSS treated 
(immature) MoDCs.  
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Figure 8. Relative expression (%) of dendritic cell activation markers (CD40, CD80/86, CD25 and 
MHCII) upon stimulation with H. suis lysate and heat-inactivated H. suis bacteria was analyzed using 
flowcytometry. Data are presented as mean percentage relative increase or decrease + standard 
deviation compared to immature MoDCs (n=6). 
 
Dendritic cell cytokine secretion upon H. suis infection may promote the differentiation 
of regulatory T-cells  
T-cell activation by DCs requires, among other signals, cytokine secretion, which will 
influence the polarization of activated T-cells, and subsequently skews the immune response 
towards a Th1, Th2, Th17 or Treg response. mRNA expression levels of IL-8 and IL-1β were 
higher in MoDCs stimulated with H. suis lysate and heat-inactivated H. suis bacteria 
compared to immature MoDCs (Figure 9). An increased expression of IL-10 mRNA levels 
was also observed in H. suis lysate-stimulated MoDCs. Interleukin-23 (IL-23) is composed 
of subunits p40 (shared with IL-12) and p19 and is secreted by several types of immune 
cells, such as natural killer cells and dendritic cells (Li et al., 2016).  IL-23p19 mRNA 
expression levels were significantly increased in H. suis lysate-stimulated MoDCs. However, 
no significant differences were observed for IL-12p40 mRNA expression levels.  
 
H. suis-stimulated porcine MoDCs trigger the expansion of Tregs 
In order to determine the functional relevance of H. suis-stimulated DCs, co-culture 
experiments with allogenic CD6+ cells were carried out. Increased T-cell proliferation was 
observed when H. suis-stimulated MoDCs were co-incubated with CD6+ cells in comparison 
to control MoDCs. The highest proliferation counts were noted at the 1:10 and 1:30 ratio of 
H. suis lysate-stimulated MoDCs:T-cells (Figure 10A). Heat-inactivated H. suis-stimulated 
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MoDCs also induced significantly increased T-cell proliferation compared to the control 
MoDCs at all ratios except for 1:270 (Figure 10B). Next, the T-cell differentiation was 
characterized by measuring the mRNA expression profile of several key genes involved in T- 
cell polarization. Increased mRNA expression levels of transforming growth factor beta 1 
(TGF-β1) (P=0.006) and the transcription factor Forkhead-box P3 (FoxP3) (P=0.086), a Treg-
specific marker, were observed in the co-culture of H. suis lysate-stimulated MoDCs and 
CD6+ cells. Increased mRNA expression levels of IL-17A were never observed (Figure 9D). 
No significant results were obtained in cytokine expression profile of heat-inactivated H. suis-
stimulated MoDCs co-cultured with CD6+ cells (data not shown). 
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Figure 9. H. suis induces pro-inflammatory cytokine production by porcine MoDCs. mRNA 
cytokine expression levels of LPS, H. suis lysate (A,B) and heat-inactivated (C) H. suis-stimulated 
MoDCs. Cytokine mRNA expression levels of IL-10, IL-1β, IL-12/23p40, IL-23p19 and IL-8 were 
examined by qPCR. Data are presented as the mean fold change with standard deviation (n=6). 
Significant differences in expression levels between infected groups and the negative control group are 
noted with an * (P<0.05) or ** (P<0.01). H suis-stimulated porcine DCs elicit increased TGF-β 
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and FoxP3 mRNA expression. mRNA cytokine expression levels in the co-culture of LPS or H. suis 
lysate-stimulated MoDCs and CD6+ T-cells. mRNA expression levels of (D) IL-17A, IL-10, IL-4, 
IFN-γ, TGF-β and FoxP3 were examined by qPCR. Data are presented as the mean fold change with 
standard deviation (n=6). Significant differences in mRNA expression levels between infected groups 
and the negative control group are noted with an ** (P<0.01). 
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Figure 10. The ability of A) H. suis lysate and B) heat-inactivated H. suis-stimulated porcine MoDCs 
to activate T-cells was analyzed in an allogenic T-cell proliferation assay. Allogenic CD6+ T-cells 
were co-cultured for 5 days with immature (HBSS), LPS, H. suis (HS5) lysate and heat-inactivated H. 
suis (HI HS5)-stimulated MoDCs. The data are presented as the mean counts per minute (cpm) + 
standard deviation (n=6). * (P<0.05) or ** (P<0.01) denote a significant difference between stimulated 
and immature MoDCs. 
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Discussion 
The results of the present study are in line with previous H. suis infection studies in murine 
models, showing persistent colonization followed by a predominant Th17 response that is 
accompanied with elevated mRNA expression levels of IL-4, KC and LIX (Flahou et al., 
2012; Zhang et al. 2015). The appearance of Th2 marker IL-4 during H. suis infection might 
originate from leakage of the genetic background of BALB/c mice, especially since this is 
less distinct in C57BL/6 mice (Flahou et al., 2012). Regardless the impact of the genetic 
background, increased INF-γ expression, as described during H. pylori infection, is not 
observed in H. suis infected BALB/c and C57BL/6 mice (Flahou et al., 2012). This could 
explain the difference in lesion severity following H. pylori and H. suis infection in human 
patients. Compared to H. pylori-associated gastritis, gastritis associated with NHPH is less 
active and less severe (Stolte et al., 1997), although a predominant acute neutrophilic 
infiltration has also been described (Yoshimura et al., 2002).  
In the present study, neutrophilic infiltration of the gastric mucosa and submucosa of BALB/c 
mice fluctuated over time and expression of KC, LIX and MIP-2 displayed different kinetics. 
LIX is known to be the most potent and abundant CXC chemokine (Wuyts et al., 1999) and 
was the highest expressed chemokine 50 days post infection which coincides with the 
increased presence of IL-17 mRNA transcripts. However, the presence of neutrophils in the 
gastric mucosa and submucosa did not resolve infection, leading to chronic inflammation.  
In pigs, the natural hosts of H. suis, prevalence of infection is very low before weaning, but 
increases rapidly hereafter and may reach up to 90%, depending on the study, in the adult 
boars and sows (Hellemans et al., 2007). Our results demonstrate that 76% of approximately 
six-month-old slaughter pigs in a Belgian abattoir were infected with H. suis.  
In line with observations made in previous experimental H. suis infection studies in mice 
(Flahou et al., 2012), increased mRNA expression levels of IL-17 and IL-10 were observed in 
the antral and fundic stomach mucosa respectively, of naturally H. suis infected pigs. On the 
other hand, upregulated expression of Th2 marker IL-4 and Th1 marker IFN-γ were not 
observed. Despite the clear immune response and infiltration of inflammatory cells in the 
porcine stomach, the infection is not cleared and prevalence rates remain very high. 
Interestingly, expression of CXCL-13, a chemokine attracting B-cells, was significantly 
upregulated in both antrum and fundus of H. suis infected pigs, compared to H. suis negative 
pigs. CXCL-13 is also known as a ligand for CXCR5, expressed by mature B-cells, Th17 
cells and Tregs (Chevalier et al., 2011). Yamamoto et al. (2014) previously described that 
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CXCL-13 is highly expressed in Helicobacter-infected mice and patients suffering from 
gastric MALT lymphoma. Histopathological evaluation of the stomach revealed that gastric 
lymphoid follicles were observed more often in the stomach of H. suis infected animals 
compared to the uninfected animals. These results are in line with a possible role of CXCL-13 
in the development of gastric MALT lymphoma after infection with H. suis in humans. The 
pathways to activation of CXCL-13 and the formation of gastric MALT lymphoma remain to 
be investigated (Zhang et al., 2015).  
H. pylori utilizes several mechanisms to evade clearance by the host immune system which 
are attributed to a great extent to the virulence factors CagA and VacA. Since these virulence 
factors are absent in H. suis, it remains to be elucidated by which mechanisms these bacteria 
are able to persist in the absence of treatment. Dendritic cells are considered to be important 
mediators of the immune response during H. pylori infection and are observed in the gastric 
epithelium upon infection (Kao et al., 2010). Evidence is growing that DCs might play an 
important role in promoting tolerance (Shiu and Blanchard, 2013). Previous reports showed 
that DCs exposed to H. pylori fail to induce an effector T-cell response of the Th17 type in 
vivo and in vitro (Kao et al., 2010; Hitzler et al., 2011; Oertli et al., 2012). In the present 
study, the function of porcine and murine DCs after stimulation with H. suis lysate/heat-
inactivated bacteria was investigated in vitro and revealed remarkable differences between 
both hosts.  
Exposure of murine BMDCs to H. suis lysate in vitro led to the secretion of IL-6 and IL-23, 
which are important players in Th17 development: IL-6 is necessary for Th17 differentiation, 
while IL-23 is required for survival and expansion of Th17 cells (Bettelli et al., 2007). Indeed, 
flow cytometric analysis showed an increased fraction of IL-17 secreting CD4+ T helper cells 
after co-culture of whole lymphocyte preparations and H. suis treated BMDCs. In addition, H. 
suis exposure of murine BMDCs resulted in DC maturation, characterized by an upregulation 
of CD40, CD80, CD86 and MHC class II molecules on its surface. These observations 
demonstrate that H. suis is able to circumvent the need for key H. pylori virulence factors 
CagA and VacA and that this absence does not compromise the major IL-17 polarized 
response in BALB/c mice. The role of Tregs was not investigated in this particular 
experiment. However, previous studies demonstrated increased expression of IL-10 mRNA 
levels after experimental H. suis infection in BALB/c mice and should therefore not be 
excluded as possible immune evasion mechanism (Flahou et al., 2012; Bosschem et al., 2015; 
Bosschem et al., 2016). 
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In contrast with the mouse model, H. suis stimulation of porcine MoDCs resulted in a semi-
mature phenotype, as shown by increased expression of CD25, CD80/86, CD40 and the 
impaired expression of MHC class II molecules on the cell surface of these cells. These 
results indicate that H. suis might be a weak activator of porcine MoDCs or possibly actively 
suppresses the DC response. The mechanisms by which H. suis manages to decrease MHCII 
presentation on porcine MoDCs remain to be elucidated. One possible hypothesis is that the 
observed reduction can be entirely attributed to the presence of the urease gene which is 
highly conserved between H. suis and H. pylori. It has been demonstrated that H. pylori 
urease binds to CD74, thus impairing correct folding and transport of MHCII molecules 
(Elliot et al., 1994; Beswick et al., 2006).  
These semi-mature porcine MoDCs were able to stimulate T-cell proliferation at different 
ratios. T-cell proliferation resulted in expression of several cytokines, including IL-8 and 
TGF-β but not IL-17, unlike in the BALB/c mouse model. FoxP3, a Treg-specific marker, 
was expressed in the co-culture of H. suis lysate-stimulated MoDCs and CD6+ cells. TGF-β is 
required for the differentiation of both Th17 and Treg cells by inducing their key transcription 
factors, RORγ/RORc and FoxP3, respectively (Li et al., 2008). Freire de Melo et al. (2012) 
described that a high concentration of TGF-β inhibits IL-23R expression, favoring Treg cell 
generation. Thus, like previously demonstrated for H. pylori, H. suis might induce a semi-
maturation of porcine DCs conferring a tolerogenic phenotype that elicits the expansion of 
Tregs while maintaining a suboptimal level of Th17 cells, which helps to establish a chronic 
infection (Kao et al., 2010). The increased IL-10 mRNA expression levels which are observed 
in the fundic region of naturally H. suis infected pigs at slaughter age might also favor this 
hypothesis. 
In conclusion, it is clear that H. suis is able to evade the host immune response, both in a 
BALB/c mouse model and in pigs, by mechanisms which are independent of the H. pylori 
virulence factors CagA and VacA. Future studies are required to unravel the H. suis virulence 
factors and molecular mechanisms involved in the immune evasion and to elucidate the 
species-specific differences in DC maturation and T helper cell responses following H. suis 
infection. Since pigs are the natural host of H. suis, these results might be of greater 
importance compared to those obtained from the BALB/c mouse model. 
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Additional files 
Additional file 1. List of genes and primers sequences used for quantitative RT-PCR in 
BALB/c mice. 
Gene Primer Sequence (5'-3') Reference 
H2afz sense CGTATCACCCCTCGTCACTT Flahou et al. ( 2012) 
  antisense TCAGCGATTTGTGGATGTGT 
 PPIA sense AGCATACAGGTCCTGGCATC Flahou et al. ( 2012) 
  antisense TTCACCTTCCCAAAGACCAC 
 HPRT sense CAGGCCAGACTTTGTTGGAT Flahou et al. (2012) 
 
antisense TTGCGCTCATCTTAGGCTTT 
 IL-4 sense ACTCTTTCGGGCTTTTCGAT Flahou et al. (2012) 
  antisense AAAAATTCATAAGTTAAAGCATGGTG 
 IFN-γ sense GCGTCATTGAATCACACCTG Flahou et al. (2012) 
  antisense TGAGCTCATTGAATGCTTGG 
 KC sense GCT GGG ATT CAC CTC AAG AA Flahou et al. (2012) 
  antisense TCT CCG TTA CTT GGG GAC AC 
 IL-17A sense TTTAACTCCCTTGGCGCAAAA Flahou et al. (2012) 
  antisense CTTTCCCTCCGCATTGACAC 
 MIP-2 sense AAA GTT TGC CTT GAC CCT GA Flahou et al. (2012) 
  antisense TCC AGG TCA GTT AGC CTT GC 
 LIX sense CCC TGC AGG TCC ACA GTG CC Flahou et al. (2012) 
  antisense TGG CCG TTC TTT CCA CTG CGA 
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Additional file 2. List of genes and primers sequences used for quantitative RT-PCR in 
pigs 
Gene Primer Sequence (5'-3') Reference 
Cyc-5 sense CCTGAACATACGGGTCCTG Collado-Romero et al. (2010) 
 
antisense AACTGGGAACCGTTTGTGTTG 
 ACTB sense CTCTTCCAGCCCTCCTTCCT Daudelin et al. (2011) 
 
antisense GCGTAGAGGTCCTTCTTCCTGATGT 
 HPRT sense GTGATAGATCCATTCCTATGACTGTAGA Li et al. (2015) 
 
antisense TGAGAGATCATCTCCACCAATTACTT 
 IL-17A sense CTCTCGTGAAGGCGGGAATC Yin et al. (2015) 
  antisense GTAATCTGAGGGCCGTCTGG 
 CXCL-13 sense GATCTTTCCCATCCAAGCAA This study 
 
antisense AACGCAAATGGTCAGTAGGG 
 IL-10 sense GATATCAAGGAGCACGTGAACTC Daudelin et al. (2011) 
  antisense GAGCTTGCTAAAGGCACTCTTC 
 IL-4 sense GGTCTGCTTACTGGCATGTACC Daudelin et al. (2011) 
 
antisense CTCCATGCACGAGTTCTTTCTC 
 IL-8 sense AGAACTGAGAAGCAACAACAACAG Daudelin et al. (2011) 
  antisense CACAGGAATGAGGCATAGATGTAG  
IFN-γ sense AGGTTCCTAAATGGTAGCTCTGGG Daudelin et al. (2011) 
 
antisense AGTTCACTGATGGCTTTGCGCT 
 TGF-β sense CGAGCCCTGGATACCAACT Bruun et al. (2013) 
 antisense GCAGAAATTGGCATGGTAG 
 FoxP3 sense TGCCATTCGCCACAACTT Luo et al. (2015) 
 antisense GGTCCGTGAAGAGTTTATCTTTCT  
IL-12p40 sense  CTTCATCAGGGACATCATCAAAC Daudelin et al. (2011) 
  antisense  AGCACGACCTCAATG  
IL-23p19 sense CCAAGAGAAGAGGGAGATGATGA Luo et al. (2015) 
 
antisense TGCAAGCAGGACTGACTGTTGT 
 IL-1β sense CCAAAGGCCGCCAAGATATAA Frandoloso et al. (2013) 
  antisense GGACCTCTGGGTATGGCTTTC  
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Abstract 
Background: Helicobacter suis (H. suis) is the most prevalent gastric non-H. pylori 
Helicobacter species in humans. This bacterium mainly colonizes the stomach of pigs, but it 
has also been detected in the stomach of non-human primates. The aim of this study was to 
obtain better insights into potential differences between pig- and primate-associated H. suis 
strains in virulence and pathogenesis.  
Materials and Methods: In vitro isolated H. suis strains obtained from pigs, cynomolgus 
monkeys (Macaca fascicularis) and rhesus monkeys (Macaca mulatta) were used for 
intragastric inoculation of BALB/c mice and Mongolian gerbils. Nine weeks and 6 months 
later, samples of the stomach of inoculated and control animals were taken for PCR analysis 
and histopathological examination. 
Results: The cynomolgus monkey-associated H. suis strain only colonized the stomach of 
mice, but not of Mongolian gerbils. All other H. suis strains colonized the stomach in both 
rodent models. In all colonized animals, severe gastric inflammation was induced. Gastric 
lymphoid follicles and destruction of the antral epithelium were observed in infected gerbils, 
but not in mice. Infection with both pig- and primate-associated H. suis strains evoked a 
similar marked Th17 response in mice and gerbils, accompanied by increased CXCL-13 
expression levels.  
Conclusions: Apart from the cynomolgus monkey-associated strain which was unable of 
colonizing the stomach of Mongolian gerbils, no substantial differences in virulence were 
found in rodent models between in vitro cultured pig-associated, cynomolgus monkey-
associated and rhesus monkey-associated H. suis strains. The experimental host determines 
the outcome of the immune response against H. suis infection, rather than the original host 
where the strains were obtained from. 
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Introduction 
Helicobacter suis (H. suis) is a Gram-negative, spiral-shaped bacterium which mainly 
colonizes the stomach of pigs. It has also been detected in the stomach of several non-human 
primates, including rhesus monkeys (Macaca mulatta) and cynomolgus monkeys (Macaca 
fascicularis) (O’Rourke et al., 2004; Nakamura et al., 2007; Haesebrouck et al., 2009). In 
addition, H. suis is the most prevalent gastric non-H. pylori Helicobacter (NHPH) species in 
humans, in which infection is associated with gastritis, peptic ulcers and certain forms of 
gastric cancer (Baele et al., 2009). Unlike infections with H. pylori, infections with H. suis 
only rarely cause gastric adenocarcinoma. Instead, infections with H. suis, as well as with 
other gastric NHPH species, are associated with an increased risk of developing gastric 
mucosa-associated lymphoid tissue (MALT) lymphoma (Morgner et al., 2001; Nakamura et 
al., 2007; Yang et al., 2014). MALT lymphoma-like lesions are also observed in mice and 
Mongolian gerbils experimentally infected with H. suis, while they are less common in 
animals infected with H. pylori (O’Rourke et al., 2004; Wiedemann et al., 2009). The lesions 
in NHPH-infected animals exhibit the classical morphological features of MALT lymphomas 
in humans, including monomorphic centrocyte-like cells invading the gastric epithelium, 
forming lympho-epithelial lesions (LEL’s) in the presence of lymphoid tissue (O’Rourke et 
al., 2004; Flahou et al., 2010). 
These differences between H. pylori and H. suis infection, observed both in natural infections 
in humans and in experimental infections in rodent models, may be due to differences in the 
host immune response towards both Helicobacter species. This has been studied in several 
rodent models using pure in vitro isolated bacterial strains for experimental infection. In 
contrast to H. pylori, evoking a Th17/Th1 response, H. suis infection leads to a Th17/Th2 
response, at least in mice, which could explain the association of NHPH infections with 
MALT lymphoma (Flahou et al., 2012). Indeed, higher expression levels of Th2 cytokines are 
observed in MALT lymphoma (Greiner et al., 1997; Yamasaki et al., 2004). In contrast, 
increased expression levels of interferon gamma (IFN-γ), a Th1 cytokine, and interleukin-17 
(IL-17), the signature Th17 cytokine, are observed in H. suis-infected Mongolian gerbils with 
severe MALT lymphoma-like lesions, however in the absence of upregulated expression of 
Th2 cytokines, showing the complexity of gastric MALT lymphomagenesis in H. suis-
infected animals (Zhang et al., 2015). Anyway, it is clear that there are differences in 
immunopathogenesis between H. pylori and H. suis. From the available literature data it 
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remains, however, unclear whether H. suis strains of different host origin may differ in 
pathogenesis. 
In contrast to the studies described above, several experimental infection studies have been 
performed using gastric mucosal homogenates or mucus from H. suis-infected animals instead 
of pure in vitro isolated strains. When using these homogenates, several other micro-
organisms are likely administered to the animals as well, which may aggravate the course of 
infection and influence the outcome of the results (Flahou et al., 2010). Besides homogenate 
obtained from pigs, several studies have used mucosal homogenates derived from H. suis-
infected non-human primates. O’Rourke et al. (2004) reported the presence of “Helicobacter 
heilmannii”-associated gastric MALT lymphomas in BALB/c mice, which started to develop 
six months after infection. The most severe pathological responses were consistently seen in 
animals infected with stomach material obtained from mandrill monkeys and a cynomolgus 
monkey, which were in fact shown to be infected with H. suis. In another study, urease 
positive gastric mucosal and mucus homogenate from a cynomolgus monkey was used to 
inoculate mice (Nakamura et al., 2007). The bacterium in the homogenate was designated as 
“Candidatus Helicobacter heilmannii”, but in fact was shown to belong to the species H. suis 
(Baele et al., 2009). Infection resulted in the formation of MALT lymphomas in 50% of the 
C57BL/6 mice 3 months post infection and in 100% of the animals six months post infection. 
A similar quick onset of severe gastric disease has so far not been demonstrated in mice 
infected with pure in vitro isolated H. suis strains obtained from pigs (Flahou et al., 2012; 
Zhang et al., 2015). Since the isolate used by Nakamura and colleagues has been maintained 
in mice for 12 years, host adaptation may have increased the virulence of the involved 
bacterial strains in this animal model. 
Several studies attribute a major role to IFN-γ, mainly produced by B-cells, in gastric 
lymphoid follicle formation in mice experimentally inoculated with stomach homogenate 
from H. suis-infected animals (Mimura et al., 2011; Yang et al., 2014). This finding, again, 
partly contradicts the findings obtained when infecting mice with in vitro isolated H. suis 
strains colonizing pigs (Flahou et al., 2012; Zhang et al., 2015).  
Clearly, conflicting results have been published regarding the pathogenesis of H. suis 
infection in various rodent models of human gastric disease. Although differences seem to 
exist in terms of virulence between H. suis isolates obtained from pigs and cynomolgus 
monkeys, comparison between these pig- and primate-associated H. suis strains is 
complicated since no pure in vitro isolated H. suis cultures from primates were available so 
far. Recently, we succeeded in in vitro cultivating H. suis strains from the stomach of 
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cynomolgus monkeys, as well as rhesus monkeys. To our knowledge, no experimental 
infection studies have been performed in rodent models using pure H. suis strains obtained 
from these animals. In addition, no experimental infection studies have been performed so far 
in Mongolian gerbils using H. suis bacteria colonizing the stomach of cynomolgus monkeys 
or rhesus monkeys. Nevertheless, this animal model has been suggested to be more suitable 
than mouse models for studying H. suis-host interactions (Flahou et al., 2010). In the present 
study, in vitro isolated H. suis strains obtained from a pig, a cynomolgus monkey and a rhesus 
monkey were used for experimental infection of BALB/c mice and Mongolian gerbils, in an 
attempt to obtain better insights in potential differences between pig- and primate-associated 
H. suis strains in terms of virulence and pathogenesis.  
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Materials and methods 
Ethics statement 
The in vivo experimental protocol was approved by the Ethical Committee of the Faculty of 
Veterinary Medicine, Ghent University, Belgium (EC2015/23; April 3rd, 2015). 
 
Animals 
Forty-eight specific-pathogen-free (SPF) female six-week-old BALB/c mice and twenty-four 
SPF female outbred gerbils (Crl:MON (Tum)) of six weeks old were purchased from an 
authorized breeder (HARLAN, Horst, The Netherlands and Charles River Laboratories, 
Brussels, Belgium, respectively). All animals tested negative for the presence of Helicobacter 
spp.. The animals were housed on autoclaved soft wood shavings (Van Huffel, Nevele-
Poesele, Belgium) in filter top cages. They were fed an autoclaved commercial diet 
(TEKLAD 2018 S, HARLAN). Autoclaved drinking water was provided ad libitum. The 
animals were monitored several times a day during the whole experiment. Enrichment was 
provided in the form of paper tissues, mouse houses and other homemade available 
enrichment products. All animals were exposed to a 12:12 light:dark cycle. 
 
Bacteria 
H. suis strain HS1 was isolated from the gastric mucosa of a sow as described previously 
(Baele et al., 2008). H. suis strains HsMmR08041a and HsMf505/1 were isolated from the 
gastric mucosa of a rhesus monkey (Macaca mulatta) and a cynomolgus monkey (Macaca 
fascicularis), respectively. These monkeys were bred and housed at the Biomedical Primate 
Research Centre (BPRC, Rijswijk, The Netherlands). The animals were socially housed in 
spacious cages and were provided with commercial food pellets (SSniff®, Soest, Germany) 
supplemented with appropriate treats. Drinking water was provided ad libitum. Enrichment 
was provided in the form of pieces of wood, mirrors, food puzzles and other homemade or 
commercially available enrichment products. Animals were monitored daily for health and 
discomfort. BPRC facilities comply with Dutch law on animal experiments and the EU 
Directive 63/2010, and are AAALAC International accredited. Stomachs were collected at 
necropsy from animals that were euthanized, for reasons unrelated to this study. 
Bacteria were cultured under microaerobic conditions (85% N2, 10% CO2, 5% O2; 37°C) on 
biphasic Brucella (Oxoid, Basingstoke, UK) culture plates supplemented with 20% fetal calf 
serum (HyClone, Logan, UT, USA), 5 mg amphotericin B/l (Fungizone; Bristol-Myers 
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Squibb, Epernon, France), Campylobacter selective supplement (Skirrow, Oxoid; containing 
10 mg/l vancomycin, 5 mg/l trimethoprim lactate and 2500 U/l polymyxin B) and Vitox 
supplement (Oxoid). In addition, the pH of the agar was adjusted to 5 by adding HCl to a final 
concentration of approximately 0.05%. Brucella broth (Oxoid) with a pH of 5 was added on 
top of the agar to obtain biphasic culture conditions. After three days of incubation, the 
bacteria were harvested and the final concentration was adjusted to 2×108 viable bacteria/ml 
Brucella broth, as determined by counting in an improved Neubauer counting chamber. 
The total number of in vitro passages to which the H. suis strains used for experimental 
inoculation of the mice and Mongolian gerbils were subjected, varied between 15 and 18.  
 
Experimental design 
One week after arrival, three groups, each consisting of 12 mice and 6 gerbils were inoculated 
twice at 48 hour interval with one of the three pure H. suis strains: HS1, HsMmR08041a and 
HsMf505/1. A volume of 0.3 ml was used. Twelve mice and six gerbils were twice inoculated 
with 0.3 ml Brucella broth (Oxoid) with a pH of 5 and served as negative controls. 
Inoculation was performed intragastrically under isoflurane anaesthesia, using a ball-tipped 
gavage needle. The mice were held in an upright position until they regained consciousness, 
to minimize the risk of reflux. At nine weeks after the first inoculation, 18 H. suis infected 
and six control mice and all gerbils were euthanized by cervical dislocation under isoflurane 
anaesthesia. Six months after the first inoculation the twenty-four remaining mice were 
euthanized. The stomach of each animal was resected and samples were taken for PCR 
analysis and histopathological examination. The antral and fundic region of the stomach were 
preserved in RNAlater (Ambion, Austin, TX, USA) at -70°C until RNA extraction. For RNA 
isolation, the stomachs were homogenized in 1 ml Tri-reagent (MRC, Brunschwig Chemie, 
Amsterdam, The Netherlands) using a MagnaLyser (Roche Applied Science, Mannheim, 
Germany). Total RNA was extracted from the upper aqueous phase using the RNeasy mini kit 
(Qiagen, Venlo, The Netherlands). DNA was extracted from the antral and fundic stomach 
tissue using the ISOLATE II Genomic DNA kit (Bioline, Luckenwalde, Germany) according 
to the manufacturer’s instructions. A longitudinal strip of tissue taken along the curvatura 
major of the stomach was fixed in phosphate buffered formaline (4%) for histopathological 
analyses.   
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Histological examination 
A longitudinal strip of gastric tissue was cut from the oesophagus to the duodenum along the 
greater curvature. This strip was fixed in 4% phosphate buffered formaldehyde, processed by 
standard methods, and embedded in paraffin for light microscopy. Five sections of 5 µm were 
cut. After deparaffinization and hydration, heat-induced antigen retrieval was performed in 
citrate buffer (pH 6.0) using a microwave oven. Slides were incubated with 3% H2O2 in 
methanol (5 min) and 30% goat serum (30 min) to block endogenous peroxidase activity and 
non-specific reactions, respectively (Flahou et al., 2010). 
The first section was stained with haematoxylin and eosin (H&E) to score the intensity of the 
gastritis, using a visual analog scale similar to the Updated Sydney System but with some 
modifications (Stolte et al., 2001). Both diffuse infiltration and the presence of lymphoid 
aggregates and lymphoid follicles were examined. In addition, in these H&E stained sections 
the presence of neutrophils was scored. On the second section, a Periodic acid-
Schiff (PAS) staining was performed to evaluate the presence of pseudo-pyloric metaplasia of 
the fundus. For detection of T and B lymphocytes, staining of CD3 and CD20 respectively, 
was performed on section three and four, using a polyclonal rabbit anti-CD3 antibody (1/100; 
DakoCytomation, Glostrup, Denmark) and a polyclonal rabbit anti-CD20 antibody (1/25; 
Thermo Scientific, Fremont, USA). These sections were further processed with 
Envision + System-HRP (DAB) (DakoCytomation) for use with rabbit primary antibodies. 
Parietal cells were identified by immunohistochemical staining for hydrogen potassium 
ATPase using a mouse monoclonal antibody on section five (1/200; Abcam Ltd, Cambridge, 
UK). This section was further processed with Envision + System-HRP (DAB) 
(DakoCytomation) for use with mouse primary antibodies. 
 
Quantitative Real-Time PCR for the quantification of the bacteria 
Quantitative Real-Time PCR (RT-PCR) was performed using the C1000TM Thermal cycler 
(CFX96TM Real-Time System, Bio-Rad, Hercules, CA, USA). Each sample contained 5 µl of 
iQTM SYBR® Green Supermix (Bio-Rad), 0.25 µl of each primer, 3.5 µl of distilled water and 
1 µl of DNA. For enumeration of colonizing bacteria, a fragment of the ureA gene of H. suis 
was amplified using the following primers: sense primer BF_HsuisF1: 5′-AAA ACA MAG 
GCG ATC GCC CTG TA-3′ and anti-sense primer BF_HsuisR1: 5′-TTT CTT CGC CAG 
GTT CAA AGC G-3′. For generation of the standard, part of the ureAB gene cluster (1236 
bp) from H. suis strain HS5 was amplified using primers U430F and U1735R, as described 
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previously (O’Rourke et al., 2004). The copy number concentration was calculated based on 
the length of the amplicon and the mass concentration. The standard consisted of 10-fold 
dilutions starting at 108 PCR amplicons for each 10 µl of reaction mixture. Data analysis was 
done using the Bio-Rad CFX Manager Version 3.0 software (Bio-Rad). 
 
Quantitative Real-Time PCR for the analysis of cytokine and chemokine expression  
Total RNA was extracted from the stomach tissue, which was stored in RNAlater (Ambion) 
using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. The RNA concentration was adjusted to 1 μg/μL and cDNA was synthesized 
immediately after RNA purification using the iScript™ cDNA Synthesis Kit (Bio-Rad).  
Messenger RNA expression levels in fundus and antrum were determined for the following 
genes: IL-1β, IL-4, IL-10, IL-17, IFN-γ, CXCL-13. In addition, mRNA expression levels 
were determined for hydrogen potassium ATPase and ASCT2, which were previously shown 
to reflect effects of H. suis infection on the gastric epithelium of the host (Zhang et al., 2015). 
The H+/K+ ATPase is responsible for acid secretion by parietal cells (Forte et al., 1989). 
ASCT2 is described to be a major glutamine transporter (Shimizu et al., 2014). For the RT-
PCR reaction, a C1000TM Thermal cycler (CFX96TM Real-Time System, Bio-RAD, Hercules, 
CA, USA) was used. All reactions were performed in a final volume of 12 µl containing 5 
pmole of the sense and 5 pmole of the antisense primers, 5 µl iQ SYBR mix (Bio-Rad) and 2 
µl cDNA. The reaction protocol consisted of an initial activation phase at 95°C for 15 minutes 
followed by 40 cycles of 95°C for 20 seconds, 60°C for 30 seconds and 73°C for 30 seconds. 
Melting curve analysis was done by increasing the temperature with 0.5°C every 5 seconds 
starting from 65°C until 95°C. The reference genes H2afz, PPIA and HPRT were shown to 
have a stable expression in mice and were included as references. For the gerbil model, β-
actin, GADPH and HPRT1 were used as reference genes (Zhang et al., 2015). The sequences 
of all used primers are summarized in Table I and II. The threshold cycle values (Ct) were 
first normalized to the geometric means of the reference genes and the normalized mRNA 
levels were calculated according to 2(-∆∆Ct) method for each individual animal (Livak and 
Schmittgen, 2001) 
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Table I. List of genes and primers sequences used for quantitative RT-PCR in 
Mongolian gerbils 
Gene Primer Sequence (5'-3') Reference 
CXCL-13 sense GAATGGCTGCCCCAAAACTGAA Zhang et al., 2015 
  antisense TCACTGGAGCTTGGGGAGTTGAA 
 GAPDH sense AACGGGAAGCTCACTGGCATG Zhang et al., 2015 
  antisense CTGCTTCACCACCTTCTTGATGTCA 
 HPRT1 sense GCCCCAAAATGGTTAAGGTTGCA Zhang et al., 2015 
  antisense TCAAGGGCATATCCAACAACAAAC 
 IL-1β sense GGCAGGTGGTATCGCTCATC Zhang et al., 2015 
  antisense CACCTTGGATTTGACTTCTA 
 IFN-γ sense CCATGAACGCTACACACTGCATC Zhang et al., 2015 
  antisense GAAGTAGAAAGAGACAATCTGG 
 IL-10 sense GGTTGCCAAGCCTTATCAGA Joosten et al., 2013 
  antisense GCTGCATTCTGAGGGTCTTC 
 IL-17 sense AGCTCCAGAGGCCCTCGGAC Zhang et al., 2015 
  antisense AGGACCAGGATCTCTTGCTG 
 ATP4b sense GGGGGTAACCTTGAGACCTGATG Joosten et al., 2013 
  antisense AAGAAGTACCTTTCCGACGTGCAG 
 β-actin sense TCCTCCCTGGAGAAGAGCTA Zhang et al., 2015 
  antisense CCAGACAGCACTGTGTTGGC 
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Table II. List of genes and primers sequences used for quantitative RT-PCR in BALB/c 
mice  
Gene Primer Sequence (5'-3') Reference 
CXCL-13 sense GAATGGCTGCCCCAAAACTGAA Zhang et al., 2015 
  antisense TCACTGGAGCTTGGGGAGTTGAA 
 GAPDH sense AACGGGAAGCTCACTGGCATG Flahou et al., 2012 
 
antisense CTGCTTCACCACCTTCTTGATGTCA 
 HPRT1 sense GCCCCAAAATGGTTAAGGTTGCA Flahou et al., 2012 
  antisense TCAAGGGCATATCCAACAACAAAC 
 IL-1β sense GGCAGGTGGTATCGCTCATC Flahou et al., 2012 
 
antisense CACCTTGGATTTGACTTCTA 
 IFN-γ sense CCATGAACGCTACACACTGCATC Flahou et al., 2012 
  antisense GAAGTAGAAAGAGACAATCTGG 
 IL-10 sense GGTTGCCAAGCCTTATCAGA Flahou et al., 2012 
  antisense GCTGCATTCTGAGGGTCTTC 
 IL-17 sense AGCTCCAGAGGCCCTCGGAC Flahou et al., 2012 
  antisense AGGACCAGGATCTCTTGCTG 
 ATP4b sense GGGGGTAACCTTGAGACCTGATG Zhang et al., 2015 
 
antisense AAGAAGTACCTTTCCGACGTGCAG 
 β-actin sense TCCTCCCTGGAGAAGAGCTA Flahou et al., 2012 
  antisense CCAGACAGCACTGTGTTGGC 
 ASCT2 sense  GCTACCGGAATCATAATTCATTGTTAACCTCC Bungard et al., 2004 
  antisense  AGATCTGGAGTAGCGGTTACCAGCCAGAGAAAG 
 
     
Statistical analysis 
For all analyses, SPSS23 (IBM, Armonk, New York, USA) was used. Differences in H. suis 
colonization and cytokine expression among groups were assessed by using one-way 
ANOVA analysis. A Bonferroni post-hoc test was used for comparisons between the different 
groups. Histological inflammation scores, ATPase and ASCT expression were compared by a 
Kruskal-Wallis analysis, followed by a Mann-Whitney U test. A level of probability of 0.05 
was used as criterion for significance. 
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Results 
Colonization  
All animals in the negative control groups were negative for the presence of H. suis as 
determined by quantitative RT-PCR. Colonization rates at nine weeks after the first 
inoculation with the H. suis strains HS1, HsMmR08041a and HsMf505/1 in the Mongolian 
gerbil model and BALB/c mouse model are shown in figure 1A and figure 1B. Strains 
HsMmR08041a and HS1 were able to colonize both fundus and antrum of the BALB/c mice 
and Mongolian gerbils. Interestingly, strain HsMf505/1 could not be detected in the gerbil 
stomachs. This strain did colonize the stomach of the mice but colonization rates were lower 
compared to strains HsMmR08041a and HS1. In the mouse model, colonization was seen 
throughout the entire glandular stomach, both in antrum and fundus. In Mongolian gerbils, 
colonization levels were significantly higher in the antrum compared to the fundic region 
(P<0.01). At six months after the first inoculation, the three H. suis strains did not differ from 
each other in their capacity to colonize BALB/c mice (Figure 1C). 
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Figure 1. Colonization rates nine weeks post infection with H. suis strains HS1, HsMmR08041a 
and HsMf505/1 in the Mongolian gerbil model (A) and in the BALB/c mice model (B). 
Colonization rates six months after infection with the H. suis strains HS1, HsMmR08041a and 
HsMf505/1 in the BALB/c mice model (C). The amount of bacteria colonizing the antrum and the 
fundic region of the stomach are illustrated as log (10) of H. suis copies/mg stomach. The individual 
animals are presented as triangles. Significant differences between the different groups are noted by * 
(P<0.05) and ** (P<0.01). H. suis strain HS1 was isolated from the gastric mucosa of a sow. H. suis 
strains HsMmR08041a and HsMf505/1 were isolated from the gastric mucosa of a rhesus monkey 
(Macaca mulatta) and a cynomolgus monkey (Macaca fascicularis), respectively. A negative control 
group (Neg. con.) was included. 
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Histopathological evaluation of the gastric mucosa 
The stomachs of all negative control animals and the gerbils that were infected with strain 
HsMf505/1 showed very little infiltration of inflammatory cells. In gerbils infected with 
rhesus monkey strain HsMmR08041a and porcine strain HS1, the observed inflammation was 
characterized by a diffuse infiltration of T lymphocytes, as shown by immunohistochemical 
CD3 staining, and the formation of lymphoid follicles in the lamina propria in the antrum of 
the stomach. The presence of gastric lymphoid follicles seemed more pronounced in the 
gerbils infected with HsMmR08041a compared to the porcine strain HS1, although this was 
not statistically significant (P=0.171) (Figure 2). Immunohistochemical CD20 staining of the 
stomach of Mongolian gerbils infected with strains HS1 and HsMmR08041a showed the 
presence of B lymphocytes in the germinal centers of lymphoid follicles (Figure 3). In the 
fundic region of the stomach, very little infiltration of inflammatory cells was observed. In the 
forestomach-stomach transition zone, limited infiltration of lymphocytes was also observed.  
 
 
Figure 2. Immunohistochemical CD3 staining of the antrum of a gerbil infected with primate-
associated H. suis strain HsMmR08041a for nine weeks, showing infiltration of T-lymphocytes 
(brown) in large gastric lymphoid follicles with expanding germinal centers, lamina propria and 
submucosa (Original magnification 100x). 
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Figure 3. Immunohistochemical CD20 staining of the antrum of a Mongolian gerbil infected with pig-
associated H. suis strain HS1 at 9 weeks post inoculation, showing B lymphocytes (brown) in 
germinal centers of a lymphoid follicle (arrow) (Original magnification: 100x).  
 
In the mouse model, diffuse infiltration of lymphocytes was seen throughout the entire 
glandular stomach, both in antrum and fundus for all strains. Neutrophil infiltration was 
moderate in the stomach mucosa in all infected mice and gerbils. In contrast to the gerbil 
model, no lymphoid follicles were observed at nine weeks and six months after infection in 
BALB/c mice. Overall gastric inflammation scores are presented in figure 3.  
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Figure 3. Overall gastric inflammation scores after experimental infection. Antral (a) and fundic 
(b) inflammation in BALB/c mice and Mongolian gerbils was scored using a visual analog scale 
similar to the Updated Sydney System but with some modifications. Both diffuse infiltration and the 
presence of lymphoid aggregates and lymphoid follicles were examined. Scoring: 0=normal, 1=mild, 
2=moderate, 3=marked, 4=severe inflammation. Individual animals are depicted as triangles around 
the mean (lines). Statistical significant differences between the groups are indicated by * (P<0.05) and 
** (P<0.01).  
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Relative gene expression of cytokines and chemokines  
In the mouse model, a clear Th17 response was observed, as shown by increased expression 
levels of IL-17 mRNA (P<0.05) for all H. suis strains in the fundic region. Increased mRNA 
expression levels were observed for IL-4, but this was only statistically significant (P=0.043) 
for the fundic region of HsMf505/1 infected mice. An increased expression of the anti-
inflammatory IL-10 was observed in the fundic region of infected BALB/c mice for all three 
H. suis strains (P<0.01). Although mRNA expression levels of IL-1β also seemed higher in 
the fundus of H. suis infected mice, this was not statistically significant. CXCL-13 expression 
was significantly (P<0.05) upregulated in the fundic region of all infected animals and in the 
antrum of HS1 infected animals. 
In the gerbil model, a clear increased expression of IL-17 mRNA levels was shown in the 
antrum (P<0.01) of infected animals. Increased expression levels of IL-1β, one of the 
important pro-inflammatory mediators of the innate immune system, were observed in the 
antrum of animals infected with HsMmR08041a (P<0.001) and HS1 (P<0.001). For INF-γ, a 
signature Th1 cytokine, an increased expression was observed in gerbils inoculated with 
HsMmR08041a (P<0.01) and HS1 (P<0.01) when compared to the non-infected control 
animals. In contrast, this was not the case in H. suis infected mice. Increased CXCL-13 
mRNA expression levels were observed both in the antrum and fundic region for gerbils 
infected with HsMmR0841a and HS1, although this was only significant (P= 0.026) in the 
fundus of animals infected with strain HsMmR08041a. The relative gene expression levels of 
cytokines and chemokines in the stomach of BALB/c mice and Mongolian gerbils after nine 
weeks of infection, are presented in figures 4 and 6. 
The immune response was also investigated six months after infection in BALB/c mice. 
Interestingly, CXCL-13 was the only cytokine for which expression levels remained 
significantly upregulated in all infected animals, both in antrum and fundus, when compared 
to the negative control animals. mRNA expression levels of IL-17 seemed increased in the 
antrum of infected BALB/c mice, but this was not statistically significant (Figure 5).  
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Figure 4. Relative gene expression of cytokines and chemokines in the stomach of challenged 
mice nine weeks post infection. Cytokine mRNA expression levels in the fundus and antrum of the 
stomach were examined by quantitative RT-PCR. mRNA expression levels of IL-17, CXCL-13, IL-
10, IL-4, IFN-γ and IL-1β are shown. Data are presented as the fold change in gene expression 
normalized to three reference genes and relative to the negative control group (Neg. con.). The results 
are shown as means with standard deviation (n=6). Significant differences in expression levels 
between infected groups and the negative control group are noted with an * (P<0.05) or ** (P<0.01). 
H. suis strain HS1 was isolated from the gastric mucosa of a sow. H. suis strains HsMmR08041a and 
HsMf505/1 were isolated from the gastric mucosa of a rhesus monkey (Macaca mulatta) and a 
cynomolgus monkey (Macaca fascicularis), respectively. No significant differences were observed 
between the different H. suis infected groups. 
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Figure 5. Relative gene expression of IL-17 and CXCL-13 in the stomach of challenged mice six 
months after infection. Cytokine mRNA expression levels in the fundus and antrum of the stomach 
were examined by quantitative RT-PCR. mRNA expression levels of IL-17 and CXCL-13 are shown. 
The results are presented as the fold change in gene expression normalized to three reference genes 
and relative to the negative control group (Neg. control). Data are shown as means with standard 
deviation (n=6). Significant differences in expression level between inoculated groups and the 
negative control group are noted with an ** (P<0.01) or *** (P<0.001). H. suis strain HS1 was 
isolated from the gastric mucosa of a sow. H. suis strains HsMmR08041a and HsMf505/1 were 
isolated from the gastric mucosa of a rhesus monkey (Macaca mulatta) and a cynomolgus monkey 
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(Macaca fascicularis), respectively. No significant differences were observed between the different H. 
suis infected groups. 
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Figure 6. Relative gene expression of cytokines and chemokines in the stomach of challenged 
gerbils nine weeks post infection. Cytokine mRNA expression levels in the fundus and antrum of the 
stomach were examined by quantitative RT-PCR. mRNA expression levels of IL-17, CXCL-13, IL-
10, IFN-γ and IL-1β are shown. Data are presented as the fold change in gene expression normalized 
to three reference genes and relative to the negative control group (Neg. con.). Data are shown as 
means with standard deviation (n=6). Significant differences in expression levels between infected 
groups and the negative control group are noted with an * (P<0.05), ** (P<0.01) or *** (P<0.001). H. 
suis strain HS1 was isolated from the gastric mucosa of a sow. H. suis strains HsMmR08041a and 
HsMf505/1 were isolated from the gastric mucosa of a rhesus monkey (Macaca mulatta) and a 
cynomolgus monkey (Macaca fascicularis), respectively. No significant differences were observed 
between the different H. suis infected groups. 
 
Changes in expression of epithelial cell-related factors in the stomach  
A decrease of ATP4a and ATP4b mRNA expression levels was observed in the stomach of H. 
suis-colonized mice and gerbils at nine weeks post inoculation, although this decrease was 
only statistically significant in the antrum of colonized gerbils (p<0.05) and in the fundic 
region of HS1 infected mice (P<0.05). In accordance with the H+/K+ ATPase staining of the 
stomach mucosa of the gerbils, the loss of parietal cells was only clear in the antrum and the 
transition zone between fundus and antrum, and not in the fundic region (Figure 7). The 
expression of ASC amino-acid transporter 2 (ASCT2) is depicted in figure 8. Compared to the 
control animals, a distinct decrease in ASCT2 mRNA expression levels was observed in H. 
suis infected BALB/c mice after six months of infection. 
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Immunohistochemical ATPase staining 
 
mRNA expression levels of H+/K+ ATPase 
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Figure 7. Immunohistochemical staining of the hydrogen potassium ATPase, responsible for 
gastric acid secretion by parietal cells. The figure on the left shows the ATPase staining of the 
proximal antrum of the stomach of an uninfected Mongolian gerbil. The figure on the right shows the 
ATPase staining of the proximal antrum of the stomach of a Mongolian gerbil, infected with primate-
associated H. suis strain HsMmR08041a, showing abrupt parietal cell loss (Original magnification: 
50x).  
mRNA expression levels of hydrogen potassium ATPase (H+/K+ ATPase) in the antrum and 
fundic region of the stomach of BALB/c mice and Mongolian gerbils nine weeks post infection. 
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mRNA expression levels were examined by quantitative RT-PCR. The results are presented as the fold 
change in gene expression normalized to three reference genes and relative to the negative control 
group. Data is shown as means with standard deviation. Significant differences in expression levels 
between inoculated groups and negative control group are indicated by * (P <0.05). No significant 
differences were observed between the different H. suis infected groups. 
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Figure 8. mRNA expression levels of ASC amino-acid transporter 2 (ASCT2) in the antrum and 
fundic region of the stomach of BALB/c mice nine weeks and six months post infection. mRNA 
expression levels were determined by quantitative RT-PCR. The results are presented as the fold 
change in gene expression normalized to three reference genes and relative to the negative control 
group. Data is shown as means with standard deviation. Significant differences in expression levels 
between infected groups and negative control group are indicated by * P <0.05 or ** P <0.01. No 
significant differences were observed between the different H. suis infected groups. 
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Discussion 
In the present study, the porcine H. suis strain HS1 and rhesus monkey-associated H. suis 
strain HsMmR08041a were able to colonize the stomachs of both BALB/c mice and 
Mongolian gerbils. In contrast, the cynomolgus monkey-associated H. suis strain HsMf505/1 
could be detected in the stomachs of BALB/c mice, both at nine weeks and six months pi, but 
not in those of gerbils. This might indicate that the infection was cleared within nine weeks or 
that strain HsMf505/1 was not at all capable of colonizing the gastric mucosa of Mongolian 
gerbils. Liang and colleagues (2015) have previously described the unsuccessful colonization 
of porcine H. suis strain HS5aKOL in Mongolian gerbils, which was probably due to long-
term, suboptimal in vitro culture, which may have altered the expression of factors essential 
for colonization and adhesion. The present study, however, is the first to report the failure of a 
low-passage H. suis strain to colonize the stomach of Mongolian gerbils.  
Several studies describe the development of MALT lymphoma (-like lesions) after infection 
with cynomolgus monkey-associated H. suis in mice (O’Rourke et al., 2004; Nakamura et al., 
2007; Yang et al., 2014). In contrast, when using pure in vitro isolated porcine H. suis 
cultures, MALT lymphoma-like lesions were observed in some gerbils, but not in mice 
(Flahou et al., 2010). Therefore, we hypothesized that primate-associated H. suis strains might 
be more virulent than porcine strains, at least in mouse models of human gastric disease. In 
the present study, however, no gastric lymphoid follicles were observed in stomachs of 
BALB/c mice after nine weeks and six months of infection with H. suis strains HS1, 
HsMmR08041a or HsMf505/1, indicating no differences between pig- and primate-associated 
H. suis strains in terms of immunopathogenesis. On the other hand, O’Rourke et al. (2004) 
detected gastric lymphoid follicles, from which MALT lymphoma develops, in BALB/c mice 
only from six months infection onwards. So possibly, differences between H. suis strains used 
in this study may appear after longer duration of infection. In accordance with the study by 
Flahou and colleagues (2010), we did observe the formation of gastric lymphoid follicles with 
expanding germinal centers in virtually all gerbils that were infected with strains 
HsMmR08041a and HS1. 
MALT lymphoma is characterized by an extensive proliferation of B-lymphocytes which may 
be dependent on Th2-type cytokines. Previous studies have shown that an experimental H. 
suis infection, with a strain obtained from pigs, in BALB/c mouse models evokes a 
Th17/Th2-polarized response (Flahou et al., 2012), which is confirmed by the results of the 
present study. Th2 cells are known to secrete IL-4, IL-5, IL-10 and IL-13, which mediate B-
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cell activation and antibody production (Murphy et al., 2012). In the fundic region of the 
stomach of mice, we detected an increased expression of IL-4, which was, however, only 
significant in animals infected with HsMf505/1. Expression levels of CXCL-13, a B 
lymphocyte chemoattractant that is mainly produced by follicular dendritic cells and that has 
been shown to play a role in Helicobacter-induced lymphoid follicle formation (Yamamoto et 
al., 2014), were also increased in the stomach of all infected mice. No differences were 
observed between animals infected with pig- and primate-associated H. suis strains. 
Previous studies have revealed a role for IFN-γ in the pathogenesis of gastric lymphoid 
follicle formation in mice experimentally infected with cynomolgus-associated H. suis 
(Mimura et al., 2011). The present study is the first to confirm these results when using pure 
in vitro isolated primate and porcine H. suis strains, as shown by the significant increase of 
IFN-γ mRNA expression levels in the antrum of infected Mongolian gerbils. In BALB/c mice 
on the other hand, mRNA expression levels of IFN-γ seemed increased, but this increase was 
not statistically significant and not associated with the formation of gastric lymphoid follicles. 
Gastric acid secretion is mediated by the gastric hydrogen potassium ATPase 
(H+/K+ ATPase), that functions as a proton pump in gastric acid-secreting parietal cells (Forte 
et al., 1989). Histopathological evaluation of the stomach mucosa of H. suis infected 
Mongolian gerbils revealed parietal cell loss at the transition zone between fundus and antrum 
in all H. suis infected gerbils. These observations were confirmed by quantitative RT-PCR. A 
clear downregulation of ATP4a and ATP4b mRNA expression levels was observed in the 
stomach of infected mice and gerbils at nine weeks post infection and no differences were 
observed between animals infected with primate- and pig-associated H. suis strains. This, 
along with the alterations in ASCT2 expression as described above, shows that infection with 
all three H. suis strains has a profound effect on the function and homeostasis of the gastric 
epithelium. 
Long term infection with different H. suis strains in BALB/c mice, showed that H. suis 
colonization persisted during at least six months. Colonization rates at six months pi were 
indeed similar to those at nine weeks pi, with no significant differences between the different 
H. suis strains used in this study (P>0.05). Interestingly, only CXCL-13 showed increased 
mRNA expression levels compared to the uninfected control mice at six months post 
inoculation, whereas expression levels of IL-17 were less pronounced compared to those at 
nine weeks post inoculation. Previous studies have shown a direct relation between IL-17 
expression levels and protection against H. suis infection, so the attenuated IL-17 expression 
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levels after six months of infection observed in the present study might contribute to the 
chronicity of the infection (Vermoote et al., 2012). 
In conclusion, the results of this comparative virulence study indicate that no substantial 
differences in virulence exist between in vitro cultured pig-associated, cynomolgus monkey-
associated and rhesus monkey-associated H. suis strains in mouse models of gastric disease, 
in contrast to what may be expected based on previous studies performed by different 
research groups. Cynomolgus monkey-associated strain HsMf505/1 was not capable of 
colonizing the stomach of Mongolian gerbils, which have been suggested to be superior to 
mice for studying H. suis-host interactions. The present study also revealed that mainly the 
experimental host determines the outcome of the immune response against H. suis infection, 
rather than the original host where strains are isolated from. Future research should include 
comparative genomics/transcriptomics of the primate-associated H. suis strains, which may 
help to elucidate the underlying reasons why the cynomolgus monkey-associated strain 
HsMf505/1 was unable to colonize the gastric mucosa of Mongolian gerbils. In addition, it 
might be interesting to verify whether these primate-associated strains are able to colonize the 
stomach of pigs. 
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Abstract 
Helicobacter suis (H. suis) is a widespread porcine gastric pathogen, which is also of zoonotic 
importance. The first goal of this study was to investigate the efficacy of several vaccine 
adjuvants (CpG-DNA, Curdlan, Freund’s Complete and Incomplete, Cholera toxin), 
administered either subcutaneously or intranasally along with H. suis whole-cell lysate, to 
protect against subsequent H. suis challenge in a BALB/c infection model. Subcutaneous 
immunization with Freund’s complete adjuvant (FA)/lysate and intranasal immunization with 
Cholera toxin (CT)/lysate were shown to be the best options for vaccination against H. suis, 
as determined by the amount of colonizing H. suis bacteria in the stomach, although adverse 
effects such as post-immunization gastritis/pseudo-pyloric metaplasia and increased mortality 
were observed, respectively. Therefore, we decided to test alternative strategies, including 
sublingual vaccine administration, to reduce the unwanted side-effects. A CCR4 antagonist 
that transiently inhibits the migration of regulatory T-cells was also included as a new 
adjuvant in this second study. Results confirmed that immunization with CT (intranasally or 
sublingually) is among the most effective vaccination protocols, but increased mortality was 
still observed. In the groups immunized subcutaneously with FA/lysate and CCR4 
antagonist/lysate, a significant protection was observed. Compared to the FA/lysate 
immunized group, gastric pseudo-pyloric metaplasia was less severe or even absent in the 
CCR4 antagonist/lysate immunized group. In general, an inverse correlation was observed 
between IFN-γ, IL-4, IL-17, KC, MIP-2 and LIX mRNA expression and H. suis colonization 
density, whereas lower IL-10 expression levels were observed in partially protected animals. 
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Introduction 
Helicobacter suis (H. suis) is a Gram-negative, spiral-shaped bacterium and a worldwide 
spread pathogen colonizing the stomach of up to 90% of slaughter pigs. Even higher 
colonization rates are observed in adult boars and sows (Hellemans et al., 2007). Infection 
with H. suis causes gastritis and a decrease in daily weight gain (De Bruyne et al., 2012). 
Although not always straightforward, several studies attribute a role to this pathogen in the 
development of gastric ulcer disease in pigs (De Bruyne et al., 2012). Economic losses due to 
the stomach ulcerations are believed to be substantial (Haesebrouck et al., 2009). H. suis is 
also of zoonotic importance. Infection in human patients has been associated with gastritis, 
peptic ulceration and mucosa-associated lymphoid tissue lymphoma (Haesebrouck et al., 
2009).   
Vaccination is considered to be a potentially valuable approach to control gastric 
Helicobacter infections and related disease development (Blanchard and Nedrud et al., 2010). 
Besides the use of the appropriate antigen or combination of antigens, the choice of the 
immunization route and adjuvant play an important role in the outcome of vaccination studies. 
The use of an appropriate adjuvant has several benefits. Among other things, it reinforces the 
immune response, providing better and longer lasting protection against the pathogen. An 
adjuvant also allows the dose and dosing schedule of the antigen(s) to be decreased and 
modulated, reducing the cost and logistical complexity of administering vaccines (Davies et 
al., 2009). Most Helicobacter vaccination strategies have been designed to generate an 
optimal immune response at the mucosal surface, in line with strategies applied for other 
mucosal bacterial infections (Blanchard and Nedrud et al., 2010). As adjuvants for mucosal 
immunization, Cholera Toxin (CT) and the heat-labile toxin of enterotoxigenic Escherichia 
coli (LT) have been the most widely used in mice, although they are known to have side-
effects in humans, such as the development of diarrhoea, even at low doses (Corthésy-
Theulaz et al., 1995; Guy et al., 1998; Guy et al., 1999; Banerjee et al., 2002; Garhart et al., 
2002; Nyström et al., 2006; Sutton et al., 2007; Svennerholm et al., 2007). Several other 
adjuvants have also been used in H. pylori vaccination studies. These include linear 
polysaccharides such as chitosan (Xie et al., 2007) and immunostimulatory CpG 
oligonucleotides (Jiang et al., 2003; Raghavan et al., 2003). Different vaccination protocols 
against H. pylori have already been tested in different animal models. They usually resulted in 
a reduction in the number of bacteria colonizing the stomach, but few strategies conferred 
protection in terms of sterilizing immunity (Anderl et al., 2014). 
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In a previous H. suis vaccination study in mice, prophylactic intranasal immunization with CT 
adjuvanted H. suis whole-cell lysate resulted in a minority of animals being H. suis negative, 
as shown by conventional PCR (Flahou et al., 2009). However, increased mortality rates were 
observed in these vaccinated and challenged animals. This side-effect has not been thoroughly 
investigated yet. In addition to increased mortality rates, intranasal vaccination with a CT 
adjuvanted whole-cell lysate vaccine, induced post-vaccination gastritis as another major 
side-effect. This has also been described in H. pylori vaccination studies and its role in 
protection remains largely unclear (Vermoote et al., 2013). Besides CT adjuvanted vaccines, a 
saponin-based adjuvanted H. suis whole-cell lysate has been tested in mice. This vaccine 
formulation was administered subcutaneously and although it induced less severe adverse 
effects, its protective efficacy was shown to be inferior to CT-based vaccine formulations.  
Recent studies describe the adjuvant activity of small molecule CC chemokine receptor 4 
(CCR4) antagonists (Bayry et al., 2008; Bayry et al., 2014). CCR4 is expressed on regulatory 
T-cells (Tregs) and Th2 cells and regulates the migration of these T cell subsets in response to 
MDC (macrophage derived chemokine, CCL22) and TARC (thymus and activation-regulated 
chemokine, CCL17) (Bonecchi et al., 1998; Sather et al., 2007). CD4+ Tregs express high 
levels of CD25 (IL-2Rα) and actively control or suppress the function of both innate and 
adaptive immune cells (Anderl et al., 2014). One of the most important cytokines secreted by 
these Tregs is the anti-inflammatory interleukin-10 (IL-10) (André et al., 2009). Therefore, 
IL-10-producing Tregs play a role in suppressing inflammation-related pathological changes. 
This mechanism is, however, most likely also involved in persistence of H. suis infection in 
its hosts due to suppression of immune responses (Flahou et al., 2009; Vermoote et al., 2013).  
CCR4 antagonists have been described to amplify cellular and humoral immune responses in 
vivo in experimental models when injected in combination with Mycobacterium or 
Plasmodium yoelii vaccine antigens (Bayry et al., 2008; Davies et al., 2009). In addition, 
CCR4 antagonists induced antigen-specific CD8+ T-cells and tumor immunity against self-
antigens (Pere et al., 2011). Thus far, this promising adjuvant has not been tested in 
vaccination and challenge studies involving pathogens. The CCR4 antagonist AF-
399/42018025 used in this study is a small chemical molecule with a molecular weight of 
565.93. It contains six 5 or 6 membered aromatic rings and 3 nitrogen, sulfur, and oxygen 
atoms. The chemical name of the molecule is 4-(1-benzofuran-2-ylcarbonyl)-1-{5-[4-
chlorobenzyl)sulfanyl]-1,3,4-thiadiazol-2-yl}-3-hydroxy-5-(2-thienyl)-1,5-dihydro-2H-pyrrol-
2-one (Davies et al., 2009; Figure 1).  
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Figure 1. The chemical structure of the CCR4 antagonist. The CCR4 antagonist AF-399/42018025 
is a small chemical molecule with a molecular weight of 565.93. It contains five 5 or 6 membered 
aromatic rings and 3 nitrogen, sulfur, and oxygen atoms. The chemical name of the molecule is 4-(1-
benzofuran-2-ylcarbonyl)-1-{5-[4-chlorobenzyl)sulfanyl]-1,3,4-thiadiazol-2-yl}-3-hydroxy-5-(2-
thienyl)-1,5-dihydro-2H-pyrrol-2-one (Davies et al., 2009).  
 
The purpose of the first study was (1) to explore the efficacy of several established vaccine 
adjuvants (CpG-DNA, Curdlan, Freund’s complete (FA), Freund’s incomplete (IFA) and CT) 
administered subcutaneously or intranasally along with H. suis lysate to protect against H. 
suis challenge in mice and (2) to assess the adverse effects associated with these vaccination 
protocols. Since substantial side-effects were observed in all vaccination strategies, a second 
study was performed, aiming at reducing these unwanted side-effects. Administered vaccine 
volumes as well as routes of administration were modified and a new adjuvant, a CCR4-
antagonist, was included.  
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Materials and Methods 
Animals 
In a first study, a total of 96 seven-week-old female Helicobacter specific pathogen-free 
BALB/c mice were purchased from an authorized breeder (HARLAN, Horst, The 
Netherlands). The animals were housed on autoclaved wood shavings in filter top cages. They 
were fed an autoclaved commercial diet (TEKLAD 2018 S, HARLAN). In a second study, a 
total of 66 seven-week-old female Helicobacter spp.-free BALB/c mice were used. All animal 
experiments were approved by the Ethics Committee of the Faculty of Veterinary Medicine, 
Ghent University (EC2010/043 and EC2013/024). The animals were monitored several times 
a day during the whole experiment. When the animals were visibly less active, lost weight or 
showed symptoms of illness, the weight of the animal was compared with the other animals of 
the group. When a decrease of 20% of the body weight was observed, the animal was 
euthanized. 
 
Antigens for immunization 
H. suis strain HS5bLP, isolated from the gastric mucosa of a sow (Baele et al., 2008), was 
grown on Brucella agar (Oxoid, Basingstoke, UK) supplemented with 20% fetal calf serum, 5 
mg amphotericin B/l (Fungizone; Bristol-Myers Squibb, Epernon, France), Campylobacter 
selective supplement (Skirrow, Oxoid; containing 10 mg/l vancomycin, 5 mg/l trimethoprim 
lactate and 2500 U/l polymyxin B) and Vitox supplement (Oxoid). In addition, the pH of the 
agar was adjusted to 5 by adding HCl to a final concentration of approximately 0.05%. 
Brucella broth (Oxoid) with a pH of 5 was added on top of the agar to obtain biphasic culture 
conditions. After 3 days of incubation at 37°C under microaerobic conditions (85% N2, 10% 
CO2, 5% O2), the Brucella broth, containing the bacteria, was harvested (Flahou et al., 2009). 
Bacteria were washed, concentrated by centrifugation (5000g, 10 min, 4°C) and suspended in 
phosphate buffered saline (PBS). The bacterial suspension was sonicated 8 times for 30 
seconds, with a frequency of 20 kHz (Sonicator ultrasonic processor XL 2015; MISONIX, 
Farmingdale, USA), resulting in lysis of the bacteria (Flahou et al., 2009). After 
centrifugation (13000g, 10 min, 4°C), the supernatant fluid was collected and stored at -70°C 
until further use. The protein concentration of the sonicate was determined using the Lowry 
assay (Flahou et al., 2009). 
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Preparation of the challenge material 
For the challenge of the mice, H. suis strain HS5bLP was cultured as described above. The 
final concentration was determined by counting the bacteria in an improved Neubauer 
counting chamber. 
 
Immunization/challenge study design 
In the first study, the mice were divided into 10 groups (Table I) and in the second study, 11 
groups of mice were used (Table II). In both studies, immunizations were performed under 
light isoflurane anaesthesia (IsoFlo; Abbott, Il, USA) on days 7, 14 and 35 after arrival. 
Appropriate controls were included consisting of sham-immunized mice that were either 
challenged (positive controls) or not (negative controls) (see Tables I and II). For sham-
immunization, Hank’s Balanced Salt Solution (HBSS; Invitrogen, Paisley, England) was 
used. 
Several adjuvants were used, inducing different immune responses. Curdlan is known to elicit 
a predominant Th17 response (Higashi et al., 2010). CpG-DNA and Freund’s complete are 
known to elicit a predominant Th1 response, whereas Freund’s incomplete and Cholera toxin 
elicit a predominant Th2 response (Cox et al., 1997). In the first study, subcutaneous 
vaccination was done by mixing 100 µg of H. suis sonicate (in a volume of 50 µl) with an 
equal volume of FA (Sigma-Aldrich, St. Louis, MO, USA), IFA (Sigma-Aldrich, St. Louis, 
MO, USA) or 200 µg Curdlan (Sigma-Aldrich, St. Louis, MO, USA). This mixture was 
injected at the lower back of the animals. For intranasal vaccination, a total volume of 15 µl 
was used, containing 100 µg of H. suis sonicate mixed with 5 µg CT (Sigma-Aldrich, St. 
Louis, MO, USA), 20 µg CpG-DNA (Hycult, biotech, The Netherlands) or 200 µg Curdlan 
(Sigma-Aldrich, St. Louis, MO, USA). The mixture was then applied on the external nares of 
the mice.  
In the second study, subcutaneous vaccination was done by mixing 100 µg of H. suis sonicate 
with 1.5 µg CCR4 antagonist or 50 µl FA. For sublingual and intranasal vaccination, a total 
volume of 7 µl was used, containing 100 µg of H. suis sonicate mixed with 5 µg CT or 1.5 µg 
CCR4 antagonist. Sublingual vaccination was performed by stretching the mouth of the mice 
open and applying the vaccine under the tongue using a micropipette. 
On day 56 of both studies, the mice were intragastrically inoculated with 0.3 ml of the 
challenge material, containing approximately 2 x 108 viable H. suis bacteria/ml, using a ball-
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tipped gavage needle. The mice were held in an upright position until they regained 
consciousness, to minimize the risk of reflux.  
In both studies, all animals were euthanized 3 weeks after challenge by cervical dislocation 
under deep isoflurane anaesthesia (IsoFlo; Abbott, Il, USA). The stomachs were removed and 
preserved in RNAlater (Ambion, Austin, TX, USA) at -70°C until DNA and RNA extraction. 
A longitudinal strip of tissue taken along the curvatura major of the stomach was fixed in 
phosphate buffered formaline (4%) for histopathological analyses. For DNA and RNA 
isolation, the stomachs were homogenized in 1 ml Tri-reagent (MRC, Brunschwig Chemie, 
Amsterdam, The Netherlands) using a MagnaLyser (Roche Applied Science, Mannheim, 
Germany). The interphase and organic phase were kept at -20°C for subsequent DNA 
extraction according to the instructions of the manufacturer. Meanwhile, total RNA was 
extracted from the upper aqueous phase using the RNeasy mini kit (Qiagen, Venlo, The 
Netherlands).  
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Table I: Experimental set-up Study 1 
 
Immunization1 Administration route2 Adjuvant/mouse3 
Total volume 
administered4 Challenged5 
Number of 
animals6 
1 Neg. Control IN / 15 µl No 6 
    SC / 100 µl No 6 
2 FA SC 50 µl 100 µl Yes 12 
3 IFA SC 50 µl 100 µl Yes 12 
4 Curdlan SC 200 µg 100 µl Yes 12 
5 CT IN 5 µg 15 µl Yes 12 
6 CpG-DNA IN 20 µg 15 µl Yes 12 
7 Curdlan IN 200 µg 15 µl Yes 12 
8 Pos. Control IN / 15 µl Yes 6 
    SC / 100 µl Yes 6 
 
Shown is the 1immunization protocol, 2the administration route of the vaccine, 3the amount of adjuvant used per mouse, 4the volume of the vaccine, 5whether 
the animals were challenged with H. suis or not and 6the number of animals in each group. (FA: Freund’s complete, IFA: Freund’s incomplete, CT: Cholera 
toxin, IN: intranasally, SC: subcutaneously, Pos. control.: sham-immunized/challenged, Neg. control: sham-immunized/not challenged). 
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Table II: Experimental set up Study 2 
  
Immunization1 Administration route2 Adjuvant/mouse3 
Total volume 
administered4 Challenged5 Number of animals6 
1 Neg. Control IN / 7 µl No 6 
2 HBSS/CCR4 SC 1.5 µg 100 µl Yes 6 
3 HBSS/CCR4 IN 1.5 µg 7 µl Yes 6 
4 HBSS/CCR4 SL 1.5 µg 7 µl Yes 6 
5 CT/lysate IN 5 µg 7 µl Yes 6 
6 CT/lysate SL 5 µg 7 µl Yes 6 
7 FA/lysate SC 50 µl 100 µl Yes 6 
8 CCR4/lysate IN 1.5 µg 7 µl Yes 6 
9 CCR4/lysate SL 1.5 µg 7 µl Yes 6 
10 CCR4/lysate SC 1.5 µg 100 µl Yes 6 
11 Pos. Control IN / 7 µl Yes 6 
 
Shown is the 1immunization protocol, 2the administration route of the vaccine, 3the amount of adjuvant used per mouse, 4the volume of the vaccine, 5whether 
the animals were challenged with H. suis or not and 6the number of animals in each group. (HBSS: Hank’s balanced salt solution, CCR4: CC chemokine 
receptor 4 antagonist, CT: Cholera toxin, FA: Freund’s complete, IN: intranasally, SC: subcutaneously, SL: sublingually, Neg. control: sham-immunized/not 
challenged, Pos. control: sham-immunized/challenged). 
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Quantitative Real-Time PCR for the quantification of the bacteria 
Quantitative Real-Time PCR (RT-PCR) was performed using the C1000 Thermal cycler 
(CFX96 Real-Time System, Bio-Rad, Hercules, CA, USA). Each sample contained 5 µl of iQ 
SYBR Green Supermix (Bio-Rad), 0.25 µl of each primer, 3.5 µl of distilled water and 1 µl of 
DNA. For enumeration of colonizing H. suis bacteria in the first study, a 218 bp fragment of 
the ureB gene of H. suis was amplified using the following primers: sense primer: 5’-TTA 
CCA AAA ACA CCG AAG CC-3’, antisense primer: 5’-CCA AGT GCG GGT AAT CAC 
TT-3’. A 1146 bp PCR fragment of the ureB gene served as an external standard (sense 
primer: 5’- CGG GAT TGA TAC CCA CAT TC-3’; antisense primer: 5’- ATG CCG TTT 
TCA TAA GCC AC-3’) (Flahou et al., 2012). For enumeration of colonizing bacteria in the 
second study, a fragment of the ureA gene of H. suis was amplified using the following 
primers: sense primer BF_HsuisF1: 5′-AAA ACA MAG GCG ATC GCC CTG TA-3′ and 
anti-sense primer BF_HsuisR1: 5′-TTT CTT CGC CAG GTT CAA AGC G-3′. For 
generating the standard, part of the ureAB gene cluster (1236 bp) from H. suis strain HS5 was 
amplified using primers U430F and U1735R, as described previously (O’Rourke et al., 2004). 
The copy number concentration was calculated based on the length of the amplicon and the 
mass concentration. The standard consisted of 10-fold dilutions starting at 107 PCR amplicons 
for each 10 µl of reaction mixture. Data analysis was done using the Bio-Rad CFX Manager 
Version 3.0 software (Bio-Rad). 
 
Quantitative Real-Time PCR for the analysis of cytokine and chemokine expression  
Messenger RNA expression levels in stomach tissue were determined for the following genes: 
IL-17, IL-4, IFN-γ, keratinocyte chemoattractant (KC or CXCL1), LPS-induced CXC 
chemokine (LIX), macrophage inflammatory protein 2 (MIP-2 or CXCL2) and IL-10. For the 
RT-PCR reaction, a C1000 Thermal cycler (CFX96 Real-Time System, Bio-RAD, Hercules, 
CA, USA) was used. All reactions were performed in a final volume of 10 µl containing 5 
pmole of the sense and 5 pmole of the antisense primers, 5 µl iQ SYBR mix (Bio-Rad) and 1 
µl cDNA. The reaction protocol consisted of an initial activation phase at 95°C for 15 minutes 
followed by 40 cycles of 95°C for 20 seconds, 60°C for 30 seconds and 73°C for 30 seconds. 
A melting curve was included by increasing the temperature with 0.5°C every 5 seconds 
starting from 65°C until 95°C. The reference genes H2afz, PPIA and HPRT were shown to 
have a stable expression in all samples tested (data not shown) and were included as 
references. The sequences of all used primers are summarized in Table III. The threshold 
cycle values (Ct) were first normalized to the geometric means of the reference genes and the 
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normalized mRNA levels were calculated according to 2(-∆∆Ct) method for each individual 
animal (Livak and Schmittgen, 2001). 
Table III: List of genes and sequences of the primers used for RT-PCR gene expression 
analysis (Flahou et al., 2012). 
   Gene Primer Primer Sequence 
IFN-γ sense 5'-GCG TCA TTG AAT CAC ACC TG-3' 
 
antisense 5'-TGA GCT CAT TGA ATG CTT GG-3' 
IL-4 sense 5'-ACT CTT TCG GGC TTT TCG AT-3' 
 
antisense 5'-AAA AAT TCA TAA GTT AAA GCA TGG TG-3' 
IL-10 sense 5'-ATC GAT TTC TCC CCT GTG AA-3' 
 
antisense 5'-CAC ACT GCA GGT GTT TTA GCT CC-3' 
IL-17 sense 5'-TTT AAC TCC CTT GGC GCA AAA-3' 
 
antisense 5'-CTT TCC CTC CGC ATT GAC AC-3' 
KC sense 5'-GCT GGG ATT CAC CTC AAG AA-3' 
 
antisense 5'-TCT CCG TTA CTT GGG GAC AC-3' 
MIP-2 sense 5'-AAA GTT TGC CTT GAC CCT GA-3' 
 
antisense 5'-TCC AGG TCA GTT AGC CTT GC-3' 
LIX sense 5'-CCC TGC AGG TCC ACA GTG CC-3' 
 antisense 5'-TGG CCG TTC TTT CCA CTG CGA-3' 
H2afz sense 5’-CGT ATC ACC CCT CGT CAC TT-3’ 
 antisense 5’-TCA GCG ATT TGT GGA TGT GT-3’ 
PPIA sense 5’-AGC ATA CAG GTC CTG GCA TC-3’ 
 antisense 5’-TTC ACC TTC CCA AAG ACC AC-3’ 
HPRT sense 5’-CAG GCC AGA CTT TGT TGG AT-3’ 
 
antisense 5’-TTG CGC TCA TCT TAG GCT TT-3’ 
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Histopathological evaluation of the gastric wall 
Samples of the gastric wall were formalin-fixed, paraffin wax embedded, cut at 5 µm and 
stained with hematoxylin and eosin according to standardized protocols. Inflammation 
(infiltration of granulocytes as well as mononuclear cells) was scored separately for the 
mucosa and submucosa, using a scoring system adapted from the human updated Sydney 
System (Stolte et al., 2001). Scoring of inflammatory cell infiltration was performed as 
follows: 0=normal, 1=multifocal mild, 2=diffuse mild or multifocal moderate, 3=diffuse mild 
and (multi)focal moderate, 4=diffuse moderate or multifocal severe, 5=diffuse moderate and 
(multi)focal severe, 6=diffuse severe. Numbers of globular leukocytes were scored as follows: 
0=no globular leukocytes, 1=mild increase in globular leukocyte numbers, 2=moderate 
increase in globular leukocyte numbers, 3=severe increase in globular leukocyte numbers. In 
the second study, the presence of lymphocyte and neutrophil infiltration in the mucosa of the 
fundus was scored separately as follows: 0= normal, 1=mild, 2=moderate, 3=severe. In 
addition, Periodic acid-Schiff (PAS) staining was performed to evaluate the presence of 
pseudo-pyloric metaplasia of the fundus. 
 
Statistical analysis 
For all analyses, SPSS22 (IBM, USA) was used. Differences in H. suis colonization and 
cytokine expression among groups were assessed by using one-way ANOVA analysis. A 
Bonferroni post-hoc test was used for comparisons between the different groups. Histological 
inflammation scores were compared by a Kruskal-Wallis analysis, followed by a Mann-
Whitney U test. For correlations between different variables, Spearman’s rho coefficient (ρ) 
was calculated. A level of probability of 0.05 was used as criterion for significance. 
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Results 
Cholera toxin, Freunds’ complete adjuvant and CCR4 antagonists confer the highest 
level of protection against colonizing H. suis bacteria 
In the first study, all immunization strategies with various adjuvants and routes of 
immunization (i.e. subcutaneous immunization with FA, IFA, Curdlan or intranasal 
immunization with CT, CpG and Curdlan) resulted in the reduction of bacterial burden 
following H. suis challenge, when compared to the sham-immunized/challenged animals 
(Figure 2). However, striking differences were observed among various adjuvants in their 
capacity to decrease the amount of colonizing H. suis bacteria. Only subcutaneous FA/lysate 
(p<0.05) administration and intranasal CT/lysate (p<0.05) administration induced significant 
protection. The results obtained with CT/lysate were also confirmed in the second study, 
wherein the intranasal as well as sublingual route of immunization conferred the highest 
protection against colonization of H. suis in the stomach (P<0.001) (Figure 3). In addition, 
animals subcutaneously immunized with FA/lysate and CCR4 antagonist/lysate showed 
significantly lower H. suis colonization levels after experimental challenge (P<0.01). In 
contrast, mucosal immunization with a CCR4 antagonist (both intranasally and sublingually) 
and lysate showed no significant decrease in bacteria colonizing the stomach. Colonization 
levels in animals that were administrated the CCR4 antagonist in the absence of lysate and 
that were subsequently challenged, were similar to those in the sham-immunized and 
challenged positive control animals.  
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Figure 2. The protective efficacy of different adjuvants on the amount of colonizing H. suis 
bacteria, 3 weeks after challenge, in study 1. Subcutaneous immunization (SC) was done by mixing 
H. suis sonicate with Freund’s complete (FA), Freund’s incomplete (IFA) or Curdlan (Curd) and 
injecting this mixture at the lower back of the mice. Intranasal immunization (IN) was done by mixing 
H. suis sonicate with Cholera toxin (CT), CpG-DNA (CpG) or Curdlan (Curd) and applying this 
mixture on the external nares of the mice. Animals in the control groups were sham-immunized with 
Hank’s Balanced Salt Solution (HBSS). The bacterial load is illustrated as log(10) of H. suis 
copies/mg stomach tissue. Individual mice are illustrated as dots. Significant differences between 
immunized/challenged and non-immunized/challenged animals are noted by * (p<0.05). (con: 
uninfected, inf: infected). 
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Figure 3. The protective efficacy of the different immunization protocols on the amount of 
colonizing H. suis bacteria, 3 weeks after challenge, in study 2. Subcutaneous immunization (SC) 
was done by mixing H. suis sonicate with Freund’s complete (FA) or the CCR4 antagonist (CCR4) 
and injecting this mixture at the lower back of the mice. Intranasal immunization (IN) was done by 
mixing H. suis sonicate with Cholera toxin (CT) or the CCR4 antagonist (CCR4) and applying this 
mixture on the external nares of the mice. Sublingual immunizations (SL) were done by mixing H. 
suis sonicate with Cholera toxin (CT) or the CCR4-antagonist (CCR4). Animals in the control groups 
were sham-immunized with Hank’s Balanced Salt Solution (HBSS). The amount of bacteria 
colonizing the stomach of the mice are illustrated as log(10) of H. suis copies/mg stomach. The 
individual animals are presented as dots. Significant differences between the immunized and 
challenged groups and the positive control group are noted by ** (p<0.01) and *** (p<0.001). (neg. 
con.: sham-immunized/not challenged, pos. con.: sham-immunized/challenged). 
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Mice immunized with a CCR4 antagonist display minimal pseudo-pyloric metaplasia as 
compared to the Freund’s complete adjuvant group upon challenge with H. suis 
In both studies, a number of animals died in each group immunized with CT (both 
intranasally and sublingually), within 48 hours after challenge with H. suis. The most likely 
cause was an immunization/challenge related pneumonia, for histopathological evaluation 
showed the presence of oedema in the interstitial space of the lungs of these mice. In the first 
study, two mice from the Curdlan/intranasally vaccinated group died before challenge, and 
one mouse from the CpG/intranasally vaccinated group died of an unknown cause at week 
eleven following challenge.  
In both studies, all negative control mice showed normal histomorphology with very little to 
no inflammatory cell infiltration in the gastric mucosa (Figure 4). All positive control groups 
showed moderate to severe inflammation. 
 
Figure 4. H&E and PAS staining of a normal fundus. H&E (A) and PAS staining (B) of a normal 
fundus of an animal from the negative control group (original magnification: 100x). 
In the first study, mice immunized subcutaneously with IFA/lysate, FA/lysate and 
Curdlan/lysate clearly showed a stronger infiltration of neutrophils in the fundic mucosa and 
submucosa (p<0.05) (Table IV) as compared to animals from the intranasally 
immunized/challenged groups. Detection of neutrophils was restricted to the mucosa of the 
subcutaneously immunized groups. In addition, all immunized and challenged groups showed 
moderate lymphocyte infiltration, which was most pronounced in the group immunized with 
CT/lysate (Table IV).  
Results from the second study revealed that, compared to the positive control group, mice that 
received CT/lysate by the sublingual route showed significantly increased neutrophil 
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infiltration in the fundus (p<0.01) upon challenge with H. suis. In addition, compared to the 
positive control groups, lymphocyte infiltration was significantly increased in all the 
immunized and challenged groups except for the groups immunized with the CCR4 
antagonist/lysate by sublingual and intranasal routes (Table V).  
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Table IV: Histopathological scoring of inflammation Study 1 
 
Shown are the median scores (min-max) of pseudo-pyloric metaplasia of the fundus, infiltration of the mucosa of the fundus with neutrophils and 
mononuclear cells 3 weeks after challenge of the vaccinated mice. Scoring: 0=normal, 1= mild, 2= moderate, 3= severe. Significant differences between the 
positive control group and the immunized and challenged groups are noted by * (p<0.05). (HBSS: Hank’s balanced salt solution FA: Freund’s complete, IFA: 
Freund’s incomplete, CT: Cholera toxin, Curd: Curdlan, CpG: CpG-DNA IN: intranasally, SC: subcutaneously, con: uninfected group, inf: infected group). 
  
  Pseudo-pyloric metaplasia Neutrophil infiltration Mononuclear cell infiltration 
HBSS/sc/con 0 (0-0) 0 (0-1) 0 (0-0.5) 
HBSS/in/con 0 (0-0) 0 (0-0) 0 (0-0.5) 
HBSS/sc/inf 0 (0-0) 1 (0.5-1) 0.5 (0.5-1.5) 
HBSS/in/inf 0 (0-0) 1 (0.5-2.5) 1.5 (0.5-1.5) 
FA/lysate/SC 2.5 (0-3)* 1.5 (0.5-2)* 0.5 (0.5-1) 
IFA/lysate/SC 3 (3-3)* 1.5 (05-2)* 0.5 (0-0.5) 
Curd/lysate/SC  3 (3-3)* 1.5 (0.5-2)* 0.5 (0.5-1) 
CT/lysate/IN 0 (0-0) 0.5 (0-0.5) 0.5 (0.5-1) 
CpG/lysate/IN 0 (0-0) 0 (0-1) 0.5 (0.5-1) 
Curd/lysate/IN 0 (0-0) 0 (0-0.5) 0.5 (0.5-0.5) 
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Table V: Histopathological scoring of inflammation Study 2 
 
Shown are the median scores (min-max) of pseudo-pyloric metaplasia of the fundus, infiltration of the mucosa of the fundus with neutrophils and 
mononuclear cells 3 weeks after challenge of the vaccinated mice. Scoring: 0=normal, 1= mild, 2= moderate, 3= severe. Significant differences between the 
positive control group and the immunized and challenged groups are noted by * (p<0.05). (CCR4: CC chemokine receptor 4 antagonist, CT: Cholera toxin, 
FA: Freund’s complete, IN: intranasally, SC: subcutaneously, SL: sublingually, Neg. control: sham-immunized/not challenged, Pos. control: sham-
immunized/challenged). 
  Pseudo-pyloric metaplasia Neutrophil infiltration 
Mononuclear cell 
infiltration 
Neg. Control 0 (0-0) 0 (0-0) 0 (0-0) 
CCR4/SC 0 (0-0) 1.5 (0-2) 1.5 (0-2) 
CCR4/IN 0 (0-0) 0.5 (0-2) 0.5 (0-1)* 
CCR4/SL 0 (0-0) 1 (0-2) 1.5 (1-2)* 
CT/lysate/IN 0 (0-0) 1.5 (0-3) 2 (1-3) 
CT/lysate/SL 1.5 (1-2)* 2.5 (2-3)* 3 (3-3)* 
FA/lysate/SC 3 (3-3)* 1.5 (1-2) 2.5 (2-3) 
CCR4/lysate/IN 0 (0-0) 1 (0-1)* 0.5 (0-1)* 
CCR4/lysate/SL 0.5 (0-1) 0.5 (0-1)* 0.5 (0-1)* 
CCR4/lysate/SC 2 (0-3)* 1 (1-2) 2.5 (1-3) 
Pos. Control 1.5 (0-2) 1 (1-1) 2 (1-3) 
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Interestingly, in the first study, pseudo-pyloric metaplasia was detected in the stomach of 75% 
of the mice from the FA/lysate immunized and challenged group and even in 100% of the 
animals belonging to the IFA/lysate and SC Curdlan/lysate immunized and challenged 
animals. In all other groups, no pseudo-pyloric metaplasia was observed (Figure 5). In the 
second study, pseudo-pyloric metaplasia of the fundus was present in the group immunized 
with FA/lysate and CT/lysate/SL and challenged (Figure 6). Although pseudo-pyloric 
metaplasia was also present in the CCR4 antagonist/lysate/SC immunized and challenged 
group (Figure 7), this was nevertheless less severe and not present in all animals, compared to 
the group immunized with FA/lysate (Table V).  
 
A  B  
Figure 5. Histopathological analysis of fundus by H&E staining. Normal fundus from an 
uninfected BALB/c mouse (A). Metaplastic fundus of a Freund’s complete/lysate immunized and H. 
suis-infected BALB/c mouse, showing severe parietal cell loss, with replacement of the epithelium by 
a common glandular epithelium (B). Original magnification: 200x. 
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Figure 6. H&E and PAS staining of the fundus showing pronounced inflammation and severe 
pseudo-pyloric metaplasia. H&E (A) and PAS staining (B) of the fundus of an animal in the FA 
subcutaneously immunized and challenged group, showing pronounced inflammation and severe 
pseudo-pyloric metaplasia (original magnification: 100x). 
 
 
Figure 7. H&E and PAS staining of the fundus, showing mild inflammation and pseudo-pyloric 
metaplasia. H&E (A) and PAS staining (B) of the fundus of an animal from the CCR4 antagonist 
subcutaneously immunized and challenged group, showing mild inflammation and pseudo-pyloric 
metaplasia (original magnification: 100x). 
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Immunization with adjuvants modulates the cytokine responses in the stomach upon H. 
suis challenge  
In the first study, data from immunized/challenged groups were compared to pooled data from 
the sham-immunized/challenged positive control groups (Figure 8). Expression of IL-10, an 
important immunoregulatory cytokine, was significantly lower in all the adjuvant groups as 
compared to the sham-immunized and challenged groups (p<0.0001). In the subcutaneously 
immunized/challenged groups, adjuvants showed distinct differences in their ability to mount 
helper T-cell responses. Although FA/lysate, IFA/ lysate and Curdlan/lysate groups showed 
significantly higher Th1 and Th2 cytokine signatures (IFN-γ; p<0.0001 and IL-4; p<0.01), 
Th17 cytokine responses (IL-17) were only observed with Freund’s complete and incomplete 
adjuvant groups. Mice immunized by mucosal routes displayed distinct helper T-cell 
responses as compared to subcutaneous immunization routes. No Th2 response (IL-4) was 
induced in CT/lysate, CpG/lysate and Curdlan/lysate immunized groups, suggesting that these 
adjuvants selectively induce Th1 and Th17 responses when administered by mucosal routes. 
Clearly, Curdlan/lysate, irrespective of the route of vaccination, was less efficient to induce 
chemokine expression as compared to Freund’s adjuvants. In all immunized/challenged 
animals, LIX showed higher mRNA expression levels (p<0.05) when compared to the sham-
immunized/challenged animals. This was not the case for MIP-2 and KC. However, a clear 
upregulation of MIP-2 mRNA expression levels was observed in the FA/lysate and IFA/lysate 
groups, while a clear upregulation of KC expression was only observed in the FA/lysate and 
CT/lysate groups. Messenger RNA expression levels of these cytokines are presented in 
figure 8.  
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Figure 8. Relative gene expression of cytokines and chemokines in the stomach of challenged 
animals after immunization or after sham-inoculation in study 1. The first bar represents the 
pooled data of the animals that were sham-immunized with HBSS (intranasally and subcutaneously) 
and that were not challenged with H. suis (Neg. con). The second bar represents the pooled data of the 
animals that were sham-immunized with HBSS (intranasally and subcutaneously) and that were 
challenged with H. suis (Pos. con). Bars 3, 4 and 5 represent the groups of animals that were 
immunized subcutaneously with Freund’s complete (FA/lysate/SC), Freund’s incomplete 
(IFA/lysate/SC) or Curdlan (Curd/lysate/SC) and challenged with H. suis. Bars 6, 7 and 8 represent the 
animals that were immunized intranasally with Cholera Toxin (CT/lysate/IN), CpG-DNA 
(CpG/lysate/IN) or Curdlan (Curd/lysate/IN) and challenged with H. suis. An * (p<0.05) indicates a 
significant modulation of mRNA expression levels compared to the sham-immunized/challenged 
groups. Cytokine expression between immunized and challenged groups was also compared with each 
other. When no differences could be found between the different immunized groups, the same letter 
designation was attributed. 
 
Similar results were obtained in the second study (Figure 9). IL-10 expression was clearly 
lower in all vaccinated groups as compared to positive control groups. Of note, the use of the 
CCR4 antagonist by the subcutaneous route induced highest IFN-γ responses confirming the 
previous results obtained with this adjuvant in other models where cellular immune responses 
were significantly induced (Bayry et al., 2008; Pere et al., 2011). However, Th1 responses 
were not induced when the CCR4 antagonist was used for mucosal immunization, a protocol 
which was shown not to be able to confer protection upon challenge with H. suis. 
In both studies, correlation analysis showed a clear, positive correlation between IL-10 
expression and H. suis colonization rates. A significant inverse correlation was found between 
the mRNA expression levels of helper T-cell cytokines and chemokines tested and the 
bacterial load (Figure 10). 
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Figure 9. Relative gene expression in the stomach in challenged animals after immunization or 
after sham-inoculation in study 2. The first bar represents the pooled data of negative control 
animals that were sham-immunized with HBSS and remained unchallenged (Neg. con). The second 
bar represents positive control group where mice were sham-immunized with HBSS and were 
subsequently infected with H. suis (Pos. con). Bars 3 and 4 represent Cholera Toxin groups 
immunized intranasally (CT/lysate/IN) or sublingually (CT/lysate/SL) and challenged with H. suis. 
Bar 5 represents Freund’s complete adjuvant group (FA/lysate/SC). Bars 6 to 8 denote CCR4 
antagonists group immunized by intranasal (IN), sublingual (SL) or subcutaneous (SC) routes 
respectively followed by challenge with H. suis. The letter ‘a’ indicates a significant (p<0.05) 
difference of mRNA expression levels compared to positive control groups. The letter ‘b’ indicates 
significant (p<0.05) changes of expression levels compared to the negative control groups.  
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Figure 10. Correlation between cytokine and chemokine expression and H. suis colonization in 
study 1. Shown are the correlation analyses between IL-17, IL-10, MIP-2, LIX, IFN-γ and IL-4 
mRNA expression levels on the one hand and the number of H. suis bacteria colonizing stomach of 
mice in the immunized and challenged groups on the other hand. Correlation was measured by 
Spearman’s Rho (ρ). Statistical significance between the immunized and challenged groups and the 
positive control group is noted by the P-value.  
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Discussion 
In a previous study we showed that intranasal immunization with a CT/H. suis lysate vaccine, 
induced a partial protection against subsequent H. suis challenge, with some animals even 
showing no detectable H. suis colonization by conventional PCR (Flahou et al., 2009). In this 
same study, animals were also immunized subcutaneously using a H. suis lysate/saponin-
based adjuvant vaccine, which clearly was shown to be inferior to the intranasal immunization 
protocol with regards to its capacity to protect against a subsequent H. suis challenge (Flahou 
et al., 2009). Our current results confirm that the choice of adjuvant plays an important role in 
the efficacy of a vaccine formulation. Indeed, subcutaneous vaccination with H. suis lysate 
adjuvanted with FA or with the CCR4 antagonist induced a similar protection compared to 
intranasal vaccination with CT as an adjuvant. In contrast to parenteral immunization, 
mucosal immunization using this CCR4 antagonist as an adjuvant did not induce a good 
protection against H. suis challenge. CCR4+ effector memory regulatory T cells (Tregs) have 
homing capacity to skin and lungs (Sather et al., 2007). Therefore, the use of CCR4 
antagonists as molecular adjuvant is strictly dependent on the route of immunization. It is 
possible that lack of migration of CCR4+ Tregs to the sublingual region might have 
contributed to ineffectiveness of this route of vaccination with CCR4 antagonists. Conflicting 
results have been reported when comparing the efficacy of mucosal versus systemic 
immunization routes for Helicobacter vaccination, but most studies suggest that mucosal 
immunization is the better one of the two options (Ermak et al., 1998; Sutton et al., 2007; 
Svennerholm et al., 2007). Results from the present study however indicate that subcutaneous 
vaccination, using various well-established vaccine adjuvants, in general yields the best 
results with regards to reduction of H. suis colonization. The only mucosally applied adjuvant 
generating similar levels of protection was CT, which was shown to be equally effective when 
used for sublingual immunization (Figure 3).  
In the present study, protection was obtained in mice immunized subcutaneously with FA as 
adjuvant, which was accompanied by high expression rates of MIP-2, LIX and KC (Figure 8). 
These chemokines are known to be involved in the recruitment of neutrophils. Indeed, 
infiltration with (neutrophilic) granulocytes was more pronounced in subcutaneously 
immunized mice, both compared to intranasally immunized/challenged mice as well as sham-
immunized/challenged positive control animals. This however contrasts somewhat with the 
results of our second study, showing an increased infiltration of neutrophils in animals 
immunized mucosally using CT as an adjuvant. In any case, a more pronounced post-
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vaccination gastritis was associated with a higher degree of protection observed in both 
studies. This is in accordance with data found in the literature for H. pylori vaccination (Goto 
et al., 1999; Morihara et al., 2007; Garhart et al., 2008). However, the disparity in gastritis 
between infected animals and immunized/challenged animals has been described to disappear, 
showing that this is most likely a transient event (Garhart et al., 2002; Sutton et al., 2007). 
Whether post-vaccination gastritis is also a transient event in H. suis vaccination and 
subsequent challenge remains to be determined.  
Compared to the non-immunized/challenged animals, IL-10 expression levels were 
consistently lower in animals from all immunized/challenged groups. In addition, a mild 
positive correlation between IL-10 expression and gastric H. suis colonization rates was 
demonstrated (Figure 10). It has been suggested that H. suis and H. pylori suppress the 
generation of an efficient immune response by inducing expression of anti-
inflammatory/regulatory IL-10, which contributes to the suppression of pro-inflammatory 
Th17 and Th1 responses (Flahou et al., 2009; Kao et al., 2010). IL-10 is one of the most 
important cytokines secreted by regulatory T cells (Tregs), which actively control or suppress 
the function of other cells. Infection of IL-10-/- mice, lacking IL-10 expression, with H. pylori 
and H. felis elicited a more severe chronic gastritis compared with that seen in wild-type mice 
(Ismail et al., 2003), which even led to spontaneous eradication of Helicobacter infection 
(Matsumoto et al., 2005; Blanchard and Nedrud, 2010). Kao et al. showed that mucosal 
dendritic cells induce a Treg-biased response suppressing the induction of a Th17 response, 
which could in part be responsible for the chronicity of the infection (Kao et al., 2010). Since 
Tregs and IL-10 may contribute to persistence of an infection with H. suis, we hypothesized 
that CCR4 antagonists might help to induce protective immunity. Results of our study indeed 
reveal that a significant level of protection was achieved when using the CCR4 antagonist as 
an adjuvant and this was associated with only a mild pseudo-pyloric metaplasia, which was 
sometimes even absent. By inhibition of Treg migration at the time of vaccination we could 
achieve a certain degree of protection without undesirable side effects.  
A clear upregulation of IFN-γ mRNA expression levels was observed in all 
vaccinated/challenged groups when compared to challenged control animals. In general, an 
inverse correlation was observed between the bacterial load and IFN-γ expression levels. In 
non-immunized/H. suis-infected mice, a persistent H. suis infection does not induce a Th1 
response (Flahou et al., 2012). This indicates that immunization-evoked production of IFN-γ, 
a signature Th1 response cytokine, most likely plays a role in suppression and clearance of H. 
suis.  
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The majority of the immunization protocols that induced good protection against infection 
with H. suis, showed a clear upregulation of IL-17 mRNA expression levels. DeLyria and co-
workers showed that IL-17 expression induces the production of KC, MIP-2 and LIX 
primarily by murine fibroblasts and gastric epithelial cells (DeLyria et al., 2009). In the 
present study, this relationship was confirmed in subcutaneously immunized animals and in 
particular with Freund’s adjuvants. Although a marked upregulation of IL-17 mRNA 
expression levels was also observed in the group intranasally immunized with lysate and CT, 
this was not accompanied by an upregulation of mRNA expression levels of KC, MIP-2 and 
LIX. Also, despite imparting protection, subcutaneous vaccination with H. suis lysate 
adjuvanted with the CCR4 antagonist did not induce Th17 responses. Therefore, the role of 
IL-17 in the protection against H. suis infection requires further investigation (Figures 8 and 
9). 
The major side-effects concerning vaccination against H. suis were found to be post-
vaccination gastritis and increased mortality rates, especially when using CT-based 
vaccination protocols. In this study we aimed at reducing these side effects. In all 
immunization protocols using CT as an adjuvant, an increased vaccination/challenge-related 
mortality was observed as compared to other adjuvants. Four mice that were immunized 
intranasally with CT as adjuvant in the first study, died within 48 hours after H. suis 
challenge, most likely because of a pneumonia, which was confirmed histopathologically. In 
the second study, two mice also died in each group immunized with CT (IN and SL), within 
24 hours after challenge with H. suis, most likely of an immunization/challenge related 
pneumonia, despite drastically lowering the volume of the vaccines. Histopathological 
evaluation showed the presence of oedema in the interstitial space of the lungs of these mice. 
In the other groups, the mortality rates were lower.  
In all subcutaneously immunized/challenged groups of the first study, severe post-vaccination 
gastritis and pseudo-pyloric metaplasia of the stomach epithelium were observed. In the 
second study, pseudo-pyloric metaplasia was most pronounced in the groups immunized with 
CT/lysate/SL and FA/lysate/SC. Interestingly, in the CCR4 antagonist/lysate/SC immunized 
animals, showing a similar level of protection, this pseudo-pyloric metaplasia was shown to 
be less severe and sometimes even absent. This clearly warrants further studies with CCR4 
antagonists as adjuvant, aiming at further optimization of immunization protocols. Once 
further optimized in rodent models, these studies should also be performed in pigs, which are 
the natural hosts of H. suis. Although CT was shown to induce substantial side effects in mice 
in the present study and is known to be enterotoxic in humans, Cox et al. describe less toxicity 
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in pigs, the natural host of H. suis. In 3 to 4-week-old piglets, a dose of 1mg of CT induced 
only a pasty to semiliquid diarrhea for 2h (Cox et al., 1997). A major focus for further 
research should be the use of non-toxic derivates of CT that still retain significant 
adjuvanticity. In addition, future research should be performed on the potential use of CCR4 
antagonists in pig vaccination. 
In conclusion, subcutaneous immunization protocols with FA/lysate were shown to confer an 
equally good protection against subsequent H. suis challenge compared to the previously used 
CT/lysate intranasal immunization protocols, although a severe pseudo-pyloric metaplasia 
was observed as well. Interestingly, a newly developed CCR4 antagonist was shown to induce 
similar levels of protection when used as a vaccine adjuvant for subcutaneous vaccination, 
whilst clearly triggering less side effects. Finally, the vaccination protocols that showed good 
results in the current rodent model should be confirmed in a pig model. 
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Helicobacter (H.) suis is a pathogen, colonizing the stomach of more than 60% of pigs at 
slaughter age worldwide. Infections in these animals are associated with chronic gastritis and 
a decreased daily weight gain (De Bruyne et al., 2012). Although not always straightforward, 
several studies attribute a role to this pathogen in the development of gastric ulcer disease in 
pigs (De Bruyne et al., 2012). Economic losses due to these stomach ulcerations are believed 
to be substantial (Haesebrouck et al., 2009). H. suis is also the most prevalent non-
Helicobacter pylori Helicobacter (NHPH) species in humans and has been associated with 
gastritis, peptic ulcers and mucosa-associated lymphoid tissue (MALT) lymphoma 
(Haesebrouck et al., 2009). Unlike H. pylori, limited information is available about H. suis 
infections in the natural hosts and humans. This is due to the fastidious nature of this 
bacterium, which was only successfully cultivated in vitro in 2008 (Baele et al., 2008). The 
development of an isolation and cultivation protocol paved the way for further research on 
pathogenesis, evoked innate and adaptive host immune responses and possible strategies to 
control H. suis infections. This PhD aimed at gaining better insights in different aspects of the 
immune response which should allow to make progress in the development of an efficacious 
vaccine. 
1. Better insights in immune evasion mechanisms used by Helicobacter suis to 
establish chronic inflammation of the stomach mucosa 
H. suis is very successful in the way it colonizes the porcine stomach. The high prevalence in 
pigs indicates that this bacterium has adapted well to its specific environment. It is not only 
able to overcome the gastric acidic pH, but also evades the host immune responses. For H. 
pylori, several mechanisms have been described that might contribute to its persistence, which 
lead to chronic inflammation. Inhibition of innate immune recognition is caused by evasion of 
recognition by pattern recognition receptors, inhibition of phagocytic killing and inhibition of 
killing by reactive oxygen species and nitric oxide. Adaptive immunity is compromised by 
apoptosis of macrophages, inhibition of dendritic cell (DC) maturation and function, 
inhibition of antigen presentation and apoptosis of gastric epithelial cells. H. pylori is also 
known to inhibit T-cell responses by suppressing proliferation and mediating skewing of T-
cell responses towards a regulatory T-cell response. In addition, H. pylori is able to evade 
immune responses by its genomic diversity (Lina et al., 2014). Several of the immune evasion 
mechanisms described for H. pylori are attributed to its major virulence factors CagA and 
VacA, which are absent in H. suis (Vermoote et al., 2011). A better understanding of the 
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mechanisms used by H. suis to evade the host immune response is crucial for the design of 
successful vaccines to eliminate this highly prevalent pathogen. 
In chapter 1, we compared immunity to Helicobacter suis infection in a BALB/c mouse 
model and in its natural host, the pig. Remarkable differences were observed when comparing 
the function of porcine and murine DCs after stimulation with H. suis in vitro. Mature murine 
bone marrow-derived DCs were able to elicit a major Th17 polarized response. In contrast, H. 
suis stimulation of porcine monocyte-derived DCs resulted in a semi-mature phenotype, as 
shown by the impaired expression of MHC class II molecules on the cell surface of these 
cells. Like H. pylori, H. suis might induce semi-maturation of porcine DCs conferring a 
tolerogenic phenotype that elicits the expansion of Tregs, while maintaining a suboptimal 
level of Th17 cells. The results obtained in pigs might be more relevant than those obtained in 
BALB/c mice, since pigs are the natural host of H. suis and care should be taken when 
extrapolating data between different animal models. It remains to be determined whether DCs 
from humans, will act like porcine DCs or rather like murine DCs.  
 
Further research should also focus on virulence factors present in H. suis (including gamma-
glutamyl transpeptidase (GGT) and urease) and their molecular mechanisms that might be 
involved in immune evasion and subsequently promote persistent infection. This may 
ultimately lead to the recognition of potential intervention targets to prevent the progression 
of chronic gastritis. 
GGT has previously been shown to play a critical role in the tolerizing effects of H. pylori on 
murine DCs in vivo and in vitro, by mechanisms which are independent of their suppressive 
activities on T-cells. Zhang et al. (2015) have demonstrated that a H. suis∆ggt deletion mutant 
was able to colonize the stomach of BALB/c mice at levels comparable to WT strains. 
However, this deletion mutant induced significantly less inflammation. Zhang et al. (2015) 
conclude that the higher expression levels of IL-10 in HS5cLP∆ggt infected mice may be 
partially responsible for the attenuated inflammatory response, when compared to WT-
infected animals. Previously published data from in vitro experiments have shown that H. 
pylori GGT suppresses IL-10 secretion by activated human CD4+ T-cells (Beigier-Bompadre 
et al., 2011). This contrasts with the role of GGT in reprogramming DCs towards a 
tolerogenic phenotype. Therefore, its role in immune evasion during H. suis infection requires 
further investigation. 
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Another enzyme which is known to promote persistent gastric Helicobacter colonization by 
establishing a local microenvironment is urease (Weeks and Sachs, 2001). It protects 
helicobacters against gastric acid and facilitates the colonization of the gastric epithelium. 
Urease has also been shown to stimulate cytokine secretion by human monocytes (Harris et 
al., 1996; Phadnis et al., 1996). Experimental studies with gastric epithelial cells (GEC) have 
suggested that urease leads to increased gastric cell death. Clearly, urease plays an important 
role in the inflammatory response by H. pylori and its associated tissue damage. Several 
studies attribute a role to H. pylori urease in inducing gastric epithelial cell death by binding 
to class II MHC molecules on these cells. Beswick et al. (2006) have previously shown that 
H. pylori urease B binds to CD74, the MHC class II-associated invariant chain (Li) on GEC 
and induces NF-kB activation and IL-8 production. CD74 is best known for its role in 
regulating the intracellular transport and functions of class II MHC in antigen presenting cells 
(Elliot et al., 1994). The MHC II expression on the surface of these cells increases in the H. 
pylori-infected tissue. In addition, urease also binds to a panel of human B-cell lines 
expressing a diverse set of class II alleles (Fan et al., 2000). This unsuspected role for urease 
in H. pylori pathogenesis adds support for the use of this bacterial product in the development 
of vaccination strategies to reduce infection and cellular injury by this pathogen. It might be 
worthwhile to investigate whether this is also the case for H. suis infections. The development 
of antibodies that would block the binding of urease to class II MHC may effectively prevent 
bacterial binding to the target tissue and subsequent colonization.  
To further elucidate the molecular mechanisms by which these virulence factors play a role in 
modulating the immune response after gastric Helicobacter infection, experimental studies 
may be carried out with H. suis mutant strains lacking one or a combination of its most 
important virulence factors.  
 
2. Better insights in the development of mucosa-associated lymphoid tissue (MALT) 
lymphoma-like lesions following experimental Helicobacter suis infection in 
rodent models 
Besides pigs and humans, H. suis has also been detected in the stomach of several non-human 
primates. However, no information on the pathogenic outcome of H. suis infection for these 
animals is available, and the source of infection remains to be determined. Phylogenetic 
analysis has shown that pig- and human-associated (1), cynomolgus monkey-associated (2) 
and rhesus monkey-associated (3) H. suis strains form 3 distinct clusters. Surprisingly, 
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macaques might be the ancestral source of H. suis infection in pigs (Flahou et al., unpublished 
results). Cynomolgus monkey-associated H. suis strains have been used in several infection 
studies in mice and were associated with the development of MALT lymphoma-like lesions in 
these animals. These lesions are not observed in mice when using pure in vitro-cultured 
porcine H. suis strains. In any case, direct comparison between H. suis strains from these 
different hosts was difficult before the start of this research, since no pure in vitro-cultured 
primate-associated H. suis strains were available. Previous studies used gastric mucus or 
gastric mucosal homogenate from mice to inoculate the animals. These inocula not only 
contained H. suis but also other micro-organisms, which might influence the infection and the 
host immune response. This has been demonstrated for Kazachstania heterogenica, a yeast 
which was found colonizing the exact same regions of the stomach of Mongolian gerbils as 
gastric helicobacters. The presence of this yeast in gerbil stomachs led to more severe 
inflammation after H. suis infection (Flahou et al., 2010). Recently, we succeeded in 
cultivating pure H. suis strains, obtained from the stomach mucosa from rhesus monkeys and 
cynomolgus monkeys. In chapter 2, we describe a virulence study comparing pure in vitro-
cultured pig-associated and primate-associated H. suis strains in BALB/c mice and Mongolian 
gerbils. No substantial differences were observed between the different H. suis strains in the 
BALB/c mouse model. The cynomolgus monkey-associated H. suis strain was unable to 
colonize the stomach of Mongolian gerbils. Future research should include comparative 
genomics/transcriptomics to elucidate the underlying reasons why this strain was unable to 
colonize in Mongolian gerbils, the animal model which has been previously described to be 
superior to mice for studying H. suis-host interactions (Flahou et al., 2010).  
In the Mongolian gerbil model, both the rhesus monkey-associated H. suis strain and the 
porcine H. suis strain elicited severe inflammation in the stomach mucosa, which was 
characterized by a diffuse infiltration of T lymphocytes and the formation of lymphoid 
follicles, which resembled MALT lymphoma-like lesions. As shown by the abrupt parietal 
cell loss at the transition zone between fundus and antrum, it is clear that both strains have a 
profound effect on the function and homeostasis of the gastric epithelium. These parietal cells 
are abundant in the fundic gland region. They secrete HCl and play a vital role in the 
maintenance of the normal structure and function of the gastric mucosa. Malfunction of these 
cells leads to gastric inflammation. H. suis is often observed near or even inside the canaliculi 
of parietal cells in experimentally infected Mongolian gerbils and mice, in which signs of 
degeneration are shown. Similar observations have been made in humans with H. suis, but not 
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with H. pylori (Joo et al., 2007). A recent study describes an upregulation of ATPase, a 
marker for parietal cells in the stomach of H. suis positive pigs compared to uninfected 
animals (Zhang et al., 2016). 
In contrast with H. pylori which is known to cause gastric adenocarcinomas, H. suis is mainly 
associated with the development of MALT lymphoma-like lesions as a consequence of 
chronic inflammation in the gastric mucosa of the infected host (Nakamura et al., 2007). 
These differences may be caused by differences in host immune response towards both 
species. The development of B-cell MALT lymphoma has been associated with a Th2 
response, rather than a Th1-predominant response (Greiner et al., 1997; Stolte et al., 2002). 
However, others describe that these tumour infiltrating T-cells represent a heterogeneous 
population consisting of multiple functional subsets which secrete different combinations of 
cytokines of both the Th1- and Th2-type (D’elios et al., 2003; Floch et al., 2015). It has been 
widely reported that mainly CD4+ T cells produce IFN-γ, but there is also evidence that other 
immune cells such as B-cells, DCs, and natural killer cells have the ability to secrete this 
cytokine (Yang et al., 2015). Several studies attribute a major role for IFN-γ in the formation 
of gastric lymphoid follicles after H. suis infection (Mimura et al., 2011; Yang et al., 2015). In 
addition, IFN-γ-producing B-cells evoke gastric lymphoid follicle formation independent of 
T-cell help, suggesting that they are crucial for the development of gastric MALT lymphoma 
induced by Helicobacter infection (Yang et al., 2015). Our results are in agreement with these 
previous studies, confirming the role of IFN-γ in the development of gastric lymphoid 
follicles after infection with pure in vitro-cultured H. suis strains in Mongolian gerbils.  
As mentioned before, CD4+CD25+ regulatory T-cells are important in protecting the 
Helicobacter infected host against excessive gastric inflammation and disease signs, while on 
the other hand, they may promote bacterial colonization which may increase the risk to 
develop gastric MALT lymphoma. Local Tregs could also be of major importance for 
perseverance of a minimal bacterial load, thereby maintaining an antigen-dependent disease 
that could regress after eradication by antimicrobials (Laur et al., 2016). As shown in a gastric 
MALT lymphoma murine model involving a H. felis infection, Tregs are recruited by 
cytokines such as CCL17, CCL22 (Craig et al., 2010), CCL20 and CXCL13 (Cook et al., 
2014). Indeed, the administration of anti-CXCL13 antibodies yields promising results in 
patients where the MALT lymphoma did not regress after standard antibiotic treatment 
(Yamamoto et al., 2014). The crucial role of CXCL13 for lymphoid infiltrate formation has 
also been demonstrated for H. suis in animal models (Zhang et al., 2015). Our results in 
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chapter 2 show increased CXCL13 mRNA expression levels in both BALB/c mice and 
Mongolian gerbils. However, MALT lymphoma-like lesions were only observed in H. suis 
infected gerbils and not in mice, even after 6 months post infection. In addition, in chapter 1 
we demonstrated that in naturally H. suis infected pigs at slaughter age, increased CXCL13 
levels were present in the entire glandular stomach, which was associated with the formation 
of gastric lymphoid follicles. Therefore, the role of this B-cell chemoattractant in MALT 
lymphomagenesis might be dependent on the infected host. 
Other factors possibly involved in gastric follicle formation are CD40 and its receptor 
CD40L, which play an important role in the co-stimulation of B-cells (Greiner et al., 1997; 
Craig et al., 2010). CD40 signaling in B-cells is also known to promote germinal center 
formation, and might be essential for the survival of many cell types, including gastric cancer 
B-cells under normal and inflammatory conditions (D’Orlando et al., 2007). Floch et al. 
(2015) also attribute a major role for lymphotoxin-α, lymphotoxin-β and numerous members 
of the tumour necrosis factor family in MALT lymphoma-related pathologies. In addition to 
the involvement of cytokines, several mechanisms have been described to stimulate 
lymphomagenesis in this setting. An overexpression of miR-142-5p and miR-155 as well as 
increased lymphangiogenesis and angiogenesis, all have been shown to be involved in H. 
suis-induced gastric MALT lymphoma (Nakamura et al. 2008; Saito et al. 2012). 
 
3. The newly developed CCR4 antagonist might be a promising adjuvant in 
Helicobacter suis vaccine development 
Currently, no specific control strategies are available to decrease the prevalence of H. suis 
infections and its related pathologies in pigs. Stricter hygiene measures which have been 
shown to be useful to control the spread of other major swine pathogens, might also be 
successful in preventing the introduction of H. suis (Melnichouk et al., 1999). Eradication of 
gastric Helicobacter infections using antimicrobial therapy is expensive, time-consuming and 
may favor spread of antimicrobial resistance in the pig’s microbiota, which is also of public 
health concern (Malfertheiner et al., 2012). Moreover, antimicrobial resistance has been 
reported among porcine H. suis isolates (Vermoote et al., 2011b). A widespread control 
strategy of H. suis infections in pigs by antibiotic-based therapy is hence not recommended. 
Therefore, vaccination might be a valuable alternative approach. 
Several H. pylori immunization strategies have been tested with a wide variety of antigens, 
adjuvants and delivery routes that can significantly reduce H. pylori colonization levels in 
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mice. However, sterilizing immunity has rarely been achieved in animal models and the few 
clinical trials in humans have been unsuccessful. Before the start of this research, only a 
limited number of vaccination studies against H. suis infection had been performed. 
Promising results have been published using either H. suis whole-cell lysate or recombinant 
(r) UreB but not rNapA given prophylactically to protect against an experimental H. suis 
infection in BALB/c mice (Vermoote et al., 2012). It was also shown that vaccination with a 
combination of rGGT and rUreB protect mice against subsequent H. suis infection and is not 
associated with severe post-vaccination gastric inflammation (Vermoote et al., 2013). Despite 
the induction of a considerable degree of protection against infection, increased mortality 
rates were observed in these studies. This was most likely due to the intranasal use of Cholera 
Toxin (CT) as adjuvant, which might have caused swelling of the nasal cavity mucosae, 
resulting in asfyxia. No other adjuvants besides CT (for intranasal vaccine delivery) and a 
saponin-based adjuvant (for subcutaneous vaccine delivery) had been tested in H. suis 
vaccination studies before the start of this research. Therefore, in the third chapter we aimed 
at exploring the efficacy and safety of several established and new vaccine adjuvants (CpG-
DNA, Curdlan, Freund’s complete (FA), Freund’s incomplete (IFA), CT, CCR4 antagonist) 
administered subcutaneously, intranasally or sublingually along with H. suis whole-cell lysate 
to protect against H. suis challenge in BALB/c mice.  
In line with other infectious agents that use the mucosal surface as entry point for infection, it 
might be expected that topical application of Helicobacter vaccines at the mucosal surface is 
more suitable to induce a protective immune response than systemic application (Ogra et al., 
2001). However, our study revealed that subcutaneous immunization protocols with FA/lysate 
conferred an equally good protection against subsequent H. suis challenge compared to the 
previously used CT/lysate intranasal immunization protocols, although severe pseudo-pyloric 
metaplasia and post-immunization gastritis were observed as well. This post-immunization 
gastritis appears to be the result of a heightened immune response to residual Helicobacter 
bacteria. This has also been observed in murine vaccination studies with H. pylori. Its role in 
protection remains largely unclear (Vermoote et al., 2013). A hypothesis for the development 
of post-immunization gastritis is that in an immunized host, challenge with a gastric 
Helicobacter sp. will lead to an enhanced gastric inflammatory response which could be 
critical for the elimination of the bacteria. Several experimental studies have indeed shown 
that the severity of this gastritis is inversely correlated with the degree of protection, which is 
also confirmed by the results of the present study (Vermoote et al., 2012; Vermoote et al., 
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2013). However, post-immunization gastritis was found to be negligible in mice vaccinated 
with single proteins and mice immunized with combinations of rUreB and rGGT, although in 
these groups a significant reduction or even clearance of H. suis was achieved (Vermoote et 
al., 2013). Longterm experimental studies will have to be performed in order to determine 
whether this post-immunization gastritis is transient and if it also occurs in the natural hosts of 
H. suis. 
Interestingly, over the past ten years, several studies have demonstrated that prime-boost 
immunizations can be given with unmatched vaccine delivery methods while using the same 
antigen, in a “heterologous” prime-boost format. The most interesting and unexpected finding 
is that, in many cases, heterologous prime-boost is more effective than the “homologous” 
prime-boost approach. Further studies will be necessary to optimize such vaccination 
strategies in rodent models and pigs. 
 
In our study, CT was used for comparison with other adjuvants. CT in its current form can not 
be used in pigs due to its toxicity. Much effort has been made recently to detoxify the 
adjuvants CT and LT and simultaneously maintain the stimulatory effect. A double mutant 
form of LT (dmLT) seems to be a promising adjuvant with reduced toxicity and preserved 
stimulatory capacity (Sjökvist Ottsjö et al., 2013). In addition, CTA1-DD combines the 
activity of the holotoxin (CTA1) and an immunoglobulin binding domain (DD fragment) that 
targets and mainly activates B-cells. This adjuvant shows no toxicity in rodents (Eriksson et 
al., 2004) and non-human primates (Sundling et al., 2008). A significant reduction of H. 
pylori was observed when this adjuvant was administered intranasally together with whole-
cell lysate in a therapeutic setting in C57BL/6 mice (Akhiani et al., 2006). 
Although the use of FA was shown to induce protection in mice, its use is not permitted in 
food-producing animals, since the oil remains at the injection site and the killed mycobacteria 
in the adjuvant may induce a positive reaction to the tuberculin test. In laboratory animals, the 
use of FA is acceptable when scientifically justified and the search for alternatives is 
considered. Immunization of laboratory animals may also be performed with FA containing a 
complex glycolipid, muramyl dipeptide, which can be extracted from mycobacterial cell walls 
or synthesized, and which contains much of the adjuvant activity of whole killed 
mycobacteria (Ogawa et al., 2011). 
Interestingly, vaccination with the newly developed CCR4 antagonist together with H. suis 
whole-cell lysate induced protection when applied subcutaneously, whilst clearly triggering 
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less side effects. Mucosal administration of this adjuvant did not confer significant protection. 
CCR4 is a receptor for CCL22 and CCL17, the chemotactic agents attracting Tregs both in 
vivo and in vitro. Both chemokines are produced in large amounts by DCs upon activation and 
promote the contact between DC and CCR4+ T-cells. This small molecular weight antagonist 
to CCR4, identified by in silico approach, has previously been demonstrated to block the 
migration of CCR4+ Tregs in vitro and in vivo and to enhance DC mediated human CD4+ T-
cell proliferation in vitro (Figure 1) (Bayry et al., 2008; Vitali et al., 2012). IL-10 producing 
Tregs are known to be increased in the gastric mucosa of H. pylori infected patients. They 
play a role in controlling immunopathology but also promote persistent infection. Since Tregs 
and IL-10 contribute to persistence of an infection with H. suis, we hypothesized that CCR4 
antagonists might help to enhance immunogenicity of H. suis vaccines.  
Small molecule antagonist-based approach targeting the interaction between chemokines and 
their receptors to inhibit transiently the recruitment of Tregs at the site of immunization has 
been explored previously in other settings (Bayry et al., 2008; Davies et al., 2009). In chapter 
3, we demonstrated that this CCR4 antagonist might be a new, promising adjuvant in H. suis 
vaccination. This adjuvant is safe and efficient, since the major advantage is that the 
recruitment of Tregs at the site of immunization is blocked transiently, with no subsequent 
marks of auto-immunity (Bayry et al., 2014a). This molecular adjuvant amplifies cellular and 
humoral responses when injected in combination with various vaccine antigens (Bayry, 
2014b). This is another advantage compared to aluminum adjuvants, the only adjuvants 
licensed for human use worldwide, which almost exclusively induce humoral immune 
responses. At the downside, Tregs share most of the surface markers that are common with 
effector T-cells and hence many of the strategies that target Tregs lack specificity. CCR4 is 
also expressed by Th2 cells and by a small subset of Th17 cells. Therefore, CCR4 antagonists 
might inhibit antibody responses when used in the context of booster immunization as they 
might prevent interaction of DCs with memory Th2 cells (Bayry, 2014b). In any case, the use 
of CCR4 antagonists as adjuvant in future Helicobacter vaccines, and vaccines in general, 
requires further research before use in clinical trials.  
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Figure 1. Presentation of the CCR4 antagonist-based approach to target Treg-DC interaction in 
vaccination. (a) DC undergo maturation and activation upon receiving the signals from vaccine 
antigens. These DC secrete large amounts of chemokines CCL17 and CCL22 that attract CCR4-
positive Tregs to the proximity of DC. (b) The migrated Tregs inhibit the activation and functions of 
DC and hence dampen the immune response to vaccines. (c) The small molecule antagonists to CCR4 
block the interaction of CCR4 with CCL17 and CCL22 thus prevent the inhibitory action of Tregs on 
DC. As a consequence, DC undergo a complete activation process and induce maximum immune 
responses to vaccines (Bayry, 2014b). 
 
4. The choice of antigen plays a major role in gastric Helicobacter vaccine efficacy 
Previous immunization studies and the study described in chapter 3, have shown promising 
results in terms of protection when using H. suis whole-cell lysate as vaccine antigen 
(Vermoote et al., 2012; Vermoote et al., 2013). However, it is not likely, if not impossible, 
that a vaccine containing crude antigens will be authorized by regulatory authorities due to 
batch-to-batch variation and lack of thorough characterization of the preparation (Raghavan 
and Quiding-Järbrink, 2016). Good results on vaccine-induced protection have also been 
obtained using recombinant antigens from H. suis either alone or in combination. Urease has 
been proven to be an attractive vaccine antigen because it is highly conserved in the genus 
Heliocbacter and is required for colonization. Combination of urease with other antigens 
yields better results (Vermoote et al., 2013). Two or more recombinant proteins can also be 
genetically fused to create a multivalent vaccine, which might overcome logistical and 
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manufacturing problems that would be associated with a vaccine composed of multiple 
antigens. The search for new vaccine antigens that are surface exposed and highly conserved 
in the genus Heliocbacter is still ongoing using genomic and proteomic approaches (Bumann 
et al., 2002; Dutta et al., 2006). 
Another possible and promising vaccination strategy against Helicobacter infections, that 
recently received attention is mRNA vaccination. The use of this type of vaccines has several 
advantages. The genetic construct harbors only the elements directly required for expression 
of the encoded protein. Moreover, while recombination between single-stranded RNA 
molecules may occur in rare cases, mRNA does not interact with the genome (Chetverin et 
al., 2004). Thus, potentially detrimental genomic integration is excluded. This lack of 
genomic integration in combination with mRNA being non-replicative as well as 
metabolically decaying within a few days, makes mRNA a merely transient carrier of 
information (Probst et al., 2007). In addition, mRNA binds to pattern recognition receptors 
and mRNA vaccines may be designed to be self-adjuvanting (Fotin-Mleczek et al., 2011). A 
mRNA vaccine expressing major H. suis virulence factors, together with the CCR4 antagonist 
as adjuvant might be a promising strategy. Future studies in this field will provide more 
information on the use of mRNA vaccines to combat Helicobacter infections. 
For the further development of a successful H. suis vaccine, better understanding of the 
mechanisms of vaccine-induced protection is necessary. Results from our study are in line 
with those of previous immunization studies against H. suis infections in mice. Probably a 
combination of local Th1 and Th17 responses play a role in protective immunity (Vermoote et 
al., 2012; Vermoote et al., 2013). It remains, however, unclear why subcutaneous vaccination 
with H. suis lysate together with the CCR4-antagonist did not induce Th17 responses, while 
still achieving protection. Therefore, the role of IL-17 in protection against H. suis infection 
requires further investigation. In previous immunization studies it was shown that circulating 
antibodies could also play a role in protection, as indicated by the correlation between the 
reduction of gastric H. suis colonization and the increase of antigen-specific antibodies 
(Vermoote et al., 2012; Vermoote et al., 2013). Our results demonstrated that serum levels of 
anti-lysate IgG in immunized mice were significantly elevated compared to negative controls 
at 3 weeks post-immunization and to both negative controls and sham-immunized mice at 
final euthanasia, which may support a role for antibodies in protection. However, several 
other H. pylori and H. felis immunization studies have demonstrated that antibodies are not 
essential (Blanchard et al., 1999; Gottwein et al., 2001; Garhart et al., 2003). Table I 
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summarizes the remaining obstacles and the progress made in H. pylori and H. suis 
vaccination.  
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Table I. Summary of the remaining obstacles and the progress made in H. pylori and H. 
suis vaccination. 
H. pylori vaccination 
Obstacles Progress 
Protective immune mechanisms 
➢ Complex pathogenesis and immune response 
➢ Immune evasion strategies (Treg response)  
➢ Protective immune mechanisms that will lead to 
bacterial eradication in humans need to be further 
identified 
➢ Mice: CD4+ T helper cells but not CD8+ cytotoxic T-
cells or antibodies are crucial for vaccine induced 
protection 
➢ Probably, both Th1 and Th17 responses contribute to 
bacterial clearance 
Choice of antigen(s) 
➢ Many different virulence factors with large genetic 
variability 
➢ CagA, VacA, GGT both have pro-inflammatory and 
anti-inflammatory properties  
➢ No consensus on which antigen or combination of 
antigens should be used 
Major H. pylori virulence factors (cagPaI, CagA, VacA) have 
been well-studied and characterized. 
Administration routes 
No consensus on which administration route should be used. Emphasis has been given to immunization via mucosal 
routes. Parenteral route has also been evaluated. 
Choice of adjuvants 
➢ CT and LT: potent inducers of immune response but 
toxic in humans (diarrhea, facial paralysis) 
➢ Obvious need for safe adjuvants that are potent 
enhancers of both cellular and humoral immunity 
➢ No consensus on which adjuvant should be used 
Efforts have been made to develop molecules with reduced 
toxicity but intact adjuvanticity (CTA1-DD, dmLT,..). 
Side-effects 
Post-immunization gastritis Future studies are required 
H. suis vaccination 
Obstacles Progress 
Protective immune mechanisms 
➢ Limited information on immune responses to H. suis 
infection (especially in natural hosts) 
➢ Immune evasion strategies (Treg-response) 
➢ Immune response elicited by H. suis infection is host 
species-specific 
Mice: probably a combination of Th1, Th17 and antibody 
responses are necessary 
Choice of antigen(s) 
➢ Limited number of studies on H. suis virulence factors  
➢ H. suis lacks most important H. pylori virulence factors 
(cagPaI, CagA, VacA) that have been extensively 
studied 
Good results obtained in terms of protection with a subunit 
vaccine: combination of rUreB and rGGT in BALB/c mice. 
Administration routes 
No consensus on which administration route should be used. Most studies suggest that the mucosal route should be used. 
This research suggests that subcutaneous vaccination can be 
used as well.  
Choice of adjuvants 
➢ Previously used adjuvants in H. suis vaccination 
studies in mice:  
▪ CT: toxic for humans and pigs  
▪ saponin-based adjuvant: low efficacy 
➢ Obvious need for safe and efficient adjuvants 
CCR4-antagonist: promising adjuvant to include in H. suis 
vaccines (good protection, less pseudo-pyloric metaplasia). 
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Side-effects 
Post-immunization gastritis, pseudo-pyloric metaplasia Vaccination with combination of rUreB and rGGT together 
with CT induced less post-vaccination gastritis. Vaccination 
with CCR4 antagonist and whole cell lysate also induced less 
post-vaccination gastritis. 
 
5. Pro- and prebiotics: alternative treatment options 
Finally, it might also be worthwhile to investigate if pre- or probiotics can be used as an 
alternative therapy for H. suis-related diseases in pigs. Probiotics are live microorganisms 
which, confer a health benefit to the host, when administered in adequate amounts. Probiotics 
are not part of the current treatment therapies prescribed for H. pylori eradication, but there 
are numerous studies, most of them using probiotics as adjuvants to therapy, showing a 
reduction of side-effects in the greater majority of cases. The most frequently used probiotics 
for H. pylori infection are composed of Lactobacillus, Bifidobacterium, Saccharomyces, and 
Streptococcus spp. The mode of action of these probiotics relies on competition for nutrients 
and for adhesion to cell receptors, antimicrobial activity, and modulation of the immune 
system and microbiota. However, the clinical trials using probiotics as a complement to H. 
pylori eradication treatment are very diverse in their design and probiotic content, which may 
explain the contradicting published reports. Further studies in this field are required (Vale et 
al., 2016). 
6. General conclusions 
The results described in this doctoral thesis provide new insights into host immune responses 
evoked by H. suis infections. We demonstrated that H. suis is able to evade host immune 
responses by reprogramming porcine DCs towards a tolerogenic phenotype which skew T-
cell responses to Treg-biased responses. These mechanisms are independent of the major H. 
pylori virulence factors CagA and VacA, which are absent in H. suis. Future research should 
focus on the H. suis virulence factors and their molecular mechanisms that might be involved 
in immune evasion and subsequently promote persistent infection. This may ultimately lead to 
the recognition of potential intervention targets to prevent the progression of chronic gastritis. 
We provided new insights in the development of MALT lymphoma-like lesions following H. 
suis infection in Mongolian gerbils. These lesions might be associated with the induction of a 
mixed inflammatory response probably involving Th1 signature cytokine IFN-γ, the 
upregulation of B-cell promoting factors, including CXCL13, and the possible involvement of 
Tregs. In any case, the mechanisms that regulate the development of MALT lymphoma 
following H. suis infections need to be further elucidated.  
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Before the start of this research, few H. suis vaccination studies had been performed. H. suis 
vaccine research has been promising, but has not yet delivered an effective vaccine. We 
describe the potential use of a novel, promising adjuvant, a CCR4 antagonist that transiently 
blocks Treg migration at the site of immunization, when administered subcutaneously 
together with H. suis whole-cell lysate. The mechanisms of vaccine-induced protection, 
identification of novel H. suis antigens and the presence of post-immunization gastritis 
warrant further research. 
General Discussion 
 
192 
 
References 
Akhiani AA, Stensson A, Schön K, Lycke N. 2006. The nontoxic CTA1-DD adjuvant 
enhances protective immunity against Helicobacter pylori infection following mucosal 
immunization. Scand J Immunol. 63:97-105. 
Baele M, Decostere A, Vandamme P, Ceelen L, Hellemans A, Chiers K, Ducatelle R, 
Haesebrouck F. 2008. Isolation and characterization of Helicobacter suis sp. nov. from 
pig stomachs. Int J Syst Evol Microbiol. 58:1350-1358. 
Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri SV, Hill AV, Kazatchkine 
MD, Beverley PC, Flower DR, Tough DF. 2008. In silico identified CCR4 antagonists 
target regulatory T cells and exert adjuvant activity in vaccination. Proceedings of the 
National Academy of Sciences of the United States of America. 105:10221-10226.  
Bayry J, Tartour E, Tough DF. 2014a. Targeting CCR4 as an emerging strategy for cancer 
therapy and vaccines. Trends Pharmacol Sci. 35:163-165.  
Bayry J. 2014b. Regulatory T cells as adjuvant target for enhancing the viral disease vaccine 
efficacy. Virusdisease. 25:18-25.  
Beigier-Bompadre M, Moos V, Belogolova E, Allers K, Schneider T, Churin Y, Ignatius R, 
Meyer TF, Aebischer T. 2011. Modulation of the CD4+ T-cell response 
by Helicobacter pylori depends on known virulence factors and bacterial cholesterol 
and cholesterol alpha-glucoside content. J Infect Dis. 204:1339-1348.  
Beswick EJ, Pinchuk IV, Minch K, Suarez G, Sierra JC, Yamaoka Y, Reyes VE. 2006. The 
Helicobacter pylori urease B subunit binds to CD74 on gastric epithelial cells and 
induces NF-kappaB activation and interleukin-8 production. Infect Immun. 74:1148-
55. 
Blanchard TG, Czinn SJ, Redline RW, Sigmund N, Harriman G, Nedrud JG. 1999. Antibody 
independent protective mucosal immunity to gastric Helicobacter infection in mice. 
Cell Immunol. 191:74-80. 
Bumann D, Aksu S, Wendland M, Janek K, Zimny-Arndt U, Sabarth N, Meyer TF, Jungblut 
PR. 2002. Proteome analysis of secreted proteins of the gastric pathogen Helicobacter 
pylori. Infect Immun. 70:3396-403. 
Chetverin AB. Replicable and recombinogenic RNAs. 2004. FEBS Lett. 567:35-41.  
Cook KW, Letley DP, Ingram RJ, Staples E, Skjoldmose H, Atherton JC, Robinson K. 2014. 
CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-
infected human gastric mucosa. Gut. 63:1550-1559. 
General Discussion 
 
193 
 
Craig VJ, Cogliatti SB, Arnold I, Gerke C, Balandat JE, Wundisch T, Muller A. 2010. B-cell 
receptor signaling and CD40 ligand-independent T cell help cooperate 
in Helicobacter-induced MALT lymphomagenesis. Leukemia. 24:1186-1196. 
Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, Draper SJ, Beverley 
PC, Tough DF, Flower DR. 2009. Toward the discovery of vaccine adjuvants: 
coupling in silico screening and in vitro analysis of antagonist binding to human and 
mouse CCR4 receptors. PLoS One. 4:e8084.  
De Bruyne E, Flahou B, Chiers K, Meyns T, Kumar S, Vermoote M, Pasmans F, Millet S, 
Dewulf J, Haesebrouck F, Ducatelle R. 2012. An experimental Helicobacter suis 
infection causes gastritis and reduced daily weight gain in pigs. Vet Microbiol. 
160:449-454. 
D'Elios MM, Amedei A, Del Prete G. 2003. Helicobacter pylori antigen-specific T-cell 
responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-
grade mucosa-associated lymphoid tissue (MALT) lymphoma. Microbes Infect. 5:723-
30. 
D'Orlando O, Gri G, Cattaruzzi G, Merluzzi S, Betto E, Gattei V, Pucillo C. 2007. Outside 
inside signaling in CD40-mediated B cell activation. J Biol Regul Homeost 
Agents. 21:49-62. 
Dutta A, Singh SK, Ghosh P, Mukherjee R, Mitter S, Bandyopadhyay D. 2006. In silico 
identification of potential therapeutic targets in the human 
pathogen Helicobacter pylori. In Silico Biol. 6:43-7. 
Elliott EA, Drake JR, Amigorena S, Elsemore J, Webster P, Mellman I, Flavell RA.1994. The 
invariant chain is required for intracellular transport and function of major 
histocompatibility complex class II molecules. J. Exp. Med. 179:681-694. 
Eriksson AM, Schön KM, Lycke NY. 2004. The cholera toxin-derived CTA1-DD vaccine 
adjuvant administered intranasally does not cause inflammation or accumulate in the 
nervous tissues. J Immunol. 173:3310-9. 
Fan X, Gunasena H, Cheng Z, Espejo R, Crowe SE, Ernst PB, Reyes VE. 2000. Helicobacter 
pylori urease binds to class II MHC on gastric epithelial cells and induces their 
apoptosis. J Immunol. 165:1918-24. 
Flahou B, De Baere T, Chiers K, Pasmans F, Haesebrouck F, Ducatelle R. 2010. Gastric 
infection with Kazachstania heterogenica influences the outcome of a Helicobacter 
suis infection in Mongolian gerbils. Helicobacter. 15:67-75.  
General Discussion 
 
194 
 
Floch P, Laur AM, Korolik V, Chrisment D, Cappellen D, Idrissi Y, Dubus P, Mégraud 
F, Lehours P. 2015. Characterisation of inflammatory processes 
in Helicobacter pylori-induced gastric lymphomagenesis in a mouse model. 
Oncotarget. 6:34525-36.  
Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ. 
2011. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 
dependent adaptive immune responses and provide antitumor activity. J Immunother. 
34:1-15.  
Garhart CA, Nedrud JG, Heinzel FP, Sigmund NE, Czinn SJ. 2003. Vaccine-induced 
protection against Helicobacter pylori in mice lacking both antibodies and interleukin-
4. Infect Immun. 71:3628-33. 
Gottwein JM, Blanchard TG, Targoni OS, Eisenberg JC, Zagorski BM, Redline RW, Nedrud 
JG, Tary-Lehmann M, Lehmann PV, Czinn SJ. 2001. Protective anti-Helicobacter 
immunity is induced with aluminum hydroxide or complete Freund's adjuvant by 
systemic immunization. J Infect Dis. 184: 308-314. 
Greiner A, Knörr C, Qin Y, Sebald W, Schimpl A, Banchereau J, Müller-Hermelink HK. 
1997. Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-
type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and 
differentiation. Am J Pathol. 150:1583-93. 
Haesebrouck F, Pasmans F, Flahou B, Chiers K, Baele M, Meyns T, Decostere A, Ducatelle 
R. 2009. Gastric helicobacters in domestic animals and non-human primates and their 
significance for human health. Clin Microbiol Rev. 22:202-23. 
Harris PR, Mobley HL, Perez-Perez GI, Blaser MJ, Smith PD. 1996. Helicobacter 
pylori urease is a potent stimulus of mononuclear phagocyte activation and 
inflammatory cytokine production. Gastroenterology. 111:419-25. 
Joo M, Kwak JE, Chang SH, Kim H, Chi JG, Kim KA, Yang JH, Lee JS, Moon YS, Kim 
KM. 2007. Helicobacter heilmannii-associated gastritis: clinicopathologic findings 
and comparison with Helicobacter pylori-associated gastritis. J Korean Med Sci. 
22:63-69. 
Laur AM, Floch P, Chambonnier L, Benejat L, Korolik V, Giese A, Dubus P, Mégraud 
F, Bandeira A, Lehours P. 2016. Regulatory T cells may participate in Helicobacter 
pylori persistence in gastric MALT lymphoma: lessons from an animal model. 
Oncotarget. 7:3394-402.  
General Discussion 
 
195 
 
Lina TT, Alzahrani S, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. 2014. 
Immune evasion strategies used by Helicobacter pylori. World J 
Gastroenterol. 20:12753-66.  
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini 
GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European 
Helicobacter Study Group. 2012. Management of Helicobacter pylori infection - the 
Maastricht IV/Florence Consensus report. Gut. 61:646-664. 
Melnichouk SI, Friendship RM, Dewey CE, Bildfell RJ, Smart NL. 1999. Helicobacter-like 
organisms in the stomach of pigs with and without gastric ulceration. Swine Health 
Prod. 7:201-205. 
Mimura T, Yoshida M, Nishiumi S, Tanaka H, Nobutani K, Takenaka M, Suleiman 
YB, Yamamoto K, Ota H, Takahashi S, Matsui H, Nakamura M, Miki I,Azuma T. 
2011. IFN-γ plays an essential role in the pathogenesis of gastric lymphoid follicles 
formation caused by Helicobacter suis infection. FEMS Immunol Med 
Microbiol. 63:25-34.  
Nakamura M, Murayama SY, Serizawa H, Sekiya Y, Eguchi M, Takahashi S, Nishikawa K, 
Takahashi T, Matsumoto T, Yamada H, Hibi T, Tsuchimoto K, Matsui H. 2007. 
“Candidatus Helicobacter heilmannii” from a cynomolgus monkey induces gastric 
mucosa-associated lymphoid tissue lymphomas in C57BL/6 mice. Infect Immun. 
75:1214-1222 
Nakamura M, Takahashi S, Matsui H, Murayama SY, Aikawa C, Sekiya Y, Nishikawa K, 
Matsumoto T, Yamada H, Tsuchimoto K. 2008. Microcirculatory alteration in low-
grade gastric mucosa-associated lymphoma by Helicobacter heilmannii infection: its 
relation to vascular endothelial growth factor and cyclooxygenase-2. J Gastroenterol 
Hepatol. 23:S157-S160. 
Ogawa C, Liu YJ, Kobayashi KS. 2011. Muramyl dipeptide and its derivatives: peptide 
adjuvant in immunological disorders and cancer therapy. Curr Bioact Compd. 7:180-
197. 
Ogra PL, Faden H, Welliver RC. 2001. Vaccination Strategies for Mucosal Immune 
Responses. Clinical Microbiology Reviews. 14:430-445.  
Phadnis SH, Parlow MH, Levy M, Ilver D, Caulkins CM, Connors JB, Dunn BE. 1996. 
Surface localization of Helicobacter pylori urease and a heat shock protein homolog 
requires bacterial autolysis. Infect Immun. 64:905-12. 
General Discussion 
 
196 
 
Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG, Pascolo S. 2007. 
Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-
specific, saturable and ion dependent. Gene Ther. 14:1175-80.  
Raghavan S and Quiding-Järbrink M. 2016. Vaccination against Helicobacter pylori 
infection. Book: Helicobacter pylori research: from bench to bedside, Springer Japan. 
Saito Y, Suzuki H, Tsugawa H, Imaeda H, Matsuzaki J, Hirata K, Hosoe N, Nakamura 
M, Mukai M, Saito H, Hibi T. 2012. Overexpression of miR-142-5p and miR-155 in 
gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to 
Helicobacter pylori eradication. PLoS One. 7:e47396.  
Sjökvist Ottsjö L, Flach CF, Clements J, Holmgren J, Raghavan S. 2013. 
A double mutant heat-labile toxin from Escherichia coli, LT (R192G/L211A), is an 
effective mucosal adjuvant for vaccination against Helicobacter pylori infection. 
Infect Immun. 81:1532-40.  
Stolte M, Bayerdörffer E, Morgner A, Alpen B, Wündisch T, Thiede C, Neubauer A. 
Helicobacter and gastric MALT lymphoma. 2002. Gut. 50:III19-24. 
Sundling C, Schön K, Mörner A, Forsell MN, Wyatt RT, Thorstensson R, Karlsson Hedestam 
GB, Lycke NY. 2008. CTA1-DD adjuvant promotes strong immunity against human 
immunodeficiency virus type 1 envelope glycoproteins following mucosal 
immunization. J Gen Virol. 89:2954-64.  
Vale FF, Vitor JMB, Oléastro M. 2016. Vaccination against Helicobacter pylori infection. 
Book: Helicobacter pylori research: from bench to bedside, Springer Japan. 
Vermoote M, Vandekerckhove TTM, Flahou B, Pasmans F, Smet A, De Groote D, Van 
Criekinge W, Ducatelle R, Haesebrouck F. 2011a. Genome sequence of Helicobacter 
suis supports its role in gastric pathology. Veterinary Research. 42:51.  
Vermoote M, Pasmans F, Flahou B, Van Deun K, Ducatelle R, Haesebrouck F. 2011b. 
Antimicrobial susceptibility pattern of Helicobacter suis strains. Vet 
Microbiol. 153:339-42.  
Vermoote M, Van Steendam K, Flahou B, Smet A, Pasmans F, Glibert P, Ducatelle R, 
Deforce D, Haesebrouck F. 2012. Immunization with the immunodominant 
Helicobacter suis urease subunit B induces partial protection against H. suis infection 
in a mouse model. Vet Res. 43:72.  
Vermoote M, Flahou B, Pasmans F, Ducatelle R, Haesebrouck F. 2013. Protective efficacy of 
vaccines based on the Helicobacter suis urease subunit B and γ-glutamyl 
transpeptidase. Vaccine. 31:3250-6.  
General Discussion 
 
197 
 
Vitali C, Mingozzi F, Broggi A, Barresi S, Zolezzi F, Bayry J, Raimondi G, Zanoni 
I, Granucci F. 2012. Migratory, and not lymphoid-resident, dendritic cells maintain 
peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood. 
120:1237-45.  
Weeks DL, Sachs G. Sites of pH regulation of the urea channel of Helicobacter pylori. 2001. 
Mol Microbiol. 40:1249-59. 
Yamamoto K, Nishiumi S, Yang L, Klimatcheva E, Pandina T, Takahashi S, Matsui H, 
Nakamura M, Zauderer M, Yoshida M, Azuma T. 2014. Anti-CXCL13 antibody can 
inhibit the formation of gastric lymphoid follicles induced by Helicobacter infection. 
Mucosal Immunol. 7:1244-54. 
Yang L, Yamamoto K, Nishiumi S, Nakamura M, Matsui H, Takahashi S, Dohi T, Okada 
T, Kakimoto K, Hoshi N, Yoshida M, Azuma T. 2015. Interferon-γ-producing B cells 
induce the formation of gastric lymphoid follicles after Helicobacter suis infection. 
Mucosal Immunol. 8:279-95.  
Zhang G, Ducatelle R, Mihi B, Smet A, Flahou B, Haesebrouck F. 2016. Heliocbacter suis 
affects the health and function of gastric parietal cells. Vet Res. 47:101. 
Zhang G, Ducatelle R, De Bruyne E, Joosten M, Bosschem I, Smet A, Haesebrouck F, Flahou 
B. 2015. Role of γ-glutamyltranspeptidase in the pathogenesis of Helicobacter suis 
and Helicobacter pylori infections. Vet Res. 46:31. 
  
General Discussion 
 
198 
 
 
 
 199 
 
Summary
 200 
 
Summary 
 
201 
 
In 1984, it was reported for the first time that a bacterium, residing in the stomach, plays a 
role in the development of gastritis, peptic ulcers and gastric cancer in humans. This 
bacterium was later named Helicobacter (H.) pylori. Since the discovery of H. pylori, a large 
number of non-Helicobacter pylori helicobacter (NHPH) species have been described in a 
wide variety of animals. H. suis colonizes the stomach of more than 60% of pigs at slaughter 
age worldwide, and is also of zoonotic importance. H. suis infection in pigs causes chronic 
gastritis and a decrease in daily weight gain. It may be involved in the development of gastric 
ulcers. Since economic losses due to these infections are believed to be substantial, preventive 
measures to combat this highly prevalent pathogen are necessary. Antibiotic-based therapy for 
large scale control of gastric Helicobacter infections is a non-sustainable and sometimes 
inadequate strategy as it may favor spread of antimicrobial resistance. Alternatively, 
vaccination could potentially be used to control gastric Helicobacter infections. Although 
efforts have been made to develop safe and efficient H. suis vaccines, hitherto there is no 
consensus on which vaccine antigen or combination of antigens, adjuvants and administration 
route should be used. Unlike H. pylori, limited information is available on the immune 
response following H. suis infections in rodent models and the natural hosts. This is mainly 
due to the fastidious nature of this bacterium, which was only successfully cultivated in vitro 
in 2008. This has paved the way for further research on H. suis infections.  
The general aim of this doctoral research was to develop new control strategies against H. suis 
infection, based on a better understanding of the mechanisms of a protective immune 
response. 
Experimental H. suis infection in BALB/c and C57BL/6 mice, generally causes a 
predominant Th17 response in the stomach. Mainly in BALB/c mice this is accompanied by a 
mild Th2 response. The immune response induced by H. pylori infection on the other hand, is 
characterized by a Th17/Th1 response and the absence of a Th2 response in humans and 
rodent models. This different immune response could play a role in the development of 
different pathologies by Helicobacter species. Chronic H. suis infection in humans is 
associated with the development of mucosa-associated lymphoid tissue (MALT) lymphoma-
like lesions, whereas H. pylori infection causes predominantly adenocarcinoma. Both H. 
pylori and H. suis are able to evade the host immune responses and may cause persistent 
infection of the stomach in the absence of proper treatment. Several immune evasion 
mechanisms have been proposed for H. pylori, which focus to a great extent on its major 
virulence factors: the CagA protein encoded in the cag (cytotoxin-associated gene) 
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pathogenicity island (cagPAI) and vacuolating toxin A (VacA). However, both virulence 
factors are absent in H. suis. In Chapter 1 we aimed at investigating the species-specific 
immune response following H. suis infection. Therefore, the dynamics of cytokine expression 
were monitored in the stomach of BALB/c mice experimentally infected with H. suis and 
revealed a local Th17/Th2 response. Despite the subsequent neutrophil and mononuclear cell 
influx in the murine stomach, the host was unable to clear H. suis infection. The cytokine 
expression profile in the stomach of pigs naturally infected with H. suis was also determined. 
Natural H. suis infection in pigs evoked increased expression levels of IL-17 mRNA in the 
antrum and IL-10 mRNA in the fundus. In the next part of this study, the effect of H. suis on 
murine and porcine dendritic cell (DC) maturation and their ability to elicit T-cell effector 
responses was analyzed in vitro. This revealed remarkable differences between both hosts. H. 
suis-stimulated murine bone marrow-derived DCs induced IL-17 secretion by CD4+ cells in 
vitro. In contrast with mice, H. suis-stimulated porcine monocyte-derived DCs were unable to 
express MHCII molecules on their cell surface. These semi-mature DCs induced activation 
and proliferation of T-cells, which showed an increased expression of TGF-β and FoxP3 
mRNA levels which may result in the inhibition of Th17 responses. This led us to conclude 
that H. suis might evade host immune responses by skewing T-cell responses towards a Treg-
biased response, by mechanisms which are independent of the H. pylori virulence factors 
CagA and VacA. In order to elucidate these mechanisms and to further unravel the species-
specific differences in immunity to H. suis, further studies are required. 
H. suis mainly colonizes the stomach of pigs, but it has also been detected in the stomach of 
several non-human primates. Phylogenetic analysis has shown that pig and human-associated 
(1), cynomolgus monkey-associated (2) and rhesus monkey-associated (3) H. suis strains 
form 3 distinct clusters. Cynomolgus monkey-associated H. suis strains have been used in 
several infection studies in mice and were associated with the development of MALT 
lymphoma-like lesions in these animals. These lesions are not observed in mice when using 
pure in vitro-cultured porcine H. suis strains. In any case, direct comparison between H. suis 
strains from these different hosts was difficult before the start of this research, since no pure 
in vitro-cultured primate-associated H. suis strains were available. Our research group was the 
first to succeed in cultivating pure H. suis strains from cynomolgus monkeys (Macaca 
fascicularis) and rhesus monkeys (Macaca mulatta). In Chapter 2 we described the 
experimental infection of BALB/c mice and Mongolian gerbils with in vitro isolated H. suis 
strains obtained from pigs, cynomolgus monkeys and rhesus monkeys, in an attempt to obtain 
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better insights into potential differences between pig- and primate-associated H. suis strains in 
terms of virulence and immuno-pathogenesis. Both porcine and primate H. suis strains caused 
severe gastric inflammation in both rodent models, except for the cynomolgus monkey-
associated H. suis strain which was unable to colonize the stomach of Mongolian gerbils. All 
H. suis strains evoked a marked Th17 response in both mice and gerbils, accompanied by 
increased CXCL13 expression levels. In Mongolian gerbils increased expression of Th1 
marker IFN-γ was also observed. Nine weeks after infection, gastric lymphoid follicles 
containing CD20 positive B-cells organized in germinal centers and destruction of the antral 
epithelium were observed in all H. suis infected Mongolian gerbils, but not in mice. These 
histopathological findings resemble MALT lymphoma-like lesions, as observed in humans 
infected with NHPH. In addition, this is the first study to confirm the role of IFN-γ in the 
development of MALT lymphoma-like lesions following infection with pure in vitro isolated 
pig- and primate-associated H. suis strains.  
In conclusion, apart from the cynomolgus monkey-associated strain which was unable of 
colonizing the stomach of Mongolian gerbils, no substantial differences in virulence were 
found in rodent models between in vitro cultured pig-associated, cynomolgus monkey-
associated and rhesus monkey-associated H. suis strains. It was shown that mainly the 
experimental host determines the outcome of the immune response against H. suis infection, 
rather than the original host where the strains were obtained from.  
Before the start of this research, only a limited number of vaccination studies against H. suis 
infection had been performed. Promising results have been obtained using either H. suis 
whole-cell lysate or a combination of recombinant (r) GGT and rUreB to protect mice against 
subsequent H. suis infection. No other adjuvants besides Cholera toxin (CT) and a saponin-
based adjuvant had previously been tested in H. suis vaccination studies. However, due to the 
toxicity of CT, and the low efficacy of the saponin-based adjuvant, there was an obvious need 
for the introduction of new, safe vaccine adjuvants that might induce both cellular and 
humoral immune responses. Therefore, in Chapter 3, we investigated the efficacy of several 
established vaccine adjuvants (CpG-DNA, Curdlan, Freund’s Complete (FA) and Incomplete 
(IFA), CT), administered either subcutaneously or intranasally along with H. suis whole-cell 
lysate, to protect against subsequent H. suis challenge in a BALB/c infection model. 
Subcutaneous immunization with FA/lysate and intranasal immunization with CT/lysate were 
shown to be the best options for vaccination against H. suis, as determined by the amount of 
colonizing H. suis bacteria in the stomach, although adverse effects such as post-
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immunization gastritis/pseudo-pyloric metaplasia and increased mortality were observed, 
respectively. Therefore, alternative vaccination strategies were tested, including sublingual 
vaccine administration, to reduce the unwanted side-effects. A C-C chemokine receptor type 4 
(CCR4) antagonist, that transiently inhibits the recruitment of regulatory T-cells (Tregs) at the 
site of immunization, was also included as a new adjuvant in this second study. Results 
confirmed that immunization with CT (intranasally or sublingually) is among the most 
effective vaccination protocols, but increased mortality was still observed. In the groups 
immunized subcutaneously with FA/lysate and CCR4 antagonist/lysate, a significant 
protection was observed. Compared to the FA/lysate immunized group, gastric pseudo-pyloric 
metaplasia was less severe or even absent in the CCR4 antagonist/lysate immunized group. In 
general, in animals vaccinated with strategies that conferred the highest degree of protection, 
increased expression levels of IFN-γ, IL-4, IL-17, KC, MIP-2 and LIX mRNA were observed. 
Compared to the non-immunized and H. suis challenged animals, IL-10 expression levels 
were consistently lower in animals from all immunized/challenged groups. The use of a 
CCR4 antagonist as adjuvant in H. suis vaccines might be a promising strategy, however, 
future studies should aim at further optimization of these immunization protocols. 
In conclusion, the results described in this doctoral thesis provide new insights into host 
immune responses evoked by H. suis infections in animal models and in its natural host, the 
pig. We suggested that H. suis is able to evade host immune responses by reprogramming 
porcine DCs towards a tolerogenic phenotype which skews T-cell responses towards Treg-
biased responses. In addition, we provided new insights in the development of MALT 
lymphoma-like lesions following infection with in vitro cultured primate and pig-associated 
H. suis strains in Mongolian gerbils. Finally, we describe the potential use of a new, 
promising adjuvant, a CCR4 antagonist, in H. suis vaccination. 
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In 1984 werd voor het eerst beschreven dat een bacterie, die aanwezig is in de maag, een rol 
speelt in de ontwikkeling van maagontsteking, peptische ulcera en maagkanker bij mensen. 
Deze bacterie werd later Helicobacter (H.) pylori genoemd. Na de ontdekking van H. pylori, 
werden Helicobacter species ook aangetoond bij verschillende diersoorten. H. suis koloniseert 
de maag van meer dan 60% van de slachtvarkens wereldwijd en is ook van zoönotisch belang. 
H. suis infecties veroorzaken bij varkens een chronische maagontsteking, een daling van de 
dagelijkse gewichtsaanzet en ze worden geassocieerd met de ontwikkeling van maagulcera. 
Gezien de economische verliezen die gepaard gaan met deze infecties en het zoönotisch 
karakter ervan, zijn preventieve maatregelen om deze veel voorkomende bacterie te bestrijden 
noodzakelijk. Antibioticatherapie levert niet altijd goede resultaten op. Bovendien is het geen 
duurzame methode om H. suis infecties op grote schaal te bestrijden, aangezien het de 
spreiding van antimicrobiële resistentie in de hand kan werken. Vaccinatie zou mogelijks 
gebruikt kunnen worden om gastrale Helicobacter infecties te bestrijden. Hoewel er reeds 
onderzoek is gebeurd om een veilig en efficiënt H. suis vaccin te ontwikkelen, is er tot dusver 
geen consensus over welke antigenen, adjuvantia en toedieningsroutes gebruikt moeten 
worden. In tegenstelling tot H. pylori, werd slechts sporadisch onderzoek uitgevoerd naar de 
immuunrespons na een H. suis infectie. Dit geldt voor knaagdieren zoals muizen en 
Mongoolse gerbils, die vaak als model voor de mens gebruikt worden, maar is nog meer het 
geval voor de natuurlijke gastheer, het varken. Dit is vooral te wijten aan het feit dat H. suis 
zeer moeilijk te cultiveren is. Pas in 2008 werd deze kiem succesvol geïsoleerd in vitro. Dit 
zorgde ervoor dat verder onderzoek naar H. suis infecties mogelijk was. 
Het algemene doel van dit doctoraatsonderzoek was om nieuwe controle strategieën te 
ontwikkelen tegen H. suis infecties, gebaseerd op een betere kennis van de mechanismen van 
een beschermende immuunrespons. 
Een experimentele H. suis infectie in BALB/c en C57BL/6 muizen veroorzaakt over het 
algemeen een predominante Th17 respons in de maag. Voornamelijk in BALB/c muizen 
wordt deze vergezeld door een milde Th2 respons. In knaagdiermodellen en bij de mens is de 
opbouw van immuniteit als reactie op een H. pylori infectie, daarentegen gekenmerkt door 
een Th17/Th1 respons en de afwezigheid van een Th2 respons. Dit verschil in 
immuunrespons zou een rol kunnen spelen in de ontwikkeling van de verschillende 
pathologieën door deze Helicobacter species. Een chronische H. suis infectie wordt bij 
mensen geassocieerd met de ontwikkeling van mucosa-geassocieerd lymfoïd weefsel 
(MALT) lymfomen, terwijl een H. pylori infectie voornamelijk adenocarcinoma’s kan 
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veroorzaken. Zowel H. pylori als H. suis zijn in staat om de immuunrespons van de gastheer 
te omzeilen en kunnen aldus een chronische maaginfectie teweeg brengen in afwezigheid van 
een gepaste behandeling. Verschillende mechanismen om het immuunsysteem van de 
gastheer te omzeilen werden reeds beschreven voor H. pylori. De belangrijkste 
virulentiefactoren die hierbij tussen komen zijn het CagA eiwit, dat gecodeerd wordt in het 
cag (cytotoxine-geassocieerd gen) pathogeniciteitseiland (cagPAI) en het vacuoliserend 
toxine A (VacA). Deze zijn echter afwezig in H. suis. In hoofdstuk 1 werd de immuniteit na 
een H. suis infectie bij muizen en varkens onderzocht. De dynamiek van de cytokine 
expressie werd opgevolgd in de maag van BALB/c muizen die experimenteel geïnfecteerd 
werden met H. suis en bracht een lokale Th17/Th2 respons aan het licht. Ondanks de hierop 
volgende infiltratie van neutrofielen en mononucleaire cellen in de maag van de muizen, 
waren deze niet in staat de infectie te eradiceren. Bij varkens die geïnfecteerd waren werd het 
expressie profiel van verschillende cytokines in de maag bepaald. Een natuurlijke H. suis 
infectie veroorzaakte bij varkens een verhoogde expressie van IL-17 mRNA in het antrum en 
IL-10 mRNA in de fundus. In het volgende deel van deze studie werd het effect van H. suis 
op dendritische cellen (DC), afkomstig van muizen en varkens in vitro geanalyseerd. Het 
vermogen van deze antigen-presenterende cellen om T-cel responsen uit te lokken werd 
eveneens onderzocht. Dit bracht opmerkelijke verschillen tussen beide gastheren aan het licht. 
H. suis-gestimuleerde DCs afkomstig van het beenmerg van BALB/c muizen induceerden IL-
17 secretie door CD4+ cellen. In contrast met het muismodel, waren H. suis-gestimuleerde 
DCs afkomstig van monocyten van varkens niet in staat om MHCII moleculen tot expressie te 
brengen op hun celoppervlak. Deze onvolledig gematureerde DCs induceerden activatie en 
proliferatie van T-cellen, die een verhoogde expressie van TGF-β en FoxP3 mRNA 
vertoonden. Dit zou kunnen resulteren in de inhibitie van Th17 responsen. Dit duidt erop dat 
H. suis de immuunrespons van de gastheer kan ontwijken door het uitlokken van een Treg-
gemedieerde respons, via mechanismen die onafhankelijk zijn van de H. pylori 
virulentiefactoren CagA en VacA. Verdere studies zijn noodzakelijk om deze mechanismen 
verder te ontrafelen en om de verschillen in immuniteitsopbouw bij verschillende 
gastheerspecies te verklaren.   
H. suis koloniseert niet enkel de maag van varkens en mensen. Deze bacterie werd ook 
gedetecteerd in de maag van verschillende niet-humane primaten. Fylogenetische analyse 
heeft uitgewezen dat de H. suis stammen kunnen ingedeeld worden in drie verschillende 
clusters. Een eerste cluster omvat stammen die voorkomen bij varkens en mensen. Stammen 
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die aangetoond werden bij cynomolgus apen (Macaca fascicularis) vormen een tweede 
cluster. Een derde cluster omvat H. suis stammen van rhesus apen (Macaca mulatta). In de 
literatuur werd beschreven dat muizen die geïnoculeerd werden met H. suis stammen die 
aanwezig waren in maaghomogenaat van cynomolgus apen, MALT lymfomen ontwikkelden. 
Deze letsels werden niet geobserveerd bij muizen na infectie met zuivere in vitro 
gecultiveerde porciene H. suis stammen. Hoe dan ook, een directe vergelijking tussen de H. 
suis stammen van deze verschillende gastheren was voor de start van dit onderzoek niet 
mogelijk omdat er geen zuivere, in vitro gecultiveerde H. suis stammen van apen beschikbaar 
waren. Onze onderzoeksgroep slaagde er als eerste in om zuivere H. suis stammen van 
cynomolgus apen en rhesus apen te cultiveren. In hoofdstuk 2 werd een experimentele 
infectie van BALB/c muizen en Mongoolse gerbils beschreven met in vitro gecultiveerde H. 
suis stammen, die werden geïsoleerd uit de maag van varkens, cynomolgus apen en rhesus 
apen. Deze studie had als doel een beter inzicht te verwerven in potentiële verschillen 
betreffende virulentie en immunopathogenese tussen deze H. suis stammen. Zowel de varken- 
als de primaat-geassocieerde H. suis stammen veroorzaakten ernstige gastrale inflammatie in 
beide diermodellen, met uitzondering van de cynomolgus aap-geassocieerde H. suis stam die 
niet in staat was om de maag van Mongoolse gerbils te koloniseren. Alle H. suis stammen 
induceerden een uitgesproken Th17 respons, vergezeld van verhoogde CXCL13 mRNA 
expressie in zowel muizen als Mongoolse gerbils. Bij Mongoolse gerbils werd eveneens een 
verhoogde expressie van IFN-γ mRNA geobserveerd. Bij vrijwel alle geïnfecteerde gerbils 
werd 9 weken na de infectie destructie van het maagepitheel ter hoogte van het antrum 
aangetoond en werden gastrale lymfoïde follikels teruggevonden met CD20 positieve B-
cellen die georganiseerd waren in germinale centra. Dergelijke histologische bevindingen 
lijken op de MALT lymfomen, die gezien worden bij mensen die geïnfecteerd zijn met H. 
suis. Ze werden niet aangetoond bij de muizen. Dit is de eerste studie die de rol van IFN-γ 
bevestigt in de ontwikkeling van MALT lymfomen na een infectie met zuivere in vitro 
geïsoleerde varken- en primaat-geassocieerde H. suis stammen. 
Als conclusie kunnen we stellen dat, behalve de cynomolgus aap-geassocieerde stam die niet 
in staat was om de maag van Mongoolse gerbils te koloniseren, er geen noemenswaardige 
verschillen in virulentie werden gevonden in beide knaagdiermodellen tussen in vitro 
gecultiveerde varken-geassocieerde, cynomolgus aap-geassocieerde en rhesus aap-
geassocieerde H. suis stammen. Er werd aangetoond dat het type van immuunrespons 
verschilt afhankelijk van de diersoort die geïnfecteerd wordt. Dit geld zowel voor stammen 
die geïsoleerd werden bij varkens als voor stammen afkomstig van apen. 
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Voor de start van dit onderzoek waren er maar een beperkt aantal vaccinatie studies tegen H. 
suis uitgevoerd. In experimentele infectiestudies bij muizen, werden veelbelovende resultaten 
bekomen wanneer een cellysaat van H. suis of een combinatie van recombinant (r) 
aangemaakt γ-glutamyl transpeptidase (rGGT) en Urease B (rUreB) gebruikt werden als 
vaccin. Enkel Cholera toxine (CT) en een saponine-gebaseerd adjuvans werden in deze 
voorgaande H. suis vaccinatie studies gebruikt. Omwille van de toxiciteit van CT, en de 
beperkte werkzaamheid van het saponine-gebaseerd adjuvans, was er duidelijk nood aan de 
introductie van een nieuw, veilig vaccin adjuvans dat zowel cellulaire als humorale 
immuniteit zou kunnen induceren. In hoofdstuk 3, werd er onderzoek gedaan naar de 
werkzaamheid van verschillende bestaande adjuvantia (CpG-DNA, Curdlan, volledig (FA) en 
onvolledig Freund’s adjuvans (IFA), CT). Deze werden subcutaan of intranasaal samen met 
H. suis cellysaat toegediend aan BALB/c muizen die daarna intragastraal geïnoculeerd 
werden met H. suis. Subcutane vaccinatie met FA/lysaat en intranasale vaccinatie met 
CT/lysaat induceerden de beste bescherming, wat zich onder andere uitte door een significant 
lager aantal H. suis bacteriën in de maag. Er werd evenwel ook een post-immunisatie 
gastritis/pseudo-pylorische metaplasie vastgesteld bij de muizen die subcutaan gevaccineerd 
werden met FA/lysaat en een verhoogde mortaliteit bij muizen die intranasaal gevaccineerd 
werden met CT/lysaat. Om deze ongewenste bijwerkingen tegen te gaan, werden in een 
tweede studie alternatieve vaccinatie strategieën uitgetest, waaronder sublinguale vaccinatie. 
Als nieuw adjuvans werd een C-C chemokine receptor type 4 (CCR4) antagonist uitgetest. 
Deze zorgt voor een kortstondige inhibitie van de rekrutering van regulatoire T-cellen naar de 
plaats van immunisatie. De resultaten van deze studie bevestigden dat immunisatie met CT 
(intranasaal of sublinguaal) behoort tot de meest effectieve vaccinatie protocollen, maar de 
verhoogde mortaliteit was nog steeds aanwezig. In de groepen die gevaccineerd werden met 
FA/lysaat en CCR4 antagonist/lysaat, werd een significante bescherming waargenomen. In 
vergelijking met de FA/lysaat gevaccineerde groep was gastrale pseudo-pylorische metaplasie 
minder ernstig en soms zelfs afwezig in de CCR4 antagonist/lysaat gevaccineerde groep. 
Over het algemeen werd bij dieren gevaccineerd met protocollen die de beste bescherming 
boden, een verhoogde expressie van IFN-γ, IL-4, IL-17, KC, MIP2 en LIX mRNA 
aangetoond. In vergelijking met de niet-gevaccineerde en H. suis geïnfecteerde dieren, was de 
IL-10 mRNA expressie consequent lager bij alle gevaccineerde en H. suis geïnfecteerde 
dieren. Het gebruik van een CCR4 antagonist als adjuvans in H. suis vaccins zou een 
veelbelovende strategie kunnen zijn. Een verdere optimalisatie van deze vaccinatie strategieën 
is evenwel noodzakelijk.  
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Als conclusie kan gesteld worden dat dit doctoraatsonderzoek toeliet om nieuwe inzichten te 
bekomen in de immuunrespons na een H. suis infectie in knaagdiermodellen en de natuurlijke 
gastheer, het varken. De resultaten duiden erop dat H. suis bacteriën in staat zijn om de 
immuunrespons bij een geïnfecteerd varken te ontwijken door DCs te reprogrammeren naar 
een tolerogeen fenotype dat een Treg-gemedieerde respons uitlokt. Er werden eveneens meer 
inzichten bekomen in de ontwikkeling van MALT lymfomen na infectie van Mongoolse 
gerbils met zuivere, in vitro gecultiveerde H. suis stammen, afkomstig van varkens en 
primaten. Tenslotte werd aangetoond dat het gebruik van een CCR4 antagonist als adjuvans in 
een H. suis vaccin, nuttig kan zijn. 
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Een doctoraat behaal je zeker niet alleen. Daarom zou ik hier graag een aantal mensen willen 
bedanken die door hun goede begeleiding, enthousiasme, motivatie en steun ervoor gezorgd 
hebben dat ik mijn doel heb kunnen bereiken. 
In de eerste plaats gaat mijn dank uit naar mijn promotoren. Prof. Haesebrouck, hartelijk 
bedankt om mij de kans te geven dit doctoraat te starten en voor uw vertrouwen. Uw lessen 
hebben er destijds voor gezorgd dat mijn interesse in het onderzoek en de bacteriologie 
groeiden. Dankzij uw uitstekende begeleiding is dit doctoraat tot een goed einde gekomen. 
Uw interesse en steun voor het verdere verloop van mijn loopbaan zullen mij ook altijd 
bijblijven. Bedankt! Prof. Ducatelle, bedankt voor de professionele ondersteuning, de 
zorgvuldige verbeteringen van mijn artikels en deze doctoraatsthesis, de constructieve 
gesprekken en vooral het enthousiasme voor mijn onderzoek. Uw feedback bracht steeds 
nieuwe ideeën en inzichten met zich mee. Dr. Flahou, Bram, bedankt voor de goede 
begeleiding tijdens alle aspecten van dit onderzoek. Ondanks je druk werkschema maakte je 
toch tijd vrij om mij te helpen. Je hebt me ook alle inzichten gegeven om zelfstandig te 
kunnen werken als wetenschappelijk onderzoekster. Ik kan met zekerheid zeggen dat je 
expertise in het labo en daarbuiten gemist worden. Veel geluk en succes met je carrière bij 
Novartis!   
Mijn oprecht dank gaat eveneens uit naar de leden van mijn begeleidings- en 
examencommissie: prof. dr. Dominiek Maes, prof. dr. Niek Sanders, prof. dr. Fátima 
Gärtner, prof. dr. Irina Amorim, dr. Bert Devriendt en prof. dr. Cox. Hartelijk dank om 
mijn doctoraatsthesis zo zorgvuldig na te lezen. De constructieve opmerkingen hebben ervoor 
gezorgd dat dit werk sterk verbeterde. Prof. Gärtner and prof. Amorim, I am very grateful to 
you both for accepting the invitation to be a member of my examination committee and for 
flying over from Portugal to attend my public defense.  
Dit onderzoek was mogelijk door een geconcerteerde onderzoeksactie (GOA 01G00408) van 
de Universiteit Gent, waarvoor dank. 
Ik zou ook graag alle co-auteurs van de publicaties in deze doctoraatsthesis willen bedanken 
voor de fijne samenwerking: prof. dr. Jiri Volf, dr. Stefaan De Koker, dr. Jaco Bakker, 
dr. Edwin Heuvelman, dr. Jan AM Langermans en prof. dr. Jagadeesh Bayry. 
Dankwoord 
 
 
224 
 
Ik heb altijd met heel veel plezier gewerkt aan de Vakgroep Bacteriologie, Pathologie en 
Pluimveeziekten en zou dan ook iedereen willen bedanken voor de voorbije 5 jaar. Een aantal 
mensen verdienen een extra woordje van dank.  
De Helicobacter onderzoeksgroep was een zeer leuke groep om in terecht te komen, en ik wil 
dan ook iedereen die er de afgelopen jaren deel van uit maakte bedanken voor de goede 
samenwerking. Ellen, ik overdrijf niet als ik zeg dat ik hier zonder jou niet zou gestaan 
hebben. Jij liet me 5 jaar geleden weten dat er misschien wel een functie zou vrijkomen aan 
de vakgroep bacteriologie, en de rest is geschiedenis. Je zorgde ervoor dat ik snel geïntegreerd 
was en mijn plan kon trekken in het labo. Bedankt! Ik kijk er al naar uit om terug collega’s te 
zijn! Myrthe, Dr. Joosten ondertussen, jij was dan ook één van de eersten aan wie ik door 
Ellen werd voorgesteld. Bedankt voor alle hulp tijdens mijn onderzoek en bij de laatste fases 
van mijn doctoraat, ik had me geen betere voorganger kunnen voorstellen! Ellen en Myrthe, 
bedankt om er altijd voor mij te zijn, zowel tijdens de leuke, als tijdens de iets minder leuke 
momenten. Ik heb heel erg veel aan jullie steun en ben erg dankbaar dat we zo’n goede 
vriendinnen zijn. Hannah, jij was deel van het Helicobacter team voor 2 jaar. Bedankt voor 
de leuke tijd en de steun! Ondertussen ben je een nieuwe weg ingeslagen, heel veel succes 
hiermee.  
Guangzhi, I enjoyed our conversations in the office a lot. Good luck with your postdoctoral 
research in Berkeley and regards to Yan and Zebao. Hopefully we can meet up again one day 
in California! Lien DC, bedankt voor de steun en de leuke momenten tijdens het congres in 
Helsingör. Miet en Kim VD, bedankt aan beiden om het pad naar de zoektocht naar een H. 
suis vaccin al wat te effenen. Prof. Smet, Annemieke, ook al was je geen officiële promotor, 
je deur stond altijd open als ik vragen had. Bedankt! Cheng, I wish you good luck with your 
career in China! Chloë, al van in het begin was het duidelijk dat je een gemotiveerde 
onderzoekster bent! Het was heel leuk om samen aan enkele projecten te kunnen werken. Ik 
wil je nog heel veel succes wensen met het verdere verloop van je doctoraat! Caroline, 
bedankt voor alle leuke momenten en de steun. Heel veel succes met de laatste loodjes van je 
doctoraat, je bent er bijna! Eva, ik bewonder je gedrevenheid voor het onderzoek, ook als het 
niet loopt zoals gepland. Bedankt voor de steun en de leuke babbeltjes. Nog heel veel succes 
met je doctoraat! Helena, de allernieuwste aanwinst van het Helicobacter team. Met jouw 
enthousiasme voor het onderzoek zal je zeker een mooi doctoraat behalen. Sofie DB, de 
snelheid waarmee jij qPCR’s tot een goed einde brengt is ongezien. Heel erg bedankt voor al 
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je hulp in het labo! De gezellige ritjes naar Moeskroen zullen me ook bij blijven, ook al was 
de bestemming iets minder gezellig. Nathalie VR, ook van jou heb ik veel geleerd. Bedankt 
voor alle hulp in het labo! 
Marleen, ook jij begeleidde me bij mijn eerste stappen in het labo. Heel erg bedankt voor de 
leuke babbeltjes, uw enthousiasme en vrolijkheid.  
De routine diagnostiek was voor mij een hele leuke afwisseling tussen het labo- en 
schrijfwerk door. Filip B, bedankt om me zoveel bij te leren over bacteriële diagnostiek en 
antimicrobiële resistentie. Serge en Arlette, bedankt voor alle hulp en tips in het labo. Koen, 
Jo en Gunter, heel erg bedankt voor de hulp bij administratieve en/of computerproblemen. 
Erna, heel erg bedankt om onze bureaus zo proper te houden en voor de leuke babbeltjes. 
Ilias, you joined our office more than a year ago. Good luck with the completion of your 
thesis, I’m sure you will do great. We will meet up soon! Jonas, it was fun having you as an 
office member. Good luck with the completion of your PhD in Denmark. Kirsten, nog maar 
net gestart met je doctoraat en direct de stress en chaos van de laatste loodjes 
meemaken…sorry daarvoor. Maar tegelijk ook heel erg bedankt voor de oppeppende 
babbeltjes en de hulp met de lay-out van mijn doctoraatsthesis! Succes met je doctoraat! 
Lore, ik vind het echt jammer dat we maar 1 maandje samen de bureau hebben kunnen delen. 
Veel succes! 
Christian, hartelijk bedankt voor de snelle verwerking van mijn weefselstaaltjes en dit altijd 
met enthousiasme. Ook bedankt aan Delphine, Sarah en Astra voor de hulp met het kleuren 
van de weefselstaaltjes. 
De vakgroep immunologie was een beetje mijn ‘tweede thuis’ tijdens het laatste jaar van mijn 
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